EDISON

Deutsches Eigenkapitalforum
23 – 25 November 2015

Edison Conference Book 2015

Company profiles

Published by Edison Investment Research

Welcome to the Edison Conference Book for the Deutsches Eigenkapitalforum 2015. As in past years Edison is delighted to support this event as partner of Deutsche Börse. We are looking forward to three days of engaging discussions between companies, investors and analysts, not only from Germany but all over world.

With the creation of its Venture Network, Deutsche Börse has taken an innovative step to enhance the possibilities of Pre-IPO companies to meet potential investors and secure growth funding. As such this initiative is a logical extension of the guiding theme of the Eigenkapitalforum to promote greater engagement between capital seeking companies and investors.

As in previous years the book opens with a strategy piece by Alastair George. A number of the themes from last year have remained remarkably constant. Central Bank policies in Europe and the US are still at the centre of attention for the markets. The fear of a slowdown in economic activity and profit momentum is also weighing on the markets.

The situation on the capital markets is mixed. The German IPO market has shown some encouraging signs. We have seen a number of successful high profile listings this year and the IPO pipeline is well filled. Ongoing market volatility and headwinds, however, have meant that some offerings had to be adjusted. Effective communication between entrepreneurs and asset managers remains as important as ever.

It is evident that interaction between companies and investors is changing significantly. Companies compete with their global peers for international capital. To be successful in this competition companies need to have a clear strategy to ensure their equity story is visible and understood by the international investment community. Given the resource and time constraints many IR departments face, ensuring efficiency and effectiveness is a big challenge.

This challenge has become even bigger by the changes imposed by recent and upcoming regulation on the investment research market. At present it is not 100% certain what regulation will finally be implemented and how the research model going forward will look. However, it is safe to predict that asset managers will be more focused and selective in how they spend their research commissions. Investment banks have already been cutting their research budgets over the past years.

As a result, companies can no longer rely on research coverage and investor access being freely available. Many IR managers have already adapted their strategy and take a much more pro-active approach to ensure visibility, transparency and presence with investors. Those companies are much more mindful of reaching out to new, incremental investors and also focusing on meeting the right investors. Innovative digital platforms and instruments play an increasing role in this activity.

In this context the Deutsches Eigenkapitalforum is a great platform to help companies across all sectors and market caps to network and connect directly with investors.

Edison is Europe's leading investment intelligence firm, setting the standards for investor interaction with corporates. Our team of over 120 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 450 retained corporate and 60 investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Our research can be accessed free of charge at www.edisongroup.com.

Klaus Schinkel, Director of Edison Germany

Neil Shah, Director of Research

For more information please contact:	

Director of Edison Germany
Klaus Schinkel

+49 (0)69 78 8076 960
kschinkel@edisongroup.com

Contents

Prices, information and consensus estimates as at 23 October

Edison research clients*

Note: Edison client PBT and EPS are normalised

Published 9 November 2014

Fact sheet profiles

2G Energy AG
7C Solarparken AG
Abivax S.A.
adesso AG
Adler Modemärkte AG
Advanced Vision Technology (AVT) Ltd.
Affimed N.V.
Ahlers AG
amp biosimilars AG
ATOSS Software AG
AURELIUS AG
AutoBank AG
Basler AG
Bastei Lübbe AG
bet-at-home.com AG
Biofrontera AG
CANCOM SE
CARBIOS S.A.
CENTROTEC Sustainable AG
CEWE Stiftung & Co. KGaA
comdirect bank AG
C-QUADRAT Investment AG
CropEnergies AG
Daldrup & Söhne AG
DATAGROUP AG
DEAG Deutsche Entertainment AG
Delticom AG
Deutsche Lufthansa AG
Dürr Aktiengesellschaft
Eckert & Ziegler Strahlen- und Medizintechnik AG
ecotel communication ag
Einhell Germany AG
Elmos Semiconductor AG
Energiekontor AG
Ergomed plc.
euromicron AG
Evolva
First Sensor AG
Formycon AG
Francotyp-Postalia Holding AG
GESCO AG
GK Software AG
GLOBAL ECOPOWER
GRAMMER AG
GRENKELEASING AG
Hannover Rück SE
Hawesko Holding AG
Heliocentris Energy Solutions AG
HELMA Eigenheimbau AG
Hochdorf Holding
Hypoport AG
INDUS Holding AG
init innovation in traffic systems AG
Integer
Intershop Communications AG
ISARIA Wohnbau AG
ISRA VISION AG
ItN Nanovation AG
IVU Traffic Technologies AG
JDC Group AG
JENOPTIK AG
Klöckner & Co SE
KROMI Logistik AG
KTG Agrar SE
LifeWatch AG
LPKF Laser & Electronics AG
M.A.X. Automation AG
Manz AG
Masterflex SE
MBB SE
MLP AG
Motif Bio plc
MPC Münchmeyer Petersen Capital AG
msg life ag
mVISE AG
mybet HoldingSE
Nemetschek AG
Nexus AG
OTI Greentech Group AG
OHB SE
PANTALEON Entertainment AG
Pfeiffer Vacuum Technology AG
Progress-Werk Oberkirch AG
Publity AG
PVA TePla AG
RIB Software AG
ROFIN-SINAR Technologies Inc.
S&T AG
Sartorius AG
Schaltbau Holding AG
SINGULUS TECHNOLOGIES AG
SKW Stahl-Metallurgie Holding AG
SLM Solutions Group AG
SMT Scharf AG
Softing AG
Software AG
Store Electronic Systems
SURTECO SE
SÜSS MicroTec AG
SYZYGY AG
TAKKT AG
technotrans AG
telegate AG
TLG IMMOBILIEN AG
TOM TAILOR Holding AG
TOMORROW FOCUS AG
Transgene S.A.
USU Software AG
Verona Pharma plc
Villeroy & Boch AG
Viscom AG
Wacker Neuson SE
WashTec AG
WCM Beteiligungs- und Grundbesitz-Aktiengesellschaft
Wincor Nixdorf AG
ZhongDe Waste Technology AG
zooplus AG

Global perspectives: Help to buy?

Analyst

Alastair George

+44 (0)20 3077 5700

institutional@edisongroup.com

- **Market sentiment has refocused on the scope for central banks to ease policy.** Interest rates have been cut in China, while the ECB has signalled as clearly as it can that more monetary stimulus will be deemed necessary by December. Forward expectations for interest rates have continued to move lower, in both the US and Europe.
- **This central bank 'help-to-buy' dynamic has buoyed equity prices, as we have previously suggested it might.** However, we have misgivings on the sustainability of this risk-on environment. The underlying parameters that dictate the long-run returns on global equity markets, namely valuations and the outlook for profits growth, are discouraging. Equity valuations in general remain extended and, in addition, the recent economic volatility has led to a marked deterioration in earnings momentum in every major economic region.
- **The recent rally in global markets is therefore, in our view, an example of volatility rather than a new uptrend.** While the term volatility and falling prices appear to have become synonymous in global media in recent years, we prefer to use the traditional definition; volatility describes the variability of prices. In this respect we would not be at all surprised to see markets give up some of the recent gains.
- **Yesterday's FOMC statement was more hawkish than we expected.** The rebound in global markets also seems to have rekindled the US Fed's willingness to raise interest rates in December, even as US economic momentum has slowed. It is hard to avoid the impression that the US Fed has become market-and-date rather than data-dependent. In our view, this statement will make investors hesitate before chasing this rally.
- **Conclusion.** Investors have correctly anticipated further easing from the ECB and China's central bank. However, the most recent FOMC statement clearly indicates a much higher probability that the US Fed will raise rates in 2015 than the market appeared to be expecting. While the looser-for-longer global monetary policy outlook may have been a reason to refrain from panic and not exit equities during August, it is not at all clear that October's mini rally will run much further without implicit encouragement from the US Fed.

Help to buy?

Recent weeks have seen a remarkable recovery in global equity prices given the very limited change in the fundamental outlook. But at the same time as this recovery in equity risk appetite, earnings estimates have continued to fall across each of the major economic regions. The downgrades in the basic industry sector were well anticipated and this sector has been the strongest performer in the recent rally, Exhibit 1.

Exhibit 1: Global sector performance end-September to 28 October 2015 (US$)



Source: Thomson Reuters Datastream

However, we would highlight that the knock-on effects of lower commodity and energy prices are still feeding through to downgrades in the industrial sector in the US, UK and eurozone, Exhibit 2. These second-order effects on the supply chain are likely to result in a continued drip-feed of declining profits guidance into the end of the year.

Exhibit 2: Industrials sector – downward earnings revisions as percentage total



Source: Thomson Reuters Datastream, Edison calculations

Despite the recent equity market rally, the bond market remains unconvinced; yields remain significantly lower than at the mid-point of the year, reflecting lower inflation expectations, Exhibit 3.

Exhibit 3: No rebound in 10-year bond yields since highs of June 2015



Source: Thomson Reuters Datastream

In our view, behind these apparently contradictory market moves (with growth-sensitive assets such as equities higher and bond yields lower) lie the still highly visible hands of the world's major central banks. In September, a long-flagged US interest rate increase did not materialise, while in China monetary policy is now being eased. During its October monetary policy press conference, the ECB could not have sent a clearer signal that it believed further monetary easing would be required by December, sending the euro down 3% against the dollar on the day.

The anticipation of this monetary response has helped investors buy into (or at least stop selling into) the recent deterioration in global growth prospects. Furthermore, within the strong rebound in global markets during October, it has been cyclically sensitive sectors such as basic materials, autos and technology that have outperformed, Exhibit 1.

But as a liquidity-driven rally, with very little support from the underlying economic and corporate data, which to date have shown few signs of reaching a turning point, we believe this rally is at risk of at least a partial reversal following the most recent FOMC statement released yesterday.

Is the Fed data-, date- or market-dependent?

October's FOMC statement gives us pause for thought as the statement was widely expected (including by us) to be dovish. The market-implied probability for a December increase in US interest rates had declined to its year low going into the FOMC meeting.

However, the insertion of language that highlights December's meeting as one where a rate increase will be considered appears to be an attempt to focus the market on a calendar date. The more hawkish tone of the statement also contrasts with the FOMC taking note of the slowing pace of US job growth. Commentary referring to the potential for recent economic and financial events to restrain economic activity has been removed.

In the context of a slowing US economy, the most recent FOMC statement leans towards the uncomfortable interpretation that, subject to benign market conditions, the US Fed aims to raise US rates in December with relatively little weight being given to the loss of near-term US economic momentum

Furthermore, as the ECB's thoughts on the need for additional monetary stimulus were published only days earlier, this statement also implies a Fed that is relaxed about the depreciation of the euro, which dropped by a further 2% against the dollar post the FOMC statement. This may help Europe, but will not ease concerns over the strength of the dollar on US corporate profits. An additional implication may be that Fed policymakers' concern has eased in terms of the potential for a destabilising rise in the dollar against emerging market currencies, an outcome that many investors continue to fear following the market declines during August.

Therefore, despite the initially positive US equity market reaction to the statement, we believe investors should reserve judgment; this looks more like a statement of intent to raise US interest rates in December, rather than to delay into 2016. It was only a few weeks ago that some commentators believed further US QE was just around the corner; that prospect now seems remote.

Conclusion

Incoming data during October continu to indicate that profits momentum is slowing on a global basis, and yet markets have rebounded strongly from the lows of September. Given the strong hints that the ECB will be loosening monetary policy further during December, yesterday's hawkish FOMC statement strikes a somewhat discordant note in this risk-on period for the markets.

The initially positive US equity market reaction to the statement may well prove unsustainable in our view. To us, subject to stable market conditions, the Fed appears much less dovish than we thought one month ago. While the looser-for-longer global monetary policy outlook may have been a reason not to panic and exit equities during August, it is not at all clear that October's mini rally will run much further without implicit encouragement from the US Fed.

Floor plans and programme

Deutsches Eigenkapitalforum
23 – 25 November 2015
Frankfurt / Main

Floorplans

One-on-one floors

3rd floor, One-on-ones 3001 - 3080



4th floor, One-on-ones 4001 - 4080



5th floor, One-on-ones 5001 - 5021



Main levels

Level E2, Sheraton Hotel



Level E1, Conference Center



As of 02.11.2015

Deutsches Eigenkapitalforum

DEUTSCHE BÖRSE CASH MARKET

KFW

Analyst's conferences
Fall 2015

Participants in alphabetical order

Company name	Sector	Day	Time	Room
1-10				
2G Energy AG	Green Technology	Monday, 23.11.2015	16:00-16:30	Paris
4SC AG	Pharma & Biotech	Monday, 23.11.2015	14:30-15:00	Oslo
A				
aap Implantate AG	Other	Tuesday, 24.11.2015	14:30-15:00	Oslo
Abivax S.A.	Pharma & Biotech	Monday, 23.11.2015	15:30-16:00	Oslo
adesso AG	Software	Tuesday, 24.11.2015	17:00-17:30	Madrid
Adler Modemärkte AG	Retail		1-on-1 only	
ADLER Real Estate AG	Other	Tuesday, 24.11.2015	10:30-11:00	Paris
Advanced Vision Technology (AVT) Ltd.	Industrial	Monday, 23.11.2015	13:00-13:30	Milan
Affimed N.V.	Pharma & Biotech	Monday, 23.11.2015	10:30-11:00	Oslo
Ahlers AG	Consumer	Wednesday, 25.11.2015	10:30-11:00	London
All for One Steeb AG	Software	Tuesday, 24.11.2015	11:00-11:30	Madrid
amp biosimilars AG	Pharma & Biotech	Monday, 23.11.2015	17:30-18:00	Oslo
artnet AG	Retail	Monday, 23.11.2015	13:00-13:30	Zurich
Asklepios Kliniken GmbH	Pharma & Biotech	Tuesday, 24.11.2015	13:30-14:00	Zurich
ATOSS Software AG	Software	Tuesday, 24.11.2015	10:00-10:30	Madrid
AURELIUS AG	Other	Wednesday, 25.11.2015	15:30-16:00	Madrid
AutoBank AG*	Banks	Wednesday, 25.11.2015	16:30-17:00	Madrid
B				
Basler AG	Technology	Tuesday, 24.11.2015	11:30-12:00	Milan
Bastei Lübbe AG*	Media	Wednesday, 25.11.2015	14:00-14:30	London
BB Biotech AG*	Pharma & Biotech	Monday, 23.11.2015	11:30-12:00	Oslo
Berentzen-Gruppe Aktiengesellschaft	Consumer	Tuesday, 24.11.2015	11:30-12:00	Zurich
bet-at-home.com AG*	Consumer	Tuesday, 24.11.2015	10:00-10:30	Zurich
Biofrontera AG*	Pharma & Biotech	Tuesday, 24.11.2015	13:00-13:30	Oslo
Borussia Dortmund GmbH & Co. KGaA	Media	Tuesday, 24.11.2015	11:00-11:30	Zurich
C				
C-QUADRAT Investment AG *	Financial Services	Monday, 23.11.2015	15:30-16:00	Madrid
CANCOM SE	Software	Tuesday, 24.11.2015	15:30-16:00	London
Capital Stage AG	Basic Resources		1-on-1 only	
CARBIOS S.A.	Chemicals	Monday, 23.11.2015	14:00-14:30	London
CENIT AG	Software	Tuesday, 24.11.2015	13:30-14:00	Madrid
CENTROTEC Sustainable AG	Industrial	Tuesday, 24.11.2015	18:00-18:30	Milan
CEWE KGaA	Consumer	Monday, 23.11.2015	11:30-12:00	Zurich
CHORUS Clean Energy AG	Green Technology	Monday, 23.11.2015	18:00-18:30	Paris
co.don AG*	Pharma & Biotech	Tuesday, 24.11.2015	13:30-14:00	Oslo
comdirect bank AG	Banks	Monday, 23.11.2015	14:30-15:00	Madrid
Constantin Medien AG*	Media	Wednesday, 25.11.2015	13:00-13:30	London
CropEnergies AG	Green Technology	Tuesday, 24.11.2015	14:00-14:30	London
D				
Daldrup & Söhne AG*	Green Technology	Monday, 23.11.2015	13:30-14:00	Paris
DATAGROUP AG	Software		1-on-1 only	
DEAG Deutsche Entertainment AG*	Media	Monday, 23.11.2015	14:00-14:30	Zurich
Delticom AG	Automobile		1-on-1 only	
DEMIRE Deutsche Mittelstand Real Estate AG	Other	Tuesday, 24.11.2015	11:00-11:30	Paris
Deutsche Beteiligungs AG	Financial Services	Wednesday, 25.11.2015	13:00-13:30	Madrid
Deutsche Börse AG	Financial Services	Monday, 23.11.2015	11:30-12:00	Madrid
Deutsche Lufthansa AG	Transportation		1-on-1 only	
DF Deutsche Forfait AG*	Financial Services	Wednesday, 25.11.2015	13:30-14:00	Madrid

Dürr Aktiengesellschaft	Other	Monday, 23.11.2015	11:00-11:30	Madrid
E				
Eckert & Ziegler Strahlen- und Medizintechnik AG*	Pharma & Biotech	Monday, 23.11.2015	11:00-11:30	Oslo
ecotel communication ag	Telecommunications	Monday, 23.11.2015	17:00-17:30	London
Einhell Germany AG*	Other	Monday, 23.11.2015	13:30-14:00	Zurich
Elmos Semiconductor AG	Technology	Tuesday, 24.11.2015	09:30-10:00	London
Energiekontor AG	Green Technology	Monday, 23.11.2015	17:30-18:00	Paris
Enterprise Holdings Limited	Insurance	Tuesday, 24.11.2015	14:30-15:00	Zurich
Epigenomics AG	Pharma & Biotech	Tuesday, 24.11.2015	11:30-12:00	Oslo
Ergomed plc.	Pharma & Biotech	Monday, 23.11.2015	16:00-16:30	Oslo
Erytech Pharma S.A.	Pharma & Biotech	Tuesday, 24.11.2015	10:00-10:30	Oslo
ETERNA Mode GmbH	Consumer	Tuesday, 24.11.2015	16:00-16:30	Zurich
euromicron AG*	Telecommunications	Monday, 23.11.2015	14:30-15:00	London
Evolva Holding SA	Consumer	Wednesday, 25.11.2015	10:00-10:30	London
Evotec AG*	Pharma & Biotech	Tuesday, 24.11.2015	14:30-15:00	London
exceet Group SE*	Technology	Monday, 23.11.2015	10:30-11:00	London
EYEMAXX Real Estate AG*	Financial Services	Tuesday, 24.11.2015	14:00-14:30	Zurich
F				
Fair Value REIT-AG	Financial Services	Tuesday, 24.11.2015	13:30-14:00	Paris
Ferratum Oyj	Financial Services	Monday, 23.11.2015	16:00-16:30	Madrid
FinLab AG*	Financial Services	Wednesday, 25.11.2015	16:00-16:30	Madrid
FinTech Group AG	Financial Services	Monday, 23.11.2015	16:30-17:00	Madrid
First Sensor AG*	Technology	Tuesday, 24.11.2015	10:30-11:00	Milan
Formycon AG*	Pharma & Biotech	Tuesday, 24.11.2015	14:00-14:30	Oslo
Francotyp-Postalia Holding AG	Industrial	Monday, 23.11.2015	14:00-14:30	Milan
G				
gamigo AG	Software	Tuesday, 24.11.2015	17:30-18:00	Zurich
GESCO AG	Industrial	Tuesday, 24.11.2015	16:00-16:30	Milan
GFT Technologies AG	Technology	Tuesday, 24.11.2015	16:00-16:30	London
GK Software AG	Software	Tuesday, 24.11.2015	09:30-10:00	Madrid
GLOBAL ECOPOWER	Green Technology	Monday, 23.11.2015	17:00-17:30	Paris
GRAMMER AG	Automobile	Wednesday, 25.11.2015	10:30-11:00	Madrid
GRENKELEASING AG	Financial Services	Tuesday, 24.11.2015	13:30-14:00	Milan
H				
Hannover Rück SE	Insurance		1-on-1 only	
Hawesko Holding AG	Retail	Monday, 23.11.2015	11:00-11:30	Zurich
Heliocentris Energy Solutions AG*	Green Technology	Monday, 23.11.2015	13:00-13:30	Paris
HELMA Eigenheimbau AG*	Construction	Tuesday, 24.11.2015	14:00-14:30	Paris
Highlight Communications AG	Media	Wednesday, 25.11.2015	13:30-14:00	London
HOCHDORF Holding AG*	Other	Tuesday, 24.11.2015	09:00-09:30	Zurich
Hypoport AG*	Financial Services	Wednesday, 25.11.2015	14:00-14:30	Madrid
I				
INDUS Holding AG	Industrial		1-on-1 only	
init innovation in traffic systems AG	Technology	Monday, 23.11.2015	11:30-12:00	London
Integer.pl SA	Transportation	Monday, 23.11.2015	10:30-11:00	Milan
Intershop Communications AG	Software	Monday, 23.11.2015	15:30-16:00	London
InVision Aktiengesellschaft	Software	Tuesday, 24.11.2015	13:00-13:30	Madrid
ISARIA Wohnbau AG*	Other	Tuesday, 24.11.2015	13:00-13:30	Paris
ISRA VISION AG	Technology	Tuesday, 24.11.2015	11:00-11:30	Milan
ItN Nanovation AG*	Industrial	Tuesday, 24.11.2015	17:30-18:00	Milan
IVU Traffic Technologies AG*	Software	Tuesday, 24.11.2015	09:00-09:30	Madrid
J				
JDC Group AG*	Financial Services	Monday, 23.11.2015	17:00-17:30	Madrid
JENOPTIK AG	Technology		1-on-1 only	
K				
Klöckner & Co SE	Other	Tuesday, 24.11.2015	11:00-11:30	London
KROMI Logistik AG	Industrial	Tuesday, 24.11.2015	14:30-15:00	Milan

KTG Agrar SE*	Consumer	Wednesday, 25.11.2015	11:00-11:30	London
KTG Energie AG	Basic Resources	Monday, 23.11.2015	11:00-11:30	Paris
L				
Leifheit AG	Consumer	Wednesday, 25.11.2015	11:30-12:00	London
LifeWatch AG	Pharma & Biotech	Monday, 23.11.2015	13:30-14:00	London
Lotto24 AG	Retail	Tuesday, 24.11.2015	09:30-10:00	Zurich
LPKF Laser & Electronics AG	Technology	Tuesday, 24.11.2015	10:00-10:30	London
M				
M.A.X. Automation AG	Industrial		1-on-1 only	
MagForce AG	Pharma & Biotech	Monday, 23.11.2015	13:30-14:00	Oslo
Masterflex SE	Industrial	Tuesday, 24.11.2015	16:30-17:00	Milan
MBB SE*	Industrial	Monday, 23.11.2015	14:30-15:00	Milan
Mensch und Maschine Software SE*	Software	Tuesday, 24.11.2015	14:00-14:30	Madrid
migme Limited	Media	Monday, 23.11.2015	10:30-11:00	Zurich
MLP AG*	Financial Services	Wednesday, 25.11.2015	11:30-12:00	Madrid
MOLOGEN AG	Pharma & Biotech	Tuesday, 24.11.2015	15:30-16:00	Oslo
MorphoSys AG	Pharma & Biotech	Tuesday, 24.11.2015	10:30-11:00	Oslo
MPC Münchmeyer Petersen Capital AG	Financial Services		1-on-1 only	
msg life ag*	Software	Tuesday, 24.11.2015	16:00-16:30	Madrid
mutares AG	Other	Wednesday, 25.11.2015	14:30-15:00	Madrid
mVISE AG	Software		1-on-1 only	
mybet Holding SE*	Consumer	Tuesday, 24.11.2015	10:30-11:00	Zurich
N				
Nanogate AG	Other	Tuesday, 24.11.2015	09:00-09:30	Milan
Nemetschek AG	Software	Tuesday, 24.11.2015	13:00-13:30	London
Neovacs S.A.	Pharma & Biotech	Tuesday, 24.11.2015	16:00-16:30	Oslo
Neue ZWL Zahnradwerk Leipzig GmbH*	Automobile	Tuesday, 24.11.2015	13:00-13:30	Zurich
Newron Pharmaceuticals S.p.A.	Pharma & Biotech	Tuesday, 24.11.2015	11:00-11:30	Oslo
Nexus AG	Software	Tuesday, 24.11.2015	11:30-12:00	Madrid
O				
OHB SE	Other	Tuesday, 24.11.2015	09:30-10:00	Milan
OTI Greentech Group AG	Green Technology	Monday, 23.11.2015	15:30-16:00	Paris
P				
PAION AG	Pharma & Biotech	Tuesday, 24.11.2015	09:00-09:30	Oslo
PANTALEON Entertainment AG*	Media	Wednesday, 25.11.2015	15:30-16:00	London
PA Power Automation AG	Software		1-on-1 only	
paragon AG	Automobile	Monday, 23.11.2015	18:00-18:30	Milan
Peach Property Group*	Other	Tuesday, 24.11.2015	17:00-17:30	Zurich
Pfeiffer Vacuum Technology AG	Industrial	Tuesday, 24.11.2015	13:30-14:00	London
Phoenix Solar Aktiengesellschaft	Industrial	Monday, 23.11.2015	14:30-15:00	Paris
Piteco Spa	Software	Monday, 23.11.2015	17:30-18:00	London
PNE WIND AG*	Green Technology	Monday, 23.11.2015	11:30-12:00	Paris
Probiodrug AG*	Pharma & Biotech	Monday, 23.11.2015	17:00-17:30	Oslo
Progress-Werk Oberkirch AG*	Automobile	Monday, 23.11.2015	17:00-17:30	Milan
PSI Aktiengesellschaft	Software	Tuesday, 24.11.2015	14:30-15:00	Madrid
Publity AG*	Other	Tuesday, 24.11.2015	14:30-15:00	Paris
PVA TePla AG	Industrial	Monday, 23.11.2015	11:30-12:00	Milan
R				
Reply SpA	Software	Tuesday, 24.11.2015	16:30-17:00	Madrid
RIB Software AG	Software	Tuesday, 24.11.2015	09:00-09:30	London
Rickmers Holding AG	Transportation	Tuesday, 24.11.2015	16:30-17:00	Zurich
ROFIN-SINAR Technologies Inc.	Technology	Tuesday, 24.11.2015	13:00-13:30	Milan
S				
S&T AG	Technology	Monday, 23.11.2015	13:00-13:30	London
Sartorius AG	Pharma & Biotech	Monday, 23.11.2015	11:00-11:30	London
Schaltbau Holding AG	Industrial	Tuesday, 24.11.2015	15:30-16:00	Milan
SFC Energy AG	Green Technology	Monday, 23.11.2015	14:00-14:30	Paris

SINGULUS TECHNOLOGIES AG	Industrial	Monday, 23.11.2015	15:30-16:00	Milan
SinnerSchrader AG	Software	Tuesday, 24.11.2015	17:30-18:00	Madrid
SKW Stahl-Metallurgie Holding AG	Chemicals	Tuesday, 24.11.2015	09:30-10:00	Paris
SLM Solutions Group AG	Industrial	Monday, 23.11.2015	13:30-14:00	Milan
SMT Scharf AG	Industrial	Monday, 23.11.2015	17:30-18:00	Milan
Snowbird AG	Retail	Monday, 23.11.2015	17:00-17:30	Zurich
SNP Schneider-Neureither & Partner AG*	Software	Monday, 23.11.2015	16:00-16:30	London
Softing AG	Industrial	Monday, 23.11.2015	11:00-11:30	Milan
Software AG	Software		1-on-1 only	
SOLUTIONS30 SE	Technology	Monday, 23.11.2015	18:00-18:30	London
Store Electronic Systems SA	Industrial	Monday, 23.11.2015	16:30-17:00	London
STRATEC Biomedical AG	Pharma & Biotech	Tuesday, 24.11.2015	10:30-11:00	London
SURTECO SE	Industrial	Monday, 23.11.2015	16:00-16:30	Milan
SYGNIS AG	Pharma & Biotech	Monday, 23.11.2015	16:30-17:00	Oslo
SYZYGY AG	Media	Monday, 23.11.2015	14:30-15:00	Zurich
SÜSS MicroTec AG	Technology	Tuesday, 24.11.2015	10:00-10:30	Milan
T				
TAKKT AG	Retail	Monday, 23.11.2015	15:30-16:00	Zurich
technotrans AG*	Industrial	Tuesday, 24.11.2015	17:00-17:30	Milan
telegate AG	Media	Wednesday, 25.11.2015	14:30-15:00	London
TLG IMMOBILIEN AG	Other	Monday, 23.11.2015	14:00-14:30	Madrid
TOMORROW FOCUS AG	Software	Tuesday, 24.11.2015	10:30-11:00	Madrid
TOM TAILOR Holding AG	Consumer		1-on-1 only	
Transgene S.A.	Pharma & Biotech	Monday, 23.11.2015	13:00-13:30	Oslo
U				
Uniwheels AG	Automobile	Wednesday, 25.11.2015	10:00-10:30	Madrid
USU Software AG	Software	Tuesday, 24.11.2015	15:30-16:00	Madrid
V				
Verona Pharma plc	Pharma & Biotech	Tuesday, 24.11.2015	09:30-10:00	Oslo
Villeroy & Boch AG	Consumer		1-on-1 only	
Viscom AG	Industrial	Tuesday, 24.11.2015	14:00-14:30	Milan
VST BUILDING TECHNOLOGIES AG*	Construction	Tuesday, 24.11.2015	15:30-16:00	Zurich
W				
Wacker Chemie AG	Chemicals	Monday, 23.11.2015	13:00-13:30	Madrid
Wacker Neuson SE	Industrial		1-on-1 only	
WashTec AG	Industrial	Monday, 23.11.2015	16:30-17:00	Milan
WCM Beteiligungs- und Grundbesitz-Aktiengesellschaft	Other	Tuesday, 24.11.2015	11:30-12:00	Paris
WILEX AG	Pharma & Biotech	Monday, 23.11.2015	14:00-14:30	Oslo
Wincor Nixdorf AG	Software	Monday, 23.11.2015	13:30-14:00	Madrid
Z				
ZEAL Network SE	Retail	Monday, 23.11.2015	16:00-16:30	Zurich
ZhongDe Waste Technology AG	Green Technology	Monday, 23.11.2015	16:30-17:00	Paris
zooplus AG	Retail	Monday, 23.11.2015	16:30-17:00	Zurich

* Presentation in German

Consumer

Leifheit AG

General retailers

On the front foot

Ahead of Q3 results on 11 November, Leifheit's focus on brands and margins continues to deliver, with a double-digit rise in H115 underlying EBIT and the prospect of more of the same for the rest of the year (reported 2014 was particularly flattered by currency). In addition, there should be increasing benefit from a newly-refined strategy, notably a 'full category' product and price approach to complement longstanding commitment to innovation, increased e-commerce, brand presence at the point of sale, targeted expansion and cost control. Strong finances (€59m net cash at June) should facilitate this and a generous dividend payout.

Further progress in H115

The half to June saw a similar pattern to 2014 with growth (revenue +5%) driven, as intended, by successful product innovation in Leifheit's largest branded operations, cleaning and laundry care. Germany remained buoyant (revenue +9%), while Eastern Europe, an identified growth market, was once more subdued by Russia and Ukraine. The Volume business, which is no longer the company's strategic focus (just 15% of overall revenue), was patchy, as expected. The overall performance at the EBIT level was again impressive. Adjusting for €1.9m boost from foreign currency (€0.5m in H114), underlying EBIT in the first half was up 12%.

Consensus forecasts look sensible

Reported 2014 profit was materially flattered by currency, hence the lower levels forecast for this year (see below). August's guidance of 2015 EBIT at the top end of its c €19-20m forecast range appears reasonable, assuming c €1.5m currency benefit, since this suggests in H2 a similar double-digit increase in underlying EBIT to that in the first half. This would fit with management's slight raising of full-year revenue expectations to +3-4% and positive initial comment about the new strategy.

Valuation: Be patient

While Leifheit's premium rating (prospective P/E of c 18.6x) may offer little room for disappointment, the implementation of its enhanced strategy is still in its early stages (by definition, 'Leifheit 2020' is a medium-term play). We are encouraged by this renewed emphasis on growth, with management's goal of organic top-line gain of 5-6% pa and EBIT margin of 8%. We are also encouraged by the scale of investor support when the majority shareholding was sold at €49 per share in April.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/13	220.9	13.3	2.16	1.50	21.3	3.3
12/14	220.7	19.8	2.97	1.80	15.5	3.9
12/15e	231.7	19.0	2.48	1.83	18.6	4.0
12/16e	241.3	17.0	2.75	1.95	16.8	4.2

Source: Company data, Thomson Reuters

Price €46.10
Market cap €231m

Share price graph

Share details

Code	LEI
Shares in issue	5.0m
Net cash (€m) at June 2015	58.9

Business description

Leifheit is a leading European brand supplier of household items, notably cleaning, laundry care, kitchen goods and well-being.

Bull

- Well-known brands with strong market positions.
- Product innovation.
- Strong finances (net cash).

Bear

- Pressures on consumer spending.
- Secondary Volume business in decline (being managed for profitability).
- Exchange rate exposure (52% of H115 revenue from outside Germany).

Analyst

Richard Finch +44 (0)20 3077 5700

tmt@edisongroup.com

EDISON

Snowbird AG

Textiles

IPO placing underpins strong growth

Prior to Snowbird's IPO in September 2014, management invested in capacity to meet rising demand for down and down products in China and enable greater penetration of export markets. The IPO placing funds help finance the working capital required to take full advantage of this greatly increased capacity and thus drive growth.

Key strategic steps completed during H115

Snowbird completed three strategic activities during H115. It completed ramping-up production at its second facility for processing down. The facility has increased capacity by more than four times to over 4,000t/year, is equipped with software controlled equipment that is expected to improve productivity by around 30% while maintaining industry-leading down purity levels, and has extensive warehousing space for inventories of either processed or unprocessed down. It completed the second sewing facility for manufacturing down-filled clothing and bedding. This more than doubles production capacity and is equipped with computerised sewing machines, improving production efficiency and garment quality. It also opened a small sales office near Frankfurt to sell down bedding in Europe.

Strategy delivers strong growth during H115

Total H115 revenues rose by 24% year-on-year to €96.9m. Down sales fell by 18%, through a combination of lower average selling prices and reduced demand from a key customer in Taiwan, which the order book indicates will recover during Q3. Domestic down sales rose by 50%. Sales of down clothing grew by 167%, reflecting strong demand from export customers. Gross margin improved by 4.6pp, reflecting a greater proportion of revenues from clothing and bedding. PBT grew by 38% to €29.3m. Net cash reduced by €35.2m to €11.5m following a €22.3m increase in inventory. Management used the majority of the €9.5m net funds raised at the IPO for working capital, helping to stock-up on raw materials during H1, while prices were seasonally low, and to build up finished goods ahead of the seasonally stronger second half, when most purchases of warm clothes are made.

Valuation: Trading on an unusually low P/E

The share price has been adversely affected by problems associated with other Germany-listed Chinese textile companies, resulting in low P/E ratios. Our analysis of China-listed textile companies gives an average prospective P/E of 16.5x, suggesting scope for a rerating, though we note the potentially dilutive impact of a further fund-raising and expiry of the post-IPO lock-up period on 4.5m shares.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	136.9	39.0	0.94	N/A	5.5	N/A
12/14	191.5	54.0	1.26	0.25	4.1	4.8
12/15e	231.3	69.0	1.63	0.33	3.2	6.3
12/16e	292.4	88.5	2.10	0.42	2.5	8.1

Source: Company data, Thomson Reuters

Price	€4.95
Market cap	€156m

Share price graph

Share details

Code	8S9
Shares in issue	31.6m
Net cash (€) as at Jun15	11.5

Business description

Snowbird is a China-based manufacturer of processed down (50% FY14 revenues), down-filled clothing (39%), down-filled bedding (7%) and work clothing for OEMs (4%). It is one of the largest producers of down in China. The group listed in September 2014 at €6.0/share.

Bull

- Strong growth in demand for down-filled clothing and bedding in China driven by continued improvement in disposable incomes.
- Development of exports (26% FY14 revenues).
- Investment in technology results in more efficient processing and ability to produce higher purity down than competitors.

Bear

- Price of the main raw material, unprocessed down, subject to seasonal fluctuation (less expensive in H1) and supply potentially affected by outbreaks of bird-flu.
- Demand for down-filled clothing seasonal (stronger in H2).
- Low free float (22%).

Analysts

Anne Margaret Crow +44 (0)20 3077 5700

Roger Johnston +44 (0)20 3077 5722

industrials@edisongroup.com

Borussia Dortmund

Travel & leisure

Meeting its goals

Ahead of Q1 results on 13 November, a positive annual report and continued on-field success reinforce confidence in our current-year forecasts and a possible step change in returns in FY17, assuming Champions League qualification. Forecasts for next year suggest a near-doubling in pre-transfer EBITDA (our key metric) and strong cash generation for player investment (we estimate €74m net cash at June 2017). An EV/EBITDA (pre-transfer) of 5x FY17e seems to ignore the long-term potential of powerful brand development and valuable media rights.

Current-year resilience

Assuming progress to Europa League's knockout stage (on course after three of six group matches), we expect pre-transfer EBITDA to lag only slightly behind FY15 (before the estimated c €12m benefit of a 'negative outcome' insurance claim), which is impressive, given the absence of the Champions League. Profit should be bolstered by a new deal on the international marketing of Bundesliga media rights and by higher Europa League fees. Excluding transfers, our forecasts are in line with annual report guidance. Although surprising, given robust finances, the halving of the FY15 dividend reflects management focus on sporting achievement.

FY17 Champions League kicker

Our forecasts assume qualification for next year's Champions League (also on track after a third of the Bundesliga season) and an advance to its knockout stage, as in the three years to FY15. As well as clearly boosting advertising and merchandising, the Champions League may be expected to generate c €30m more TV marketing revenue for Dortmund than the Europa League in the current period. While mindful of cost pressures associated with success, we look for just a 7% rise in labour expenses as the squad is already run on Champions League lines.

Valuation: Too low

Dortmund's season has begun as well as could have been envisaged, hence justifiable optimism about renewed access to Champions League riches, yet the FY17e EV/EBITDA rating is not extravagant. In addition, the scope for transfer gains remains high. Albeit notional, the surplus of market value to net player assets is c €190m if the reported June 2015 carrying value of €96m is set against sports website www.transfermarkt.de's current valuation of €287m.

Edison estimates

Year end	Revenue* (€m)	EBITDA* (€m)	PBT** (€m)	EPS** (€)	DPS (€)	EV/EBITDA* (x)
06/14	256.3	44.7	37.1	0.51	0.10	9.2
06/15	263.6	48.0***	44.2***	0.43***	0.05	7.1
06/16e	256.0	34.0	25.5	0.23	0.05	9.8
06/17e	300.0	60.0	51.0	0.47	0.05	4.9

Source: Borussia Dortmund, Edison Investment Research. Note: *Before player transfer income. **PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments. ***Including insurance claim benefit (our estimate c €12m).

Price	**€4.00**
Market cap	**€368m**

Share price graph

Share details

Code	BVB
Shares in issue	92.0m
Net cash (€) as at June 2015 including finance leases	29.6m

Business description

The group operates Borussia Dortmund, a leading German football club, recent back-to-back champions of the Bundesliga and competing in this season's UEFA Europa League (Round of 16 participant in 2014/15 UEFA Champions League).

Bull

- One of the best supported clubs in Europe with major brand and stadium assets.
- Successful squad of players with significant transfer value potential.
- Strong finances (net cash).

Bear

- Unpredictable business (eg yet to prove return to forthcoming Champions League), although increasingly mitigated by long-term commercial contracts.
- Subject to external governing bodies.
- Pressures on consumer spending.

Analyst

Richard Finch +44 (0)20 3077 5700

consumer@edisongroup.com

Borussia Dortmund is a client of Edison Investment Research Limited

EDISON

Lotto24 AG

Travel & leisure

Well positioned in the online lottery market

Lotto24 extended its market leadership in 2014, with its market share up from 12% to 21%. This demonstrates its core USPs: first mover advantage in the German online lottery market, management experience and marketing know-how. Top-line growth remains very strong (2015 billings forecast by management to increase by 50%+). The business continues to invest heavily in technology and marketing as it scales up, but a €7.7m capital increase in July 2015 should largely cover funding requirements until break even. There is plenty of room for online lottery to take a bigger slice of the overall German lottery market.

Online lottery still only 6% of total market

The German lottery market is estimated to be worth €6.9bn, with only modest growth forecast to 2019 (source: GBGC). The online segment was closed between 2009 and 2012, when new licences were awarded (advertising permitted from 2013). Online is growing rapidly, up over 50% in 2014 to €390m (source: Deutscher Lottoverband). However, this is still only 6% penetration (2013: 4%), versus 54% for online banking and 45% for online holidays (source: Bundesverband deutscher Banken), suggesting plenty of scope for continued strong market growth. Mobile is an important driver, allowing lottery ticket purchases anywhere, any time.

Lotto24 billings growing at 50%+

Billings jumped by 168% in 2014, to €82m and Lotto24 expects over 50% growth in 2015 (H115 up 70% to €62.6m). H115 growth was assisted by high jackpots, which stimulate customer interest. The 16 federal state lotteries still account for over 70% of the market, but Lotto24's 2014 market share gain (to 21%) suggests that it is successfully capitalising on its first mover advantage. It is materially bigger than the next nine private providers combined. This is important since once they have signed up, lottery customers are generally very loyal.

Valuation: Still early-stage

Lotto24 has an attractive business model with no bookmaking risk and long-term contracts with all 16 lottery operators. Investment in marketing and IT means that it is still loss-making: 28 September management guidance was that 2015 EBIT and net loss will be on a par with 2014. Market consensus is for Lotto24 to achieve over €3m of profit before tax (PBT) in 2018 and the brokers' current mean target price is €4.88 (source: Thomson).

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	2.8	(11.2)	(68)	0.0	N/A	N/A
12/14	7.7	(14.2)	(79)	0.0	N/A	N/A
12/15e	12.3	(12.6)	(49)	0.0	N/A	N/A
12/16e	18.0	(5.7)	(21)	0.0	N/A	N/A

Source: Company data, Thomson Reuters

Price	**€3.64**
Market cap	**€88m**

Share price graph

Share details

Code	LO24
Shares in issue	24.15m
Net cash (€m) at 30 June 2015*	3.7

*Before a gross €7.7m capital increase on 14 July.

Business description

Lotto24 is Germany's market leader in the online market of state-licensed lotteries. It receives commissions when customers enter lotteries such as 'Lotto 6aus49' and does not bear any bookmaking risk. It was founded by Tipp24 (now ZEAL Network) in 2010 and spun off and listed in 2012.

Bull

- Strong organic growth.
- Management expertise and experience.
- Scalable technology, online and mobile.

Bear

- Still in a start-up phase and loss-making (consensus is for break even in 2017).
- Competitive markets.
- Ongoing regulatory restrictions and uncertainties (but no material recent change).

Analysts

Jane Anscombe	+44 (0)20 3077 5740
Eric Opara	+44 (0)20 3681 2524

tmt@edisongroup.com

EDISON

ZEAL Network SE

Travel & leisure

Leveraging lottery expertise

The odds have been against ZEAL over the past six months, with two large winners of the EuroMillions lottery affecting short-term results. However, the underlying secondary lottery business remains highly profitable and cash generative and EBIT has benefited from a change in UK gaming tax rules from December 2014. This enables ZEAL to invest in developing its B2B and B2G businesses to take advantage of new opportunities as lottery markets liberalise and move online. ZEAL's new dividend policy is to pay out at least €2.80 a year, implying a 2015 yield of over 6%.

Expanding into new markets

About 95% of revenues still come from the B2C segment where MyLotto24 organises 'secondary lotteries' based on European lotteries. It is a mature and profitable business but results can fluctuate materially since ZEAL bears the bookmaking risk (partly hedged). The B2B/B2G segment provides technology and marketing services to business and government clients such as the ONCE Spanish lottery operator and on a white-label basis. A UK JV has launched GeoLotto and a new instant win game. ZEAL's executive board has changed in 2015 with former CMO Dr Helmut Becker taking over as CEO on Dr Hans Cornehl's retirement, Jonas Mattsson joining as CFO and Susan Standiford becoming CTO.

Strong growth in profits expected in FY15/6

H115 revenue fell 65% from €68.2m to €25.7m due to a large prize payout in May (statistically adjusted total operating performance fell 8% to €65.5m). H115 EBIT increased from €6.0m to €18.5m, largely due to a €9.2m reduction in UK gaming duty (now levied on a point of consumption basis, which will benefit the full year by €15-18m since most of MyLotto24's customers are outside the UK). Of the H115 EBIT, B2C generated €26.9m, B2B/B2G a loss of €4.1m and reconciling items a loss of €4.3m. After another big jackpot payout in September, management's guidance is for revenue of €120-130m and EBIT of €20-30m (previously €35-40m). However, ZEAL's strong financial position and successful relocation to London in 2014 have allowed it to guide to a dividend payout of €2.80/share in 2015.

Valuation: Attractive yield and growth opportunities

An FY15e EV/EBITDA of c 5.0x and prospective yield of 6.7% suggest plenty of upside if the B2B/B2G segment takes off, even allowing for a discount for the unexpected nature of jackpot pay-outs.

Consensus estimates

Year end	Revenue* (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/13	133.7	18.8	1.23	0.00	33.9	N/A
12/14	145.7	12.5	0.63	7.50**	66.3	3.9
12/15e	119.5	28.4	2.74	2.80	15.2	6.7
12/16e	151.4	39.8	3.81	2.84	11.0	6.8

Source: Company data, Thomson Reuters. Note: *Revenue is total operating performance; **One-off special.

Price €41.75

Market cap €351m

Share price graph



Share details

Code	TIM
Shares in issue	8.4m
Net cash (€m) at 30 June 2015	111.7

Business description

ZEAL is an online lottery business, founded in 1999 (the holding company name changed from Tipp24 in November 2014). It offers both consumer-facing lottery games and business-to-business (B2B) solutions, under several brands. MyLotto24 is licensed by the UK Gambling Commission.

Bull

- Online lottery expertise.
- New growth opportunities in Europe and the US as lotteries move online.
- Strong balance sheet.

Bear

- Unexpected earnings fluctuations due to large (unhedged) lottery payouts.
- Competitive markets.
- Regulatory and tax/VAT risks.

Analysts

Jane Anscombe +44 (0)20 3077 5740
Eric Opara +44 (0)20 3681 2524
tmt@edisongroup.com

Berentzen Gruppe AG

Food & beverages

Slimmed down and getting healthier

As a leaner, fully restructured business, Berentzen is successfully diversifying into higher-margin 'healthy' non-alcoholic drinks. The 2014 Citrocasa acquisition contributes to a consensus 4.5% three-year revenue CAGR, with EBIT margins expanding 370bp to 7%. The stock has risen 85% ytd, but still trades at an attractive 12.0x 2017e P/E and 4.1x EV/EBITDA. In the short term, Aurelius's 56% holding remains an overhang.

Restructuring by Aurelius complete

Following years of instability and a complex shareholding structure, Berentzen was taken over by Aurelius in 2008 and has now successfully returned to profitability. With a newly rationalised cost base, the company has diversified away from pure-play spirits, with a particular focus on health and energy drinks. Non-alcoholic beverages and fresh juice systems now comprise 38% of total revenues.

Revenue growth from 'healthy' drinks

Against a backdrop of lacklustre market conditions and disappointing initial results from the Sinalco partnership, group sales are expected to grow from €154m in 2014 to €175m by 2017 (consensus estimates). The increase is predominately due to the acquisition of TMP/Citrocasa (fruit juice systems) in 2014, which now comprises c 10% of revenues. Mio Mio Mate (energy tea) also showed high double-digit growth in H115 and management expects these 'healthier' drinks to leverage the established distribution network, implying limited additional investment.

Citrocasa helps EBIT margin expansion

Group cost-cutting initiatives have already provided €17m savings and, with its high cash conversion rates, management expects Citrocasa to contribute meaningfully to margin expansion. This is reflected in a consensus 7% EBIT margin in 2017.

Attractive 2017 multiples, but overhang remains

On the back of Berentzen's new strategy, the share price has risen 85% ytd. The stock trades on a 2015e P/E of 29.1x but, with growing profits, this falls to 11.9x in 2017e. Together with a c 4.1x EV/EBITDA, the valuation seems attractive vs larger peers. The conversion of all preference shares into ordinary shares has simplified the shareholding structure, although Aurelius's 56% holding remains an overhang.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/14	153.5	6.5	0.44	0.16	16.3	2.2
12/15e	162.8	4.3	0.25	0.14	29.1	1.9
12/16e	169.0	6.2	0.43	0.15	16.9	2.1
12/17e	175.3	8.5	0.61	0.20	11.9	2.7

Source: Company data, Thomson Reuters

Price	€7.28
Market cap	€70m

Share price graph



Share details

Code	BEZ
Shares in issue	9.6m
Net debt (€m) at end December 2014	11.2

Business description

Berentzen is a German manufacturer of alcoholic and non-alcoholic drinks and a provider of fresh juice systems. Germany represents 83% of sales, where it has 4% market share in spirits. Its two main spirits brands are Berentzen and Puschkin. Non-alcoholic and fresh juice systems now comprise 38% of sales.

Bull

- The company has finalised its restructuring programme and has returned to profitability.
- Growth in non-alcoholic drinks with success of Mio Mio Mate and the acquisition of Citrocasa, which in turn benefit from the existing German distribution network.
- Recent share buyback scheme of €1.5m should support the shares.

Bear

- German spirits market is in structural decline. The loss of Pepsi as a concession partner in 2014 has not been fully replaced by Sinalco.
- Turkish business has only recently reached operational break-even and may fail to fully stabilise.
- Significant 56% overhang of major shareholder.

Analyst

Victoria Pease +44 (0)20 3077 5700
consumer@edisongroup.com

artnet AG

Retail, internet

Online art market specialist

artnet has a strong reputation supplying online data and services to the global fine art market. The group has been investing heavily in the functionality and user experience of its website, at short-term cost to profits. However, the spend has given it the tools to exploit opportunities afforded by the growing online fine art market and to increase advertising revenues. Success in building its online auctions business is key to top-line growth. The share price is at a discount to other quoted art and online businesses, which should narrow with a return to profitability.

Good Q2 progress in euros

Q215 results showed good progress expressed in euros, with the currency translation restraining reported performance in US dollars. artnet News is becoming well established as a prime source of market information, with monthly unique visits averaging 1.3 million over the first six months. The aim is for it to become self-sustaining by the year end. Higher traffic is helping drive advertising revenues from vendors of luxury goods, lifting the performance of the Gallery segment in both revenue and margin. Costs in H115 have been kept well under control and full-year guidance remains consistent with our projections.

Online art market established and growing

The latest Hiscox Online Art Trade Report 2015 gives the value of the global online art market at an estimated \$2.64bn in 2014, up 68% on the prior year and accounting for 4.8% of the estimated \$55.2bn value of the global art market. It projects that the value of the online art market could reach \$6.3bn in 2019, with the key drivers relating to searchability and discoverability. 84% of transactions are at under £10k. The size of the potential prize has attracted a large number of participants and consolidation, and partnerships are gaining pace.

Valuation: Discounted

The global quoted cohort of art-related stocks has performed very poorly to date in 2015, with the initial excitement of Etsy's flotation back in April quickly ebbing away. With artnet's return to profitability (post the heavy burden of exceptional costs in 2014) and with increased consistency in the investment story, its market valuation is looking more firmly underpinned.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	13.0	0.1	3.2	0.0	61.3	0.0
12/14	13.9	(0.6)	(14.1)	0.0	N/A	0.0
12/15e	15.5	0.3	3.0	0.0	65.3	0.0
12/16e	16.6	0.6	7.1	0.0	27.6	0.0

Source: artnet, Edison Investment Research

Price	€1.96
Market cap	€11m

Share price graph

Share details

Code	ART
Shares in issue	5.631m
Net cash (€m) at end June 2015	0.28

Business description

artnet is an online business offering an integrated range of information and transaction services in the fine art, design and decorative art markets. It has four divisions: Price Database, Galleries, Auctions and News.

Bull

- artnet News gaining traction.
- Growth in luxury advertising.
- Online art trading gaining share.

Bear

- Delayed benefits from investment in website.
- Crowded competitive landscape.
- Need for strong marketing/PR investment.

Analysts

Fiona Orford-Williams +44 (0)20 3077 5739
Jane Anscombe +44 (0)20 3077 5740
media@edisongroup.com

artnet is a research client of Edison Investment Research Limited

Constantin Medien AG

Media

Firing on all cylinders

All Constantin Medien's divisions are in good shape: investments in technology and platform are starting to help the top line, key Sports rights are locked in and it is enjoying a strong box office performance in Film. Across the industry, demand for quality film, TV and sports content continues to grow and the company is very well placed to benefit from these trends.

Strategy: Managing the digital transformation

With viewing habits becoming more fragmented, Constantin Medien is ensuring that its brands are available to view anywhere at any time. In Film, this means creating brands that can be revitalised time and again across different media and a broader coverage of the value chain (more detail in the report on its subsidiary Highlight Communications on page 20). In Sports, it has invested heavily in its technical capabilities and content: Sport1 is now offered as a free and pay-TV service, online both via its website and via its Player, mobile and also via digital radio. Content investment has also increased, notably with the addition of UEFA Europa League rights over all platforms in Germany, alongside extending its broad-based motor sports, hockey, basketball and volleyball rights.

Outlook: Rights locked in, firing on all cylinders

Key rights have been locked in and its sports divisions should perform well in the coming 12 months; Sport1 is growing reach and audience share, PLAZAMEDIA has renewed its contract with ZDF to produce the Champions League games and TEAM has renewed its marketing contract with UEFA until 2020/21, and subject to TEAM's performance, up to the season 2023/24. Alongside this, its film division is also performing well, against a difficult basis of comparison; *Fack ju Göhte 2* looks set to be the biggest theatrical movie of the year, and *Er ist wieder da* is also performing very well. In August, management increased guidance for the year to revenues between €450m and €490m with net income of €2-4m.

Valuation: Quality branded content in demand

The demand for high-quality content is increasing as the new OTT platforms start to compete with established Pay and Free TV channels; companies such as Constantin Medien, with strong brands, should benefit from this. While its FY16 EV/EBIT (c 8.8x) and P/E (16.7x) ratings are broadly in line with peers, we see scope for ratings expansion in this sector, which continues to consolidate.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	458	(3.1)	(14.0)	0.0	N/A	N/A
12/14	488	8.4	(3.7)	0.0	N/A	N/A
12/15e	481	15.6	5.7	0.0	32.3	N/A
12/16e	501	21.7	11.0	0.0	16.7	N/A

Source: Company data, Thomson Reuters

Price	**€1.84**
Market cap	**€172m**

Share price graph

Share details

Code	EV4
Shares in issue	93.6m
Net debt (€m) at June 2015	30.4

Business description

Constantin Medien owns and operates its own portfolio of sports channels under the Sport1 brand and the sports production business PLAZAMEDIA. Through its 52% investment in Switzerland-based Highlight Communications it consolidates the activities of Germany's leading film group, Constantin Film, as well as the activities of TEAM, one of the world's leading sports and event marketing groups, as well as marketing and distribution organisation Highlight Event and Rainbow Home Entertainment.

Bull

- Strong position in Germany for film, TV production and sports.
- Increasing demand for quality content from OTT platforms.
- Key rights locked in.

Bear

- Investment in film and TV production can be hit and miss.
- Sports rights inflation continues unabated.
- Revenue risk for PLAZAMEDIA if the contract with Sky cannot be retained beyond the 2016/17 season.

Analysts

Bridie Barrett	+44 (0)20 3077 5727
Fiona Orford Williams	+44 (0)20 3077 5739
Dan Ridsdale	+44 (0)20 3077 5729

tmt@edisongroup.com

Highlight Communications AG

Media

Excellent H2 theatrical pipeline

With an excellent film slate for the second half and the TEAM contract with UEFA renewing until 2021, earnings visibility is enviably strong for a focused content play. This does not seem to be captured in Highlight's EV/EBIT rating, which stands at a considerable discount to peers.

Creating a portfolio of strong content brands

With audience viewing of film and TV entertainment becoming more fragmented, management is focused on creating a portfolio of brands that can drive ancillary revenue streams (eg through games or related TV shows) and create the possibility of global exploitation. *Resident Evil* and *Fantastic Four* are good examples of this strategy in action, as is its adaptation of *Shadowhunters* for TV. Outside film, TEAM, having met necessary performance criteria, has reached an agreement to act as UEFA's exclusive agent for UEFA club competitions from the 2015/16 to the 2020/21 seasons, and subject to TEAM's performance, will do so up to 2023/24.

Swiss franc affecting reported results

The sharp appreciation of the Swiss franc is taking its toll on reported results. First-half revenues decreased by 41% to CHF127m and net profit decreased by CHF5.9m to CHF0.6m, mainly due to currency movements. Taking account of the franc's appreciation, management has guided to full-year revenues between CHF310m and CHF330m, and net profit of CHF14-16m.

Excellent pipeline

Currency aside, and in the context of a tough basis of comparison, which included the international success of its own production *Pompeii* and the hit comedy *Fack Ju Göhte* in home entertainment, Constantin put in a good performance in the first half of the year with three films delivering over one million cinema ticket sales. The H215 theatrical slate is even stronger with national own and co-productions *Fack Ju Göhte 2*, which looks set to be the biggest theatrical movie of the year, and *Er ist wieder da*, which is also performing very well.

Valuation: Strong balance sheet, dividend support

With the large advance received from UEFA, Highlight Communications reported net cash of CHF41.6m at its interims. The shares trade on an EV/EBIT of c 6.7x this year and a 16.2x P/E, a considerable discount to peers, which trade closer to 9x EV/EBIT and 20x P/E. The shares also offer a 3.9% dividend yield.

Consensus estimates

Year end	Revenue (CHFm)	PBT (CHFm)	EPS (CHF)	DPS (CHF)	P/E (x)	Yield (%)
12/13	386	15.9	0.21	0.17	24.6	3.3
12/14	413	23.4	0.37	0.17	14.0	3.3
12/15e	311	20.4	0.32	0.20	16.2	3.9
12/16e	355	23.5	0.37	0.18	14.0	3.5

Source: Company data, Thomson Reuters

Price	**€4.75**
Market cap	**€225m**

Share price graph

Share details

Code	HLG
Shares in issue	47.3m
Net cash (CHFm) at June 2015	41.6

Business description

Highlight Communications focuses on film (87% revenues) and sports and event marketing (12% revenues). Through Constantin Film, Constantin Entertainment and Rainbow Home Entertainment, it is the largest independent film and TV production and distribution company in Germany. It also owns TEAM, the sports rights marketing group, and a 75% stake in Switzerland-listed events group Highlight Event & Entertainment. It is 52.4% owned by Constantin Medien, in which it also holds a 7.9% stake.

Bull

- UEFA rights locked in until 2021.
- Strong market position in Germany for film.
- OTT platforms present new opportunities for monetising content.

Bear

- Digital not fully offsetting DVD sales declines.
- Swiss franc exposure.
- DFFF cut to film funding in Germany.

Analysts

Bridie Barrett	+44 (0)20 3077 5727
Fiona Orford Williams	+44 (0)20 3077 5739
Dan Ridsdale	+44 (0)20 3077 5729

tmt@edisongroup.com

Financials

Deutsche Börse AG

Financials

A new growth programme

Deutsche Börse's new CEO has launched a growth programme called 'Accelerate' to boost the company's revenue and profits after several years of stagnant financial performance. His programme envisages significant changes to the group's day-to-day operations as well making cost savings of around €50m per year. In July it raised its net income forecast for 2015 by around 7% after a strong H1 performance and has set ambitious targets for 2018. It promises to continue paying attractive dividends and the shares currently offer a 2.6% yield.

Accelerate

The group's new growth initiative involves fundamental changes in the day to day operations of the company. It involves changes to the group's sales organisation, to its performance measure and incentivisation, to its selection of growth markets, its M&A programme and its capital allocation. It could significantly improve the company's prospects by building on its already strong market positions.

Bolt-on acquisitions

Deutsche Börse has recently engaged in two M&A actions: purchasing an FX trading platform, 360T, for €725m in July 2015 and fully acquiring the index providers, STOXX and Indexium, for CHF650m in the same month. The former expands the company's reach into a new large asset class and the latter will enable the company to benefit from the trend towards passive investment, with funds paying to use its indices.

Guidance for 2018

Deutsche Börse's new CEO has also targeted annual revenue increases of between 5-10% per year to 2018 and operating profit increases of 10-15% per year in that period. These targets, which depend on market conditions remaining broadly favourable, show the new CEO's intention to transform the company's financial performance.

Valuation: Yield premium

Consensus forecasts show Deutsche Börse's P/E ratios for 2015 and 2016 are around 18% lower than the other large international financial marketplace operators. Its yield is around 10% higher. If the company delivers on its 'Accelerate' programme, this valuation gap may close.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/13	2,217	668.1	2.60	2.10	31.9	2.5
12/14	2,404	963.4	4.14	2.10	20.0	2.5
12/15e	2,604	1,058.6	4.20	2.19	21.0	2.6
12/16e	2,783	1,217.1	4.70	2.30	17.7	2.8

Source: Company data, Thomson Reuters

Price	**€82.90**
Market cap	**€16bn**

Share price graph



Share details

Code	DB1
Shares in issue	193m
Net debt (€m) at 30 June 2015 *adjusted for banking activities.	188.2*

Business description

Deutsche Börse is a Germany-based international financial marketplace operator. It offers electronic trading systems for buying and selling securities on stock exchanges in Europe. It operates four business segments: Xetra, Eurex, Clearstream and Market Data & Services.

Bull

- 'Accelerate' programme to transform the company's day-to-day operations and lead to higher revenue and profits.
- Structural growth initiatives and potentially cyclical upswing.
- c 2.8% dividend yield, strong balance sheet and active capital management.

Bear

- Regulatory change.
- Low interest rates.
- 'Accelerate' programme could be a stretch to achieve.

Analyst

Peter Thorne +44 (0)20 3077 5765

financials@edisongroup.com

EDISON

DF Deutsche Forfait AG

Financial services

In restructuring phase

DF Deutsche Forfait's (DFAG) core business of trading emerging market trade receivables is a huge and attractive market. The company has shown that it has the skillset, brand and relationships to originate a strong flow of business. However, DFAG's balance sheet post its release from the US sanctions list (without penalty) is strained. The original proposals for a debt for equity swap and equity issuance could not be completed and new proposals will be considered while it is in a three-month creditor protection period.

Attractive core business

Emerging market trade is expected to show well above global GDP growth over the medium term, with the strongest increases in emerging market to emerging market flows. Financing trade receivables is an established way to facilitate this trade and DFAG has a proven capacity to originate a strong flow of business. In the past, it sold the majority of its receivables to banks, although it has explored a range of alternative buyers such as a trade finance fund and the ABS market.

Impact of US sanctions list despite no penalty

DFAG was added to the US sanctions list from February 2014 and removed without financial penalty in October. While on the list it was unable to conduct new business, collect many existing receivables or sell on positions. Its income collapsed and expenses and impairments rose. DF was unprofitable (including restated 2013 results). Rebuilding the business has taken time and expense, and in Q215 further losses were reported (€3.3m). Its balance sheet was severely strained (H115 negative net assets €11m) and a financial restructuring plan failed to complete by September 2015.

Now in Schutzschirmverfahren in Eigenverwaltung

On 30 September, DFAG entered a three-month phase of creditor protection with debtor-in-possession status ('Schutzschirmverfahren in Eigenverwaltung'). During this period the company retains its capacity to conduct business and can move forward with a financial restructuring using the legal instruments available during the Schutzschirmverfahren period, in addition to its previous proposals.

Valuation: Value post restructuring

The core business is attractive and means that once the restructuring is complete, there should be value in the DF franchise. However, in view of the current loss and uncertain restructuring we are unable to provide valuation comments.

Historical financials

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	2.4	(11.1)	(185)	0.0	N/A	N/M
12/14	0.6	(15.5)	(228)	0.0	N/M	N/M

Source: DF Deutsche Forfait

Price	€0.25
Market cap	€2m

Share price graph

Share details

Code	DE6
Shares in issue	6.8m
Net debt (€m) at June 2015	58

Business description

DF Deutsche Forfait AG is a specialist in the forfaiting of export receivables in emerging markets and developing countries. It has a number of marketing offices across the world and its headquarters are in Cologne, where the risk control functions are based.

Bull

- Enormous market to target.
- Growing investor interest in trade receivables as asset class.
- Scalable business model with proven expertise in origination of receivables.

Bear

- Uncertain outlook through restructuring phase.
- Speed of rebuilding business will depend on outcome of restructuring.
- Current value of shareholdings unclear.

Analyst

Mark Thomas +44 (0)20 3077 5700

financials@edisongroup.com

DF Deutsche Forfait is a client of Edison Investment Research Limited

EDISON

Ferratum AG

Consumer finance

Mobile consumer lender

Having listed in the Prime Standard segment of the Frankfurt Stock Exchange in February 2015, Ferratum (FRU) intends to continue the strong customer, revenue and profit growth reported for H115 by servicing the growing demand for mobile consumer financial services. The company is expanding its product list and the number of countries where products are on sale. It will launch mobile banking in Q116 and other products have yet to be launched in many territories where its Microloans are available.

Growing product portfolio

Ferratum has five main products available in 22 countries: Microloans of €50-€1,000 for 7-90 days (available in all 22); PLUS Loans up to €2,000 for 6-15 months (nine countries); Credit Limit, akin to an overdraft, (six countries); and FerBuy, online payments to merchants by instalments over 2-6 months, and a new SME lending business are both available in two countries. The company aims to provide loans within 15 minutes of a successful application via its mobile app or website. Ferratum's proprietary credit scoring system is constantly refined and updated, mitigating credit risk, and around 30% of first-time applicants are successful. The company's original Microloan product generated €29.7m of revenue in H115, up 23% year-on-year, although growth in newer business lines reduced Microloans' share of revenue from 78% to 60% over the same period.

Geographic expansion

Ferratum's geographic spread drives growth and diversifies risk. The company operates in all Nordic and Baltic states (except Iceland), Germany, France, Spain and the UK; its Maltese banking licence enables it to operate as a lender across the EU. Elsewhere, Microloans are available in Canada, Australia and New Zealand; Turkey, Italy and Mexico are next. On entry to new territories, Ferratum has experienced significant initial revenue growth and a rise in loan impairments in the new territory, which falls as bad debtors are written off and more business comes from repeat customers. Break even has usually been achieved within 12 months of entering a new country; over 30% EBIT margins are achieved in mature markets.

Valuation: Growth is the main driver

The 2016 P/E multiple of 21.9x is close to longer-established listed consumer finance businesses such as Cash America International (CSH, 22x) although higher than more traditional businesses, and may reflect market expectation of growth delivery.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS** (€)	DPS (c)	P/E (x)	Yield (%)
12/14	70.5*	6.6	N/A	N/A	N/A	N/A
12/15e	111.5	12.4	0.5	0.10	43.8	0.5
12/16e	172.4	23.2	1.0	0.20	21.9	0.9
12/17e	261.3	43.9	1.9	0.37	11.5	1.7

Source: Company data, Thomson Reuters. Note: *Before IPO-related costs. **Diluted EPS.

Price	€21.90
Market cap	€473m

Share price graph

Share details

Code	FRU
Shares in issue	21.58m
Net debt (€m) at 30 June 2015	22.8

Business description

Ferratum provides small loans and lending facilities to individuals using proprietary IT and credit scoring systems. SME lending and secure online payments (FerBuy) have recently begun and a mobile banking platform is to be launched in Q116. The company has 3.2m registered customers in 22 countries.

Bull

- Rapid revenue growth supported by new products (including mobile banking in Q116) and geographic expansion.
- Regulatory and economic risk diversified.
- Profitable and with a solid balance sheet.

Bear

- Highly competitive market.
- High compliance and regulatory burden.
- Price reflects expectation of successful strategy execution.

Analysts

Julian Roberts +44 (0)20 3077 5748
Martyn King +44 (0)20 3077 5745
financials@edisongroup.com

mutares AG

Holding company

European restructuring specialist

mutares is a restructuring specialist in the European market, acquiring companies that are undergoing special situations, providing extensive operational support and disposing at a profit once turnaround is complete. Having entered a very active M&A phase, the group has successfully completed several acquisition and disposal deals in 2015. With a successful capital increase on 8 October providing further funds to invest in both new opportunities and bolt-ons, following the opening of a new Paris office in March 2015, we expect to see M&A activity continuing.

Seeking turnaround situations

mutares has a clear strategy of identifying companies that are in special situations where a focus on restructuring, marketing and positioning for long-term sustainability is key. The group is not restricted by the subsectors it pursues, but is predominantly exposed to the industrial and consumer goods segments through 12 current investments. Group companies are supported by mutares' experienced team in strategy, business planning and operational efficiency, and once companies are returned to sustainable profit, management considers a sale.

Successful capital increase provides more firepower

mutares' successful completion on 8 October 2015 of a capital increase to raise an additional €24.5m provides the group with additional firepower to continue both new and add-on acquisitions. Having had an active H115 during which it has delivered four successful transactions, mutares is showing no signs of slowing the pace of M&A activity. Indeed, with the opening of a new Paris office in March 2015 – a catalyst for the most recent acquisitions of Grosbill and BSL Pipes and Fittings – the group is intent on further expanding its presence across Europe. Having delivered significant organic revenue and profit growth in H115, mutares has demonstrated its ability to quickly turn around companies and generate shareholder value.

Valuation: Value creation not reflected in discount to NAV

For a company that has achieved two successful exits in H115, we believe the current 29% discount to the last published NAV (€351.2m/€25.02 per share at 7 September 2015) does not fully reflect the group's potential to deliver earnings enhancement from its holdings.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/13	347.0	(7.2)	(0.67)	1.67	N/A	9.5
12/14	648.1	9.4	0.72	0.78	24.4	4.4
12/15e	727.0	10.6	0.60	0.78	29.3	4.4
12/16e	903.0	20.5	1.09	0.23	16.1	1.3

Source: Company data, Thomson Reuters

Price	**€17.58**
Market cap	**€271m**

Share price graph



Share details

Code	MUX
Shares in issue	15.4m
Net cash (€m) at 30 June 2015 (pre-capital increase)	27.3

Business description

mutares AG is a holding company focused on acquiring companies in special situations, such as succession and refinancing. It supports portfolio companies through the repositioning process and is active in consumer goods, industrial products, automotive and IT consulting sectors.

Bull

- Activity supported by experienced M&A professionals.
- Increased H115 revenues and EBITDA despite deconsolidating divested subsidiaries.
- Expansion through opening of Paris office shown by transaction activity.

Bear

- Two portfolio companies, GeesinkNorba and Pixmania, undergoing challenging situations. Lawsuits also active.
- Continued economic volatility in Europe provides risks (but also enhances turnaround pipeline).
- Increasing competition from start-up turnaround investors.

Analyst

Roger Johnston +44 (0)20 3077 5722

industrials@edisongroup.com

MBB SE

Holding company

Acquisition, expansion and added attention

MBB SE has a long-term record of revenue growth derived from acquiring, improving and expanding Mittelstand companies. With a long-term horizon coupled with targeted investment in subsidiaries, the family run group has delivered an impressive 23% CAGR in revenues since listing in 2006. The current portfolio consists of six subsidiaries and is projected to deliver €250m of revenues in FY15. Through value enhancement and with a progressive dividend and share buyback policy, the group has generated a 12% CAGR in total shareholder returns since listing.

Targeting technology and engineering strength

MBB has created a diversified portfolio of companies specialising in core technology and engineering-based businesses across a range of subsectors: specialist welding and assembly machinery; ecological hardwoods; tissue products; polyurethane and epoxy resins; IT services; and foam and mattress production. MBB is a long-term owner of its subsidiaries, which are typically sourced from companies undergoing succession issues or spin-offs from larger companies. The group then focuses on growing the individual subsidiaries through organic capex investment or bolt-on acquisitions. In addition, the group seeks to regularly add new subsidiaries as standalone businesses from which to further diversify.

Results demonstrate strategy is delivering

MBB has demonstrated the strength of its team in identifying, pursuing and enhancing businesses across a broad range of industrial verticals. With H115 results highlighting the continued growth of the group to some €125m of revenue, management is indicating full-year expectations of €250m with earnings of at least €1.75 per share. With a strong balance sheet including net cash, as well as an in-house M&A evaluation capability, MBB is able to act quickly to address and execute transactions.

Valuation: Track record warrants a premium

MBB's long-term value-driven approach is clearly demonstrated in its track record of growth since listing in 2006. MBB's ability to accelerate growth and deliver improved efficiency provides value enhancement opportunities. In our view, the current FY15 P/E rating of 11.5x does not reflect the long-term demonstrable track record and value enhancement, including a progressive dividend policy.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/13	228.2	15.7	2.09	0.55	9.8	2.7
12/14	236.7	14.2	2.01	0.57	10.2	2.8
12/15e	251.8	15.9	1.78	0.60	11.5	2.9
12/16e	268.0	18.3	2.08	0.62	9.9	3.0

Source: Company data, Thomson Reuters

Price	€20.52
Market cap	€135m

Share price graph

Share details

Code	MBB
Shares in issue	6.60m
Net cash (€m) at 30 June 2015	17.8

Business description

MBB is a family-owned German company, generating sales and value growth through German technological and engineering expertise. It has six subsidiaries across three segments: Technical applications (54% of H115 revenues); Industrial production (33%); and Trade & services (13%).

Bull

- Track record of revenues and profit growth.
- Ability to quickly identify and assess M&A opportunities.
- Strong balance sheet with net cash.

Bear

- M&A multiples across the industry are high.
- H115 margin erosion in plant engineering.
- European growth moderated due to Ukrainian conflict.

Analyst

Roger Johnston +44 (0)20 3077 5722

industrials@edisongroup.com

EDISON

BB Biotech AG

Investment trusts

Taking opportunities after market correction

BB Biotech (BION) is a Switzerland-based investment company aiming to generate long-term capital growth from innovative biotechnology companies. BION has a concentrated investment portfolio of 20-35 holdings, built around a core of five to eight positions. At 30 September there were six core holdings (two large and four mid-cap) making up 52.7% of the portfolio. Reflecting the make-up of the biotech industry, the majority of holdings (87%) are US-based, with the balance in European stocks. The portfolio is diversified by clinical focus, with the largest portion (38.9%) in oncology. Following the late-summer correction in global markets, BION has been reinvesting its substantial cash balance in promising companies at more favourable valuations.

Investment strategy: Profit from clinical innovation

BB Biotech aims to achieve annual average double-digit returns by investing in fast-growing biotech companies focused on developing and marketing innovative drugs and treatments to address unmet medical needs. The investment team at Bellevue Asset Management works closely with the board of directors – which has significant pharmaceutical industry experience – to identify potential holdings. There is a focus on listed companies that are already profitable rather than those at an earlier stage of development. Multi-stage due diligence is undertaken, with the team analysing financials, the competitive landscape, research pipelines and customer perceptions.

Performance: Outperforming in up and down phases

After a stellar run for biotech stocks over the four years to August, the sector sold off amid late-summer market volatility. BION has outperformed the benchmark Nasdaq Biotech index both in the bull market (share price TR +504% vs benchmark +460% over four years to 5 August 2015) and in the sell-off (-17.7% vs -21.5% for the benchmark over two months to 5 October 2015). Positive performance has been driven by stock selection, and also by M&A activity: in Q215 takeover bids for two portfolio stocks generated CHF389m in cash for BION.

Valuation: Discount close to average despite volatility

At 23 October, BION's shares stood at a 19.0% discount to cum-income NAV. While this is broadly in line with longer-term averages, 2015 has seen major moves in the discount, with a five-year low of 6.4% seen in March before widening to 24.7% in June. BION tends to trade on a wider discount than UK- or US-listed peers, although the strong long-term record along with capital distributions and share buybacks should provide some support if declines in biotech stocks continue.

12 months ending	Total share price return (%)	Total NAV return (%)	Total return NASBIOT Index (%)	Total return MSCI World HealthCare (%)	Total return DS World Pharma & Biotech (%)
30/09/12	75.6	78.2	59.0	31.2	30.8
30/09/13	40.2	52.2	42.1	22.0	22.4
30/09/14	52.4	38.6	38.3	32.6	33.9
30/09/15	44.5	27.0	13.7	5.5	3.3

Source: Thomson Datastream

Price	**CHF267.0**
Market cap	**CHF3,164.0m**
AUM	**CHF3,905.8m**
NAV*	CHF329.6
Discount to NAV	19.0%
Yield*	4.3%

*Including income. At 23 October 2015.



Three-year cumulative perf. graph



Share details

Code	BION
Listing	Zurich, Frankfurt, Milan
Shares in issue	11.85m

Business description

BB Biotech (BION) is a Switzerland-domiciled investment company, targeting long-term capital growth from biotechnology companies that are developing and marketing innovative drugs. At least 90% of the portfolio is in listed companies, primarily large- and mid-cap names that are already profitable. It is benchmarked against the NASDAQ Biotech index.

Analyst

Sarah Godfrey +44 (0)20 3681 2519

investmenttrusts@edisongroup.com

BB Biotech is a research client of Edison Investment Research Limited

Deutsche Beteiligungs AG

Private equity investor and asset manager

Celebrating its 50th year, Deutsche Beteiligungs (DBAG) is a seasoned private equity investor in mid-sized German companies, distinguished from many private equity peers by generating significant fee income from managing third-party funds. While recent market volatility and lower market valuation levels have clouded the near-term outlook, the high rate of new investment in FY15, with the addition of seven new companies to the portfolio, is encouraging for medium-term prospects.

Continued positive NAV progress in FY15

DBAG reported net income of €6.7m in Q315, bringing net income for the first nine months to €28.3m, driven by valuation gains for the carried portfolio with fee income largely covering operating expenses. NAV per share increased to €22.18 at 31 July 2015 representing a 1.9% gain in Q315 and a 10.0% advance for the first nine months of FY15, after adjusting for a €2.00 dividend payment.

Strong recent pace of investment activity

DBAG has maintained a strong pace of investment activity in FY15. New investment of €21m in Q315 takes total new investment in FY15 to date to €72m, ahead of the target €50m pa run rate and the highest level in the last 10 years. Seven new companies have been added to the portfolio in FY15, comprising five MBO and two expansion capital investments, all in DBAG's core manufacturing and industrial services sectors. This increases the number of holdings to 25.

Improved capital structure

The high level of investment activity in FY15 has seen DBAG's cash position reduce substantially, improving the overall capital structure and reducing potential cash drag on performance. With financial resources of €56.9m at 31 July 2015 and a €50m pa target investment rate, DBAG appears adequately funded for the next 12 months, with the potential for realisations to add to available funds.

Valuation: Premium to NAV has narrowed

We see the significant component of recurring fee income generated from DBAG's management of co-invested funds as the explanation for its shares trading at a significant premium to NAV. 3i in the UK has a similar business model and its shares are trading at a comparable premium to NAV. DBAG's share price premium to NAV has narrowed from 47% in March 2015 to its current level of 12%.

12 months ending	Total share price return (%)	Total NAV return (%)	Total return LPX Europe (%)	Total return DAX 30 Index (%)
31/07/12	(6.4)	5.7	(7.0)	(5.4)
31/07/13	15.8	7.4	32.6	22.2
31/07/14	28.2	17.6	12.0	13.7
31/07/15	40.6	10.0	32.5	20.2

Source: Company data, Thomson Reuters, Morningstar. Note: 12-month rolling discrete total return performance in euros up to last published NAV.

Investment companies

Price	€26.75
Market cap	€366m
NAV*	€303m
NAV per share*	€22.18
Premium to NAV	12.4%
Base dividend yield	1.6%
FY14 total dividend yield	8.0%

*As at 31 July 2015.

Share price/discount performance



Three-year cumulative perf. graph



Share details

Code	DBAN
Listing	Frankfurt
Shares in issue	13.7m

Business description

Deutsche Beteiligungs is a Germany-based and listed private equity company focused on mid-sized companies in Germany and neighbouring German-speaking countries.

Analyst

Gavin Wood +44 (0)20 3681 2503

investmenttrusts@edisongroup.com

Deutsche Beteiligungs is a research client of Edison Investment Research Limited

Real Estate

Adler Real Estate AG

Fast growth continuing

Adler's management expects funds from operations (FFO) to grow by c 100% during H215 (vs H115) and gross rental income (GRI) by 142%, and aims to reduce the cost of debt below 4% by the year end from c 4.2% in H115. These expectations reflect the first six-month contribution of Westgrund AG, whose acquisition was completed in June, taking the residential property portfolio to over 48,000 units. Further growth including the acquisition of a 24.79% stake in Austrian company conwert Immobilien (CWI), with a market cap of c €1bn, will also contribute to FY15 results.

Westgrund acquisition to make an impact

This acquisition increases exposure to the states of Lower Saxony, Berlin, Brandenburg and Saxony, allowing ADL to achieve scale in certain areas, helping optimise costs: management targets €20m of synergies over three years. The deal will also reduce ADL's LTV from 69% to nearer its peers, which have a range from 38-59%, reducing risk and future borrowing costs; it grows passing rent to €232m.

Income from sales

Adler also derives considerable income from property sales, partly through an 80% stake in privatisation and trading platform Accentro AG. In H115 FFO from property sales amounted to €27m vs a negligible amount for 2014. Unit sales (1,286) and margins (37%) increased significantly from FY14 (477 and 18%) and c 1,700 units remained for sale at 30 June 2015.

Guidance

ADL expects GRI of €196m in 2015 at a run rate of €232m by year end and €40m total FFO. EPRA NAV is not specifically forecast but the acquisition of MountainPeak Trading's stake in CWI may be the first step towards closer cooperation with that company, so further investment may occur by the year end. The original and any subsequent investments in CWI would add to EPRA NAV of €647m (€14.03 per share) at 30 June 2015. The investment was partly funded by the issue of a three-year mandatory convertible bond with a strike price of €16.50, and 0.5% coupon, improving the average cost of debt and reducing LTV.

Valuation: Similar to peers

Historical EPRA NAV per share and FFO show that a range of 1.0-1.5x EPRA NAV and 20-25x FFO1 (excludes gains on sales) is normal for established companies. Adler is now trading close to that range. We have suspended our estimates pending completion of ongoing acquisitions.

Historical financials

Period	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/14	140.7	132.8	3.57	N/A	3.4	N/A
H115	104.4	61.8	1.37	N/A	4.4	N/A

Source: Company data

Real estate

Price	**€13.83**
Market cap	**€638m**

Share price graph

Share details

Code	ADL
Shares in issue	46.1m
Net debt (€) as at 30 June 2015	1,770m

Business description

Adler Real Estate AG buys and manages high-yielding suburban German residential portfolios as well as stakes in other residential property companies in Germany and Austria. Gross assets were c €2.6bn at 30 June 2015 and a 24.8% stake in conwert Immobilien was added in August.

Bull

- German residential yields remain attractive.
- Mandatory convertible bond improves financial position and average cost of debt.
- Active asset management lifts occupancy, rents and cash flow.

Bear

- High LTV at 69%.
- High growth makes forecasting more uncertain.
- Growing fast but capitalisation still relatively low.

Analysts

Julian Roberts +44 (0)20 3077 5748
Martyn King +44 (0)20 3077 5700
financials@edisongroup.com

Adler is a client of Edison Investment Research Limited

EDISON

Demire AG

Real estate

Offer to create bigger commercial property player

Demire (DMRE) refocused its business in 2012 from Eastern Europe to Germany, where it now has a commercial portfolio of €700m generating rental income of €52.3m, having doubled in size in 2015. The proposed acquisition of Fair Value REIT (FVI), which has been recommended by FVI's board, would add a further €306m of investment property and €25.4m of income, and reduce DMRE's LTV. The deal would also give DMRE shareholders access to growth through FVI's closed-end fund investment platform. Holders of 41.9% of FVI shares and voting rights had accepted the offer as of 4 November.

Refocus almost complete

Current management took over in 2013/2014, reduced costs and has substantially redirected DMRE's strategy by concentrating solely on cash-generating German commercial property. It also opportunistically disposed of legacy Eastern European assets and smaller German properties. €2.4m of non-core assets remain. Nearly all DMRE's properties are managed internally, generating an additional revenue stream and the potential for further economies of scale in future.

Proposed acquisition to maintain NAV growth

The offer of two DMRE shares for each FVI share announced on 31 July 2015 requires a minimum acceptance rate of 50.1% and already had the backing of holders of 23.2% of FVI when it was made. The offer premium to EPRA NAV stood at 10% at 30 October 2015. Demire states that the deal would reduce leverage and borrowing costs, and would provide a new acquisition stream. FVI has historically bought into property funds below NAV, further grown its stake to take control and then benefits from the full value of the underlying properties; DMRE has concentrated on the secondary market. Demire's intention is to maintain FVI's REIT status and dividend policy (distributing 90% of net rental income) by leaving at least 15% free float; this will also stay below the 94.9% German land transfer tax (RETT) threshold. Synergy benefits of c €2m are expected. The portfolios complement each other by geography and sector.

Valuation: Estimates suspended pending deal

Consensus estimates have been suspended pending an outcome of the offer. FVI's board has recommended that FVI shareholders accept the offer despite the completion of the T6 portfolio acquisition on 30 October 2015 being at a higher price than previously envisaged, meaning that DMRE increases its equity by €2.9m less than the €43.5m previously envisaged. Statements about the offer are available on the company's website.

Historical financials

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/14	63.7	55.5	3.03	N/A	1.4	N/A

Source: Demire. Note: Estimates have been suspended pending the FVI offer.

Price	€4.33
Market cap	€118m

Share price graph



Share details

Code	DMRE
Listing	Frankfurt
Shares in issue	27.35m

Business description

Demire (Deutsche Mittelstand Real Estate) AG owns and manages a commercial real estate portfolio in Germany with an EPRA NAV of €94m at 30 June 2015. It has offered to acquire Fair Value REIT AG with a goal to create a company with gross assets nearing €1bn.

Bull

- Established player with broad portfolio.
- Potential acquisition would increase portfolio and rental income significantly.
- German economy and property market continue to improve.

Bear

- LTV and cost of debt relatively high at 75% and 4.7%.
- Vacancy rate 13.7% by value at 31 August 2015.
- No dividend.

Analysts

Julian Roberts +44 (0)20 3077 5748
Martyn King +44 (0)20 3077 5745
financials@edisongroup.com

EDISON

Fair Value REIT AG

Real estate

Offer from Demire still recommended

Fair Value REIT has responded to Demire's takeover offer by reiterating that it welcomes the potential to grow the company in combination with Demire. The board still deems the two-for-one share offer to be fair, even though Demire's acquisition of the T6 portfolio was completed at €2.9m higher than the expected price, thus slightly reducing the potential positive effect on Demire's equity.

Creating a significant commercial real estate player

Combining FVI (Q215 gross investment assets of €306m) and Demire (pro forma gross investment assets of €700m) would create a focused German commercial real estate player with c €1bn gross assets under management. The portfolios complement each other geographically and by sector. At the time of the announcement, the proposed exchange ratio represented a 37.2% premium to FVI's share price at 30 July, and a 27.6% premium to the trade-weighted share price of the previous three months. The offer depends on 50.1% acceptance and is capped at 94.9% to avoid the triggering of land transfer tax.

Possible effects

DMRE has taken on more gearing than FVI in aggressively growing its portfolio so financing costs and LTV ratio would at least temporarily increase for FVI shareholders if the offer is accepted. The combined entity will have a larger asset base that offers cost synergies and could be capable of delivering cash flow for further debt reduction and a solid covenant to help reduce the cost of debt. LTV of 50-60% is targeted in the medium term. The intention is for FVI's REIT status and dividend policy to be maintained. A more detailed treatment of the offer is available in our September update note.

Valuation: Estimates suspended during offer period

We have suspended our estimates during the offer period, which ends on 16 November. The rationale for an FVI shareholder to accept the offer would be the future potential for enhanced returns and faster growth from the combined entity. FVI has issued a statement about the offer on its website and the board has now unconditionally reiterated its recommendation that shareholders accept the offer since the announcement of the T6 transaction's completion.

Historical financials						
Year end	Revenue (€m)	EPRA net profit (€m)	EPRA EPS (€)	DPS (€)	P/NAV (x)	Yield (%)
12/13	36.4	6.4	0.69	0.25	0.90	3.1
12/14	30.1	4.4	0.47	0.25	0.94	3.1

Source: Fair Value REIT. Note: *Net profit and EPS are on an underlying EPRA basis (also referred to as FFO), excluding valuation movements and exceptional. P/NAV is also on an EPRA basis.

Price €7.75

Market cap €109m

Share price graph

Share details

Code	FVI
Shares in issue	14.03m
Net debt (€m) at 30 June 2015	133

Business description

Fair Value REIT (FVI) is a real estate investment trust managing c 275,000sqm at 44 commercial properties across Germany (at 30 June 2015). It has a diversified portfolio of office and retail assets with a focus on regional locations.

Bull

- Scale and synergies from takeover offer launched 31 July.
- Attractive yield.
- Flexible cost base.

Bear

- Potential increase in cost of debt and LTV.
- Takeover may reduce dividend.
- Takeover could affect REIT status.

Analysts

Martyn King +44 (0)20 3077 5700

Julian Roberts +44 (0)20 3077 5748

financials@edisongroup.com

Fair Value REIT is a research client of Edison Investment Research Limited

Industrials

EDISON

Carbios S.A.

Alternative energy

Innovative technology in plastics

Carbios leverages proprietary and unique enzyme-based technology for self-destruction and recovery of plastics. Its processes cover some of the most widely-used plastics. The company has recently delivered key milestones towards scaling-up for industrialisation with the launch of its pre-pilot production facility for biodegradable plastics. Our valuation range is €23-37 per share.

Well-positioned disruptive technology

Carbios's enzyme technology could enable full-time controlled biodegradation and biorecycling of some of the most widely-used plastics and bioproduction. As plastics are central to most sectors, Carbios is exposed to structural growth from some of the most important global megatrends, and is a beneficiary of tightening regulations for plastic disposal.

On the road towards industrialisation

Carbios has shown consistent progress in driving its technology forwards. It recently launched a pre-pilot plant for the production of biodegradable products. This is an important step towards scaling-up for industrialisation and commercialisation, enabling the company to eventually file for IP protection for each individual end-product – a very strong cornerstone to long-term IP.

Cash control at pre-revenues stage

Carbios is currently pre-revenues, its funding consisting essentially of grants and subsidies. With c €9m of cash and a controlled net cash burn of €3-4m pa, the company should be able to fund its activities until the research stages of its Thanaplast project are concluded in 2017. We note that Carbios needs to execute to that schedule and produce first licence revenues in 2018. Failure to do so would lead to additional funding requirements. If successful, the business model would be high-margin and asset-light, as reflected in the company's latest results (H115).

Valuation: €23-37 per share

We value Carbios on a DCF methodology with risk-adjusted cash flows. We value the most advanced processes individually based on potential market sizes, achievable royalty rates and market shares to 2030. Our fair value range is €23-37 per share (WACC 20%). Commercialisation and licensing will be key to de-risking cash flows.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	0.9	(3.1)	(57.8)	0.0	N/A	N/A
12/14	0.7	(3.3)	(59.4)	0.0	N/A	N/A
12/15e	0.5	(3.6)	(72.5)	0.0	N/A	N/A
12/16e	0.4	(4.0)	(87.7)	0.0	N/A	N/A

Source: Carbios, Edison Investment Research

Price	€11.82
Market cap	€44m

Share price graph

Share details

Code	ALCRB
Shares in issue	3.75m
Net cash (€m) at June 2015	9.6

Business description

Carbios develops enzyme-based processes for biodegradation and bioproduction of plastics, with a long-term aim of displacing current recycling and production practices.

Bull

- Disruptive technology with vast potential applications.
- Exposure to structural global megatrends.
- Tightening regulations.

Bear

- Technology and execution risk.
- Risk of further funding requirements.
- Commodities sensitivity.

Analyst

Catharina Hillenbrand-Saponar +44 (0)20 3077 5700

industrials@edisongroup.com

Carbios is a research client of Edison Investment Research Limited

EDISON

KTG Energie AG

Alternative energy

Unique positioning in biogas

KTG is uniquely positioned in biogas as a profitable developer and operator with a sustainable competitive advantage. A strong track record of organic growth and execution is now being complemented with acquisitions. This should drive revenue growth and margin expansion, with financial requirements remaining high. Our fair value is €18 per share.

Unique position and strong execution in biogas

KTG stands out as a profitable developer and operator of biogas assets. Guaranteed feed-in tariffs under the German renewable energy law result in highly visible cash flows. Because of its relationship with parent KTG Agrar and its second crop substrate method, it has a unique competitive advantage. The company has built a strong track record of execution, with capacity build above expectations and several increases to revenue and margin guidance.

Acquisitions complement organic growth

After an initial phase of rapid organic growth, acquisitions are now becoming a more important part of the company's growth strategy. We see opportunities aplenty as the industry struggles with reduced feed-in tariffs and tighter feedstock regulations. Optimisation of existing and newly acquired assets is a key part of the strategy. We expect this to drive continuous margin expansion.

Financials: Capital increases for growth

Our forecast is based on capacity growth of c 40% over the next three years, which, together with asset optimisation, is a key driver of our forecast 44% EPS CAGR 2014-18. While the business is cash generative (60% cash conversion ratio), growth capex and dividend payout largely absorb operating cash flows. We expect the company to be net cash flow positive in 2018. In August 2105, KTG raised equity (€7.7m) for the second time since its IPO to finance growth.

Valuation: €18 per share

We value KTG on a three-stage DCF methodology, which yields €18 per share, providing attractive upside. Unusually for a high-growth company, KTG offers a well covered 4.5% dividend yield.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (c)	P/E (x)	Yield (%)
10/13	54.3	2.7	0.26	0.40	43.3	3.5
10/14	73.3	4.0	0.43	0.45	26.2	4.0
10/15e	87.0	6.8	0.57	0.50	19.8	4.4
10/16e	100.4	9.3	0.75	0.55	15.0	4.9

Source: KTG Energie, Edison Investment Research

Price	€11.27
Market cap	€81m

Share price graph

Share details

Code	KB7
Shares in issue	7.2m
Net debt (€m) at 30 April 2015	132

Business description

KTG Energie develops and operates biogas facilities. The output is sold under the German renewable energy law at subsidised rates.

Bull

- Highly visible cash flows.
- Strong growth outlook from organic build and acquisitions.
- Attractive 4.5% dividend yield.

Bear

- High gearing and dependent on equity financing for growth.
- Execution risk on future growth.
- Exposure to regulatory and political risk.

Analyst

Catharina Hillenbrand-Saponar +44 (0)20 3077 5700

industrials@edisongroup.com

KTG is a research client of Edison Investment Research Limited

EDISON

Phoenix Solar AG

Alternative energy

Price	€3.72
Market cap	€28m

Execution challenges mask strong position

Phoenix Solar is a solar systems integrator with a business model that covers engineering, procurement, construction and operation, and managing solar projects. The company is well positioned to benefit from the strongest geographical growth markets in solar. Management needs to deliver on its six-point turnaround plan for the share price to reflect the company's prospects.

Downstream exposure to global solar market growth

Globally, solar installations are forecast to grow c 11% in 2015 (source: EPIA). Phoenix Solar offers flexible exposure to some of the most dynamic global solar growth markets. The company's focus is on the strongly-growing North American, Middle Eastern and Asian regions. The US utility scale market could double year-on-year to reach 6-8GW (source: EPIA); it accounts for 67% of Phoenix's 220MW pipeline. With its integrated model, Phoenix is looking for premium margins.

Mid-turnaround

Phoenix has embarked on a six-point turnaround strategy, concentrating on sales and revenue improvement through increased focus on project closure, EPC quality and service differentiation, operating cost reduction of 6-8% pa, and purchasing and strategic alliances. Order intake improvement will be key. Profitable project closures are, in our view, the most important element to improving earnings and cash flows. Backlog has improved 78% y-o-y. Y-o-y Q3 order intake is down 51%, but we recognise that this is lumpy due to timings of large projects. Declining solar module prices have led to many projects reaching grid parity, especially in the US. This should support demand and Phoenix's turnaround.

Profit warning, financed until 2016

Phoenix Solar is still loss-making and its balance sheet equity is negative to the tune of €8.6m (June 2015). Guidance is for revenues to more than triple to reach €140-160m for FY15, and management targets positive EBIT. Due to a project cancellation in Asia, Phoenix has recently reduced EBIT guidance to -€1 to +€1m, down from +€1 to €3m.The company has committed bank financing through 2016. Credible progress on its turnaround will be needed to secure follow-on financing.

Valuation: Reflects turnaround

The shares are currently trading on an EV/sales of 0.5x 2015e, compared with 0.9x for the close peers. This reflects the turnaround challenge, in our view.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/13	121.8	(6.5)	(1.45)	0.0	N/A	N/A
12/14	33.4	(9.7)	(1.38)	0.0	N/A	N/A
12/15e	140	(5.0)	(0.50)	0.0	N/A	N/A
12/16e	160	(2.0)	(0.31)	0.0	N/A	N/A

Source: Phoenix Solar, Thomson Reuters

Share price graph

Share details

Code	PS4
Shares in issue	7.4m
Net debt (€m) at June 2015	39.2

Business description

Phoenix Solar is an integrated solar project developer with global activities. Its business comprises EPC and O&M of large-scale solar projects. It is also a specialist wholesaler of complete solar systems, modules and accessories on a smaller scale.

Bull

- Exposure to fastest-growing solar markets with 227MW weighted global sales pipeline.
- Lean structure and absence of exposure to manufacturing competition from Far East. Falling module prices are a positive driver of profitability.
- Potential for significant increase in revenues and profitability.

Bear

- Execution risk on project closure and turnaround.
- Weak balance sheet and refinancing risk.
- Exposure to regulatory risk: US and EU import tariffs as well as reduction of EU subsidies for utility-scale projects, which reduce solar farm returns.

Analyst

Catharina Hillenbrand-Saponar +44 (0)20 3077 5700

industrials@edisongroup.com

EDISON

PNE Wind AG

Alternative energy

Early-stage wind and potential for yield co

PNE stands to benefit from sustained demand for wind projects. Its portfolio covers both onshore and offshore projects in Europe, North America and South Africa. It is weighted towards early-stage projects, which gives it flexibility to respond to market opportunities. The establishment of a yield co could be a positive catalyst. Wind is becoming more cost-competitive with other sources of energy.

International expansion with flexible business model

PNE develops onshore and offshore wind parks. The company is established in Germany and present in 13 countries. The pipeline is concentrated on high-growth regions, ie the US, Turkey and South Africa. It has an onshore and offshore pipeline of 4,700MW and 5,000MW respectively. The bulk of the offshore pipeline is in the North Sea, one of the strongest near-term growth regions. PNE still expects future milestone payments totalling €120m from on- and offshore projects. It can sell at various stages of development or continue to accrue milestones, or hold out for higher valuations by selling at later stages. Through selling offshore projects before construction, the company is well placed to serve the major utilities with project requirements, without taking on the well-known execution risk up to commissioning.

Yield co attractions

Yield companies, which hold portfolios consisting primarily of renewable energy projects and distribute earnings to their owners through dividends, have listed in the UK and US with investors attracted to the high cash flow visibility. PNE is building a portfolio of projects with 150MW of capacity and intends to list the vehicle in 2016.

H1 results: Return to profitability

PNE has reported EBIT of €24m (2014: €2.8m) on revenues of €72m. Net income was €18.4m (2014: -€2.4m). Financials are still strained, with an operating cash flow of -€52m and gearing of 150% as a result of building out yield co projects. Management asserts that its c €105m cash on hand provides adequate financing and guides for FY15 EBIT of €30-40m.

Valuation: Discount to peer group

The EV/EBITDA multiple of c 7.5x 2015e is below the peer group average of 10.3x. We view this as a discount for scale and visibility. The recent election of a new supervisory board at the October AGM should help restore confidence. The shares trade on a P/E of 9.0x 2015e vs 23.1x for the peer group.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/13	144.1	34.4	0.78	0.15	3.0	6.4
12/14	211.3	(15.1)	(0.22)	0.04	N/A	1.7
12/15e	138.7	22.6	0.26	0.10	9.0	4.3
12/16e	354.1	85.2	0.89	0.12	2.6	5.2

Source: Company data, Thomson Reuters

Price	**€2.33**
Market cap	**€178m**

Share price graph

Share details

Code	PNE3
Shares in issue	76.6m
Net debt (€m) at June 2015	138

Business description

PNE is based in Germany and develops and operates onshore and offshore wind projects. The company is developing nearly 10,000MW of onshore and offshore projects in various stages of development. Customers include investors/utilities such as EnBW, DONG Energy, Enel, Brookfield and Allianz.

Bull

- Exposure to long-term wind demand.
- Stable regulatory environment in target regions.
- Potential to create a yield co.

Bear

- Limited geographic diversification; execution risk.
- Exposure to regulatory risk.
- Recent re-election of new supervisory board, as well as new CEO, provides relief, although some reputational impact remains.

Analyst

Catharina Hillenbrand-Saponar +44 (0)20 3077 5700

industrials@edisongroup.com

EDISON

SFC Energy AG

Alternative energy

Contracts flow despite market volatility

SFC Energy has shown that despite market uncertainty and the low oil price, it has been able to achieve several new contract wins that support a positive medium-term outlook. Having positioned itself as a hybrid power management solutions provider, SFC is increasingly being viewed as an off-grid and backup power specialist. With both a strong position in Canada, new global partner agreements and international contracts being won, the group has a number of routes to drive further growth.

Supplying hybrid power management solutions

Since listing in 2007, SFC Energy has transformed from developing fuel cells into supplying complete hybrid power management solutions for off-grid applications. With a significant operational installed base of units and increasing portfolio of products and capabilities – first through the acquisition of PBF in 2011 and Simark in 2013 – SFC has a complete systems integration approach. With new solutions being delivered and global partnerships such as the recently announced agreement with Toyota Tsusho Corporation in Japan, SFC has both the systems and routes to market to continue its global expansion strategy.

Demand signals return

The past year has seen sharp declines in oil & gas markets due to the uncertainty caused by the oil price decline. The impact of weak oil prices has been mitigated somewhat by a greater exposure to production rather than exploration, as well as the fact that efficiency improvements generated by its systems allow for improved debottlenecking and reduced operating costs for operators at a time when a focus on costs is high. Likewise, improved demand for its defence-related products is also evident as previous cuts to European budgets begin to be rebalanced due to a change of the geopolitical landscape/situation. As a result, SFC has received several new contracts across both its largest divisions over the past six months, which will feed into FY16 onwards. Consumer, on the other hand, remains volatile but accounts for just 9% of revenues.

Valuation: Lowest rating among peers

While SFC Energy is set to remain loss-making until 2016, it currently sits as one of the lowest-rated fuel cell and alternative energy peers at just 0.7x 2015 EV/Sales, a 85% discount to global peers. As SFC demonstrates its ability to convert top-line potential into profits, the rating should react positively.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/13	32.4	(9.0)	(1.16)	0.0	N/A	N/A
12/14	53.6	(4.6)	(0.59)	0.0	N/A	N/A
12/15e	58.3	(2.9)	(0.26)	0.0	N/A	N/A
12/16e	69.4	0.2	0.01	0.0	N/A	N/A

Source: Company data, Thomson Reuters

Price €4.81
Market cap €41m

Share price graph

Share details

Code	F3C
Shares in issue	8.6m
Net debt (€m) at 30 June 2015	2.5

Business description

SFC Energy is a world-leading group of companies for mobile energy solutions and power management systems. It operates in three segments: Oil & Gas (59% of H115 revenues); Security & Industry (32%); and Consumer (9%).

Bull

- Debottlenecking of oil & gas wells increasing in importance with low oil price.
- Flexibility in Canadian workforce allows right-sizing of business and maintainable profitability.
- Improved defence spending outlook in core European markets.

Bear

- Company yet to achieve break even.
- Timing delays in H115 in Industry segment in power supply affected half-year results.
- Consumer market volatility.

Analyst

Roger Johnston +44 (0)20 3077 5722
industrials@edisongroup.com

EDISON

paragon AG

Automotive electronics

Electrifying performance

paragon is set to deliver 22%, 44% and 46% three-year CAGR in revenues, PBT and EPS respectively, driven predominantly by substantial growth from the group's move into electromobility and new product areas such as body kinematics. This is built on a strong core business in automotive electronics with a unique culture and development approach at the forefront of technological trends, many of which were exhibited by the group at IAA 2015. With few directly comparable peers that can match such growth, we use a DCF valuation approach yielding a €30.1/share fair value.

Strategy to rapidly expand non-automotive reach

Founded in 1988, paragon's core business has been built on a strategy of identifying emerging trends and developing systems ahead of, rather than in response to, requests from OEMs. This has led to significant success in automotive, accounting for 95% of 2014 revenues, 80% of which are derived from strong German OEMS. With the same R&D and systems approach being used to rapidly expand in electromobility, we forecast that 27% of revenue will come from non-automotive markets by 2017, supported by existing contracts and partnerships and providing higher growth and margin potential.

Trajectory highlighted in H1 results

H115 results highlighted the benefits of the group's growth strategy with revenues up 18% to €44.6m (H114: €37.8m), EBIT more than doubling to €3.8m (H114: €1.5m) and EPS rising to €0.46 (H114: €0.09), driven by growth across all divisions and an initial contribution from the February 2015 acquisition of SphereDesign. With significant contract wins in the period for starter batteries, intralogistics and body kinematics, the group has a 2015-19 order backlog of >€640m and 97% order cover for FY15 targets of c €100m revenue and 10% EBIT margin.

Valuation: Multiple growth drivers exist

paragon has multiple growth drivers to deliver enhanced shareholder value. With the opening of Voltabox Texas complete and delivery expected from the Chinese production facility in the coming months, we anticipate the growth trajectory to continue over the next three years. As this growth is delivered, the rating should rapidly compress. However, we feel that short-term ratings do not fully reflect this potential and therefore use a DCF approach to yield a fair value of €30.1 per share, assuming 10% margins and 2% terminal value at a 10% WACC.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/14	79.0	4.3	0.67	0.0	35.2	N/A
12/15e	99.3	7.9	1.29	0.0	18.3	N/A
12/16e	117.7	10.3	1.68	0.0	14.1	N/A
12/17e	141.8	12.9	2.10	0.0	11.2	N/A

Source: paragon AG, Edison Investment Research

Price	€23.61
Market cap	€97m

Share price graph

Share details

Code	PGN
Shares in issue	4.1m
Net debt (€m) at 30 June 2015	27.4

Business description

paragon designs and manufactures advanced automotive electronics solutions as a direct supplier to the automotive industry. Its products include sensors, acoustics, cockpit; electromobility and body kinematics. Production facilities are in Germany and the US, and production will soon begin in China.

Bull

- Automotive exposure geared to premium OEMs.
- Significant pipeline of new product introductions coming to market through R&D investment.
- Expansion into electromobility supported by contracts already received and opening of production facility in Texas.

Bear

- Market uncertainty caused by VW emission issues.
- Heavy investment year in 2015, easing from 2016.
- Highly reliant on a small number of key personnel.

Analyst

Roger Johnston +44 (0)20 3077 5722

industrials@edisongroup.com

paragon is a research client of Edison Investment Research Limited

UNIWHEELS AG

Automotive equipment

Planting future growth

A top three European supplier of alloy wheels, UNIWHEELS has several decades-long exposure to premium OEMs. With demand outstripping supply due to volume increases and greater penetration, capacity is constrained across the supply chain. UNIWHEELS' investment in a new plant at its Polish operations will expand production by 25% to 2018 while delivering the latest production methods and efficiency. Tight cost control, a healthy balance sheet and a 50% dividend payout should support enhanced shareholder returns.

Leading supplier at the forefront of technology

UNIWHEELS is a top three supplier to European OEMs (80% of sales) and the number one producer in the European accessory aftermarket (20%), with long-established relationships with the premium automotive brands. New manufacturing techniques allow cost-effective alloy wheels to be produced, driving penetration as fuel conservation and CO_2 emissions legislation force OEMs to focus on weight reduction. Likewise, as OEMs offer an increasing number of model options, alloy manufacturers require a flexibility to deliver more complex design variations.

Growth poised to accelerate with new capacity

While the industry as a whole is facing capacity shortages due to demand growth, UNIWHEELS has been able to deliver a 7% top-line CAGR from 2012-14 through continually upgrading existing production facilities to increase efficiency. To capitalise on the anticipated demand momentum from OEMs, UNIWHEELS is investing €86.8m in a further plant at its Stalowa Wola site in Poland, which will increase production capacity by 25% to c 10 million wheels by the end of 2017. Construction is on time and budget for initial production in mid 2016. In addition to capacity, the plant will also be equipped with the latest technology providing increased efficiency and greater flexibility, with the ability to produce the full range of wheels further adding to the group's cost advantage over major competitors.

Valuation: Shareholder-focused returns

The May 2015 WSE IPO raised c €60m and positioned UNIWHEELS with a healthy balance sheet, clear strategic growth direction, experienced management and a shareholder returns focus including a 50% dividend payout policy. As Plant 4 enters production over the next two years, revenue and profit are forecast to accelerate, while incremental opportunities inside and outside Europe are being explored.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	337.2	9.7	1.3	0.0	21.4	N/A
12/14	362.6	22.3	2.3	0.0	12.1	N/A
12/15e	405.5	33.0	2.7	0.8	10.3	2.9
12/16e	432.0	35.3	2.8	1.1	9.9	4.0

Source: Company data, Thomson Reuters

Price	**PLN117.7**
Market cap	**PLN1.5bn**
	PLN4.24/€

Share price graph



Share details

Code	UNW
Shares in issue	12.4m
Net debt (€m) at 30 June 2015	15.8

Business description

UNIWHEELS is a Bad Dürkheim, Germany-headquartered, Warsaw-listed manufacturer of alloy wheels using mainly low pressure die casting (LPDC) technology for passenger and professional racing cars. Production facilities are in Werdohl, Germany and Stalowa Wola, Poland.

Bull

- Top three European OEM supplier, #1 aftermarket producer with four well-known brands.
- New plant in Stalowa Wola, Poland, due to start production in mid 2016, increasing capacity by 25%.
- Balance sheet capacity to support further growth (post IPO net debt:EBITDA 0.3x).

Bear

- Current capacity constraints restrict growth.
- Accessory volumes expected to remain flat.
- Uncertainty surrounding impact of VW emissions scandal, but could be offset through increased OEM-branded aftermarket production and additional volumes for other OEMs.

Analyst

Roger Johnston +44 (0)20 3077 5722

industrials@edisongroup.com

Nanogate AG

Speciality chemicals

Not even scratching the surface

Nanogate delivered a successful H115 with a substantial 60% growth in revenues. With the group's Phase5 growth plans propelling the business towards its €100m revenue target, supported by a substantial order intake and improved cash generation, the outlook for Nanogate is positive. With further investment being made in its strategic growth areas of advanced metals and polymers, Nanogate is fast becoming the partner of choice for high-performance surface finishes across a broad, stable customer base, with further international opportunities.

Innovation partner to advanced industries

Nanogate has positioned itself as a leading integrated systems provider for high performance surfaces. The group is a key innovation partner for high-tech industries, where surface finishes are key not only to functionality but also design. With added focus being applied in the two strategic growth areas of advanced metals (N-Metals) and advanced polymers (N-Glaze), Nanogate is continuing to expand its reach in high-performance surfaces. With rapid expansion being supported by future investment, such as the construction of a new platform for multifunctional metallisation of surfaces, the group maintained a strong balance sheet through a successful capital increase in March 2015 (€11.6m).

H115 demonstrates advanced technology shift

H115 results highlighted the group's expansionary strategy with revenues up c 60% to €43.3m, with strong growth in advanced metals and polymers supplemented by the integration of Vogler. EBITDA increased by 42% to €4.9m, while EBIT was up 36% to €1.7m, despite heavy investment for the Phase5 programme. Encouragingly, cash flow from operations increased to €3.3m (H114: €0.3m), while post capital increase cash and equivalents increased to €23.5m (H114: €17.9m).

Valuation: Accelerating growth and earnings

Nanogate's current rating reflects high revenue growth rates, averaging c 30% pa since its IPO, with further growth supported by a good order base and strong visibility. The group's Phase5 strategy, initiated in 2014 to achieve €100m of sales is progressing to plan with organic growth, internationalisation, a broadened technology portfolio, M&A and internal excellence all playing a part in the step forward in 2015. With increased cash generation also being achieved, the group is making progress, however investment in growth will continue.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/13	53.0	1.2	0.32	0.11	107.2	0.3
12/14	68.6	0.8	0.15	0.11	N/A	0.3
12/15e	85.1	0.9	0.15	0.12	N/A	0.3
12/16e	96.7	2.7	0.48	0.13	71.5	0.4

Source: Company data, Thomson Reuters

Price	**€34.31**
Market cap	**€113m**

Share price graph



Share details

Code	N7G
Shares in issue	3.3m
Net debt (€) as at 30 June 2015	28.8m

Business description

Nanogate is an international integrated systems provider for high-performance surfaces. The group is based in Göttelborn (Saarland), Germany and enables the integration of multifunctional properties such as non-stick, scratchproof and anti-corrosive into materials and surfaces.

Bull

- High growth potential.
- Increasing position with premium automotive OEMs.
- Vogler acquisition provided expanded capacity and capabilities.

Bear

- Investment requirements to support short-term Phase5 growth targets.
- Start-up risk of new multifunctional metallisation of surfaces platform.
- Some market uncertainty in broader economy.

Analyst

Roger Johnston +44 (0)20 3077 5722

industrials@edisongroup.com

Pharmaceutical & healthcare

EDISON

4SC AG

Pharma & biotech

Resminostat refocused cancer strategy

4SC has fresh funds and a renewed clinical strategy for its lead epigenetic anti-cancer agent resminostat. A €29m (gross) capital increase in July provides the funds to commence a potentially pivotal Phase II trial in Europe with resminostat in CTCL in Q216. Data are expected in H218, with potential EU filing/approval possible in H219. Meanwhile, clinical data in 2016 from two Phase II studies being conducted by Japanese partner Yakult, in liver and lung cancer, offer the prospect of stimulating fresh partnership and/or financing discussions. Our fair value was recently upgraded to €141m from €115m.

Resminostat EU CTCL trial to start in H116

This year, 4SC decided to redirect its immediate focus for resminostat on CTCL, while liver cancer (HCC) remains a mid-term strategy. The company raised €29m (€27.5m net) from the issue of 7.25m shares at €4.00 per share. The resminostat EU CTCL study is expected to start in Q216. The trial is potentially pivotal and 4SC hopes to file for conditional approval on the back of positive Phase II data. EU filing and approval is possible by H219.

Positioning in CTCL will be key

Resminostat will be assessed as a maintenance therapy for advanced CTCL (stages IIB-IV) patients, after failure on standard systemic treatment like bexarotene, but in responders to chemotherapy. We note nine drugs in Phase II/III development for CTCL, but we see limited competitive threat within resminostat's targeted setting.

Particular interest still in HCC

Yakult is conducting two Phase II studies in Japan in HCC and lung cancer (NSCLC). Positive data (especially providing validation of the ZFP64 biomarker in HCC) in 2016 would therefore bring development of resminostat for HCC in western patients into play once more, subject to partnerships and/or fresh finance.

Valuation: Increased to €141m from €115m

The EU CTCL opportunity for resminostat is now in our valuation model, with peak sales estimated at €123m by 2028. Adjusting for FY15e net cash of €20m and increased R&D expenses, our overall valuation is now €141m (vs €115m), or €7.43 per share. We note that 4SC is now fully funded to complete the CTCL study in 2018.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (c)	P/E (x)	Yield (%)
12/13	4.9	(8.0)	(0.80)	0.0	N/A	N/A
12/14	7.1	(8.8)	(0.88)	0.0	N/A	N/A
12/15e	5.0	(10.7)	(0.73)	0.0	N/A	N/A
12/16e	6.8	(10.2)	(0.54)	0.0	N/A	N/A

Source: 4SC, Edison Investment Research

Price	**€2.46**
Market cap	**€47m**

Share price graph

Share details

Code	VSC
Shares in issue	18.97m
Pro forma net cash (€m) at end-July 2015 (post €27.5m net capital raise)	26.5

Business description

4SC is a Munich-based drug discovery and development company focused on small molecule compounds for cancer. Resminostat (HDAC inhibitor) is in Phase II in the EU for CTCL (cutaneous T-cell lymphoma), partnered with Yakult (Japan, Phase II HCC/NSCLC) and Menarini (Asia). Two agents (4SC-202, 4SC-205) have completed Phase I.

Bull

- Cash to complete EU CTCL trial with resminostat.
- Potential positive Phase II data from Yakult.
- Well positioned in epigenetic oncology therapy.

Bear

- Risk of failure and read-across from Yakult Phase II studies.
- Low free-float (38%); low liquidity (daily volume 27,000 shares).
- 4SC-202 & 4SC-205 (Phase II assets) require funding for further development.

Analysts

Tim Franklin	+44 (0)20 3077 5734
Christian Glennie	+44 (0)20 3077 5727

healthcare@edisongroup.com

4SC is a research client of Edison Investment Research Limited

EDISON

aap Implantate AG

Healthcare equipment & services

US LOQTEQ launch offers new growth leg

aap's expertise in trauma innovation, especially LOQTEQ, and biomaterials should help strengthen its market position, supported by its strategic relationships with global medtech partners. We expect LOQTEQ's ongoing international roll-out to spur solid revenue growth and margin expansion. Our valuation is €91m or €2.96 per share.

International roll-out of LOQTEQ drives growth

The LOQTEQ locking and compression technology improves fracture repair by providing more stable fixation, even in weak bones or multi-fragment fractures. Its innovative design could offer a number of advantages over the traditional locking compression plating systems, including increased surgeon flexibility and potential clinical advantages on plate removal. In the US aap is in an ongoing acquisition process of distribution partners (currently 11 distributors) and sees more significant revenues from Q415 onwards. We see the US as a key growth driver in 2016.

Strategy: Simplified and specialised

Since 2009, aap has focused on trauma and biomaterials (bone cements). These businesses take advantage of aap's existing relationships with leading orthopaedic surgeons and OEM partnerships with global medtech players (including Zimmer and Smith & Nephew). While opportunistic about its long-term commitment to the business, aap has lately identified new growth opportunities in high-margin biomaterials. Also, management is constantly screening the market for suitable distribution-related acquisitions and deals and is building out the US product management and distribution teams.

New products under launch and development

In 2015, aap has expanded its LOQTEQ portfolio to exceed 90% indication coverage (eg plates with polyaxial locking technology). Further portfolio additions are currently being developed (eg foot and ankle system). The next innovation is aap's antibacterial silver coating technology, which can prevent the formation of biofilms on implants, offering a potential reduction in the number of infections and reoperations. aap aims to submit its CE approval application by the end of 2015.

Valuation: €91m or €2.96 per share

Based on a DCF, our valuation is €91m or €2.96 per share. An eventual sale of biomaterials may crystallise €3.26 per share, assuming net proceeds of €35m.

Edison estimates

Year end	Revenue (€m)	PBT* (€m)	EPS* (c)	DPS (c)	P/E (x)	Yield (%)
12/13	28.6	3.7	13.8	0.0	13.3	N/A
12/14	30.6	0.7	0.9	0.0	N/A	N/A
12/15e	34.2	1.1	2.3	0.0	79.6	N/A
12/16e	38.1	3.0	8.0	0.0	22.9	N/A

Source: aap Implantate. Edison Investment Research. Note: *PBT and EPS are normalised, excluding and intangible amortisation and exceptional items. Continuing operations only 2013-2014.

Price	€1.83
Market cap	€56m

Share price graph

Share details

Code	AAQ
Shares in issue	30.83m
Net cash (€m) at end June 2015	2.8

Business description

aap Implantate is a German medtech company, focused on developing, manufacturing and selling products for bone fractures. These include the recently launched LOQTEQ trauma plating system, in addition to bone cements.

Bull

- LOQTEQ offers a number of advantages over its nearest competitors.
- Biomaterials expertise supported by OEM agreements with global medtech partners.
- Simplified business should help drive margin expansion.

Bear

- LOQTEQ is entering a competitive marketplace dominated by large players.
- Driving LOQTEQ uptake could require significant resources.
- It could take time to see sales growth and margin expansion.

Analyst

Hans Bostrom +44 (0)20 3681 2522

healthcare@edisongroup.com

aap Implantate is a research client of Edison Investment Research Limited

EDISON

co.don AG

Pharma & biotech

Leaders in cartilage repair

co.don is a leading producer of autologous cell and tissue transplants for the treatment of cartilage defects: chondrosphere is used for articular cartilage defects and chondrotransplant DISC is used for spinal disc defects. The products are successfully marketed in Germany (revenues of €4.5m in FY14, double-digit y-o-y growth). Two clinical trials of chondrosphere are underway (a Phase II and Phase III) to obtain EMA authorisation for EU-wide distribution, targeted for 2017.

Autologous cell-based transplants

co.don specialises in the regenerative treatment of articular cartilage and spinal disc defects. Cells taken from the patient's own cartilage and blood are cultivated outside the body using co.don's innovative biological techniques to create cartilage, which is then transplanted back into the damaged area. The transplant is via a minimally invasive procedure, distinguishing co.don from other autologous cartilage repair products, so conferring a distinct advantage. This cell-based replacement for the defect can be used to allay or delay the need for surgical joint replacement or spinal surgery. As of February 2015, over 7,000 patients have been treated with co.don's cell transplants in Germany, the majority with chondrosphere.

EMA authorisation expected on the back of Phase III

Although co.don's products have been sold in the German market since 1997, EMA authorisation is required for EU-wide distribution. To this end, chondrosphere is in two clinical trials for the treatment of cartilage defects. The Phase III trial evaluating its efficacy and safety is fully recruited (102 pts) and results are expected in 2017. Interim results from the long-term Phase II trial (75 pts) have shown significant improvements across two efficacy scores (patient-reported and imaging-based). EMA authorisation is expected in 2017. co.don estimates the European market for articular perseveration therapies to be over €1bn.

Valuation: EV of €32.9m

Strong revenues of €3.7m in the first nine months of FY15 (y-o-y +14%) resulted in operating break even excluding expenses related to the EMA approval (net loss -€1.5m). Consensus estimates indicate profitability is anticipated in 2017 once the authorisation expenses cease, followed by a significant increase in revenues as co.don enters new markets. With cash of €1.1m at H115, the EV is €32.9m; this appears modest given the opportunity to expand into the wider European market.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (c)	P/E (x)	Yield (%)
12/13	3.6	(2.7)	(0.23)	0.0	N/A	N/A
12/14	4.5	(2.5)	(0.18)	0.0	N/A	N/A
12/15e	5.3	(2.5)	(0.18)	0.0	N/A	N/A
12/16e	6.5	(0.8)	(0.06)	0.0	N/A	N/A

Source: Company data, Thomson Reuters

Price	€2.47
Market cap	€34m

Share price graph

Share details

Code	CNWK
Shares in issue	13.7m
Net cash (€m) at 30 September 2015	1.1

Business description

co.don AG is a fully integrated biopharmaceutical company, with a focus on commercialising its regenerative medicines for cartilage repair. Lead product chondrosphere is used for the treatment of articular cartilage defects. A second product, chondrotransplant DISC, is used for the treatment of spinal disc defects.

Bull

- Established market base and successful distribution in Germany
- Double-digit revenue growth y-o-y
- Positive interim findings from Phase II trial supports case for EMA authorisation

Bear

- EMA authorisation is delayed or fails.
- Possible need for additional financing prior to EMA authorisation (expected in 2017).
- Dependent upon positive reimbursement decisions in other EU countries.

Analysts

Dr Lucy Codrington +44 (0)20 3681 2527

Christian Glennie +44 (0)20 3077 5727

healthcare@edisongroup.com

EDISON

Epigenomics AG

Pharma & healthcare

Epi proColon – impending FDA decision

The conclusion of the behavioural study (ADMIT) may pave the way for US regulatory approval and launch of Epigenomics' novel Epi proColon blood-based colorectal cancer (CRC) test in Q415. While ADMIT proved superior compliance using Epi proColon, the abnormally high compliance rate in the control group may prolong the approval process. Eventual progress towards US approval may however, support a share price recovery.

Preference for blood tests supports Epi proColon

Epi proColon is a molecular diagnostics test for colorectal cancer (CRC) screening. Its US regulatory filing (PMA) was based on two large studies that showed sensitivity (across all CRC stages) of 68-72% at a specificity of 80-82% vs 50-68% and 98% for traditional faecal tests and 92% and 87%, respectively, for the faeces-based molecular diagnostic test, Cologuard. The ability to identify early-stage CRC and the presumed patient preference for blood- versus stool-based tests is crucial.

Epi proColon broadly accepted in ADMIT study

The ADMIT behavioural study concluded in Q2 showed 99.5% compliance of Epi proColon vs 88.1% for the standard faecal test, FIT. Designed to assess if adherence to Epi proColon would be higher than FIT plus an 8.2% margin, the study fell just short of statistical significance (p=0.059). The high compliance rates (typically 80% for blood-based tests and 12% for FIT) may protract the approval process. If the FDA deliberates for the entire 180-day response period or requests further studies, an approval may only occur in late Q415 or later (respectively).

US launch likely to be a gradual ramp

Epigenomics is preparing Epi proColon's impending US launch. As a reference point, Exact Sciences' launch in Q314 of its DNA-based Cologuard CRC test was well executed, with revenues rising from \$1.5m in Q414 to \$4.3m in Q115 and \$8.0m in Q215. Similarly, the adoption of Epi proColon will be dictated by the speed at which it secures reimbursement and the marketing power of its partner, Polymedco. It aims to price Epi proColon tests at \$75-90, assuming a lab reimbursement of \$140 per test (Cologuard is reimbursed at \$493 by Medicare).

Valuation: €76m EV reflects the FDA uncertainty

The EV of €76m reflects uncertainty on the FDA approval. It compares with its cancer diagnostic peers Exact Sciences' €0.4bn (€/\$1.13) and VolitionRx at €64m.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	1.6	(7.3)	(0.62)	0.0	N/A	N/A
12/14	1.5	(8.9)	(0.74)	0.0	N/A	N/A
12/15e	3.2	(11.2)	(0.68)	0.0	N/A	N/A
12/16e	16.1	(2.0)	(0.20)	0.0	N/A	N/A

Source: Epigenomics, Thomson Reuters

Price	**€4.79**
Market cap	**€86m**

Share price graph

Share details

Code	ECX
Shares in issue	17.9m
Net cash (€) as at end June 2015	9.8m

Business description

Epigenomics is a German molecular diagnostics company focused on early detection of cancer. Its main product is Epi proColon, a blood-based DNA test for colorectal cancer that uses a sophisticated PCR assay to detect methylated copies of the septin9 gene.

Bull

- Blood-based test likely to be preferred above existing standard stool-based FIT testing.
- Commercial agreement with established CRC test distributor.
- In the US, CRC detection screening is recommended on an annual basis.

Bear

- Cost and reimbursement may be key issues.
- Uncertainty of the FDA decision.
- Higher overall efficacy of Exact Sciences' combined FIT and a stool DNA test.

Analysts

Hans Bostrom	+44 (0)20 3681 2522
Christian Glennie	+44 (0)20 3077 57 27

healthcare@edisongroup.com

Epigenomics is a research client of Edison Investment Research Limited

EDISON

Erytech Pharma S.A.

Pharma & biotech

On-track for Graspa EU approval in 2016

Erytech's lead product Graspa/Eryasp for leukaemia has been filed in Europe. If approved, Graspa will be commercialised by EU partner Recordati. In the US, the strategy is evolving, with a potential rapid path to market via a niche indication, which Erytech could commercialise alone. Erytech's technology could have applicability beyond blood cancers, including in solid tumours, in addition to numerous other indications.

Graspa filed in Europe; potential approval by YE16

Graspa/Eryasp (encapsulated asparaginase, a mainstay leukaemia treatment in children) has successfully completed a Phase III trial for the treatment of ALL (acute lymphoblastic leukaemia), demonstrating superior safety and duration of activity in children and adult ALL patients who have relapsed on previous L-asp treatment. Graspa was filed in Europe in September, which could allow for initial approval by YE16, triggering a €7-8m milestone and first launches by EU partner Recordati.

Potential rapid path to market in the US

In the US, a Phase Ib ALL trial is ongoing, which should accelerate owing to recent protocol amendments. Furthermore, Erytech plans to commence a formal trial in patients allergic to both available L-asp forms ('double-allergic'), following encouraging data from a patient access programme. This could potentially provide an accelerated path to market in the US. Eryasp/Graspa is also being investigated in AML (acute myeloid leukaemia) and in solid tumours (pancreatic cancer). A trial in NHL (non-Hodgkin's lymphoma) is also planned. Erytech is currently considering a US IPO; timings and terms are to be determined.

Unique benefits of red blood cell technology

Erytech's red blood cell (RBC) encapsulation technology captures therapeutic proteins within RBCs. This process protects both the molecule from degradation, extending the half-life, and the patient from exposure to potentially dangerous compounds, reducing severe reactions. The increased half-life allows smaller quantities of molecule to achieve similar efficacy, thereby improving safety.

Valuation: Risk-adjusted NPV of €299m

We value Erytech at €299m including a 90% probability on Graspa in ALL in Europe in addition to risk-adjusted contributions in AML, NHL and solid tumours. Our valuation assumes that Erytech will retain development and commercialisation rights in the US in ALL, rather than seeking a partner.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	1.8	(8.2)	(174.3)	0.0	N/A	N/A
12/14	2.0	(9.0)	(150.7)	0.0	N/A	N/A
12/15e	2.6	(14.8)	(214.3)	0.0	N/A	N/A
12/16e	2.8	(15.3)	(221.5)	0.0	N/A	N/A

Source: Erytech Pharma, Edison Investment Research

Price	**€30.16**
Market cap	**€208m**

Share price graph

Share details

Code	ERYP
Shares in issue	6.9m
Net cash (€m) at end June 2015	30.3

Business description

Erytech is a French oncology company with a red blood cell encapsulation technology. Lead product Graspa has been filed in Europe for ALL and is in development in the US. A Phase IIb in AML and a Phase II in pancreatic cancer are ongoing. Graspa is partnered with Orphan Europe/Recordati in Europe.

Bull

- Graspa is now filed in Europe following a successful Phase III trial in ALL.
- Experienced partner Recordati to commercialise Graspa in Europe.
- Broad applicability of the technology platform.

Bear

- L-asp is less established in other cancers, including solid tumours.
- Clinical trial failure or delays in other indications.
- Potential execution risk and higher initial capital outlay in the US if Erytech commercialises alone in ALL.

Analysts

Dr Philippa Gardner	+44 (0)20 3681 2521
Christian Glennie	+44 (0)20 3077 5727

healthcare@edisongroup.com

Erytech Pharma is a research client of Edison Investment Research Limited

Evotec AG

Pharma & biotech

Accelerating growth

Evotec's business is in a strong position with recent alliances, +37% revenue growth reported with H115 and 2015 financial guidance recently increased. Growth was delivered by the key drivers EVT Innovate (the collaborative academic/pharma drug discovery business) and EVT Execute (the preclinical “services” business). These should remain the near- to mid-term drivers, with prospects further underpinned by the acquisition of Sanofi’s Toulouse facility.

Growth drivers: EVT Innovate supported by Execute

In the near to mid-term, the key growth drivers for Evotec are EVT Innovate, supported by EVT Execute. Evotec recently increased 2015 financial guidance given the “strong business performance of EVT Execute, accelerated growth in the EVT Innovate business and a positive outlook for the remainder of the year”, now targeting group revenue growth of 45% (from >35%).

New and broadened collaborations

One of Evotec’s main priorities has been the formation of strategic alliances and commercial partnerships. A number of new and broadened collaborations have recently been executed, including in tissue fibrosis with Pfizer (which originated from an early academic initiative), diabetes and immuno-oncology with Sanofi, Alzheimer's disease and Huntington's, broadening and diversifying Evotec's pipeline of opportunities. Evotec currently has a pipeline of >70 product opportunities, including seven in clinical development.

Sanofi deal provides more room to grow

Earlier this year, Evotec strengthened its position as a leading provider of drug discovery outsourcing services by acquiring Sanofi's Toulouse facility at no cost. The deal provides much needed additional capacity and enhances Evotec’s capabilities, particularly in the field of oncology with access to Sanofi’s library of 1.3m compounds. Furthermore, running costs of the facility are covered, with Evotec set to receive €250m over the next five years. The deal is also important to help drive future EVT Innovate and EVT Execute collaborations.

Valuation: Currently under review

Our valuation and forecasts are currently under review following the recent upgrade to guidance and pending Q315 financial results on 10 November.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	85.9	5.1	4.0	0.0	N/A	N/A
12/14	89.5	(0.7)	(2.0)	0.0	N/A	N/A
12/15e	N/A	N/A	N/A	N/A	N/A	N/A
12/16e	N/A	N/A	N/A	N/A	N/A	N/A

Source: Evotec, Edison Investment Research

Price	**€3.95**
Market cap	**€523m**

Share price graph

Share details

Code	EVT
Shares in issue	132.4m
Net cash (€m) at end June 2015	118.3

Business description

Evotec is a German healthcare company that provides high-quality drug discovery services to pharmaceutical companies (including Bayer, Boehringer Ingelheim, Janssen and Roche), in addition to collaborations with academic institutions to create novel drug discovery programmes.

Bull

- Innovative pipeline and partnerships to drive long-term growth.
- Growing and differentiated drug discovery services business.
- Well capitalised to accelerate its innovative drug discovery strategy.

Bear

- Services business growth dependent on outsourcing strategy of pharma companies.
- Pipeline products could fail in clinical trials.
- Progress of partnered products/programmes depends on licensing partners.

Analyst

Dr Philippa Gardner +44 (0)20 3681 2521

healthcare@edisongroup.com

Evotec is a research client of Edison Investment Research Limited

MagForce AG

On the path to the US; first sales in Europe

During 2015, MagForce has made progress in both the US and Europe with its NanoTherm nanoparticle-based therapy for cancer. First commercial patients have received treatment in Germany for brain cancer, where the product is already approved. A clinical trial is ongoing to drive uptake and acceptance of this novel treatment. In the US, first steps towards the initiation of a clinical study in prostate cancer have been taken.

IDE filed in the US for prostate cancer

MagForce USA has filed an IDE (investigational device exemption) in the US, which is required to commence the first clinical trial with NanoTherm therapy in the US as monotherapy focal treatment for localised prostate cancer. A trial in around 120 patients is planned. MagForce has already discussed and obtained feedback from the FDA on its proposed development strategy. We assume that MagForce will aim to install a small number of NanoActivators in the US for the trial.

Installations and commercial treatments in Europe

In Europe there are five NanoActivators installed in Germany (Berlin, Munster, Kiel, Cologne and Frankfurt) and commercial glioblastoma (GBM) patients have received therapy at three centres to date (Munster, Kiel and Cologne). We anticipate at least one further installation in coming months (in Gottingen), which should help with recruitment into the ongoing GBM post-marketing trial and continued uptake by commercial patients in 2015 and beyond.

NanoTherm represents a new approach in cancer

MagForce's NanoTherm therapy is designed to directly affect tumours from within, while sparing surrounding healthy tissue. Magnetic nanoparticles are directly injected into a tumour and are then heated in the presence of an external magnetic field generated by specialist equipment (NanoActivator), which either destroys or sensitises the tumour for additional treatment such as chemo or radiotherapy.

Valuation: Risk-adjusted NPV of €252m

We value MagForce at €252m or €9.8/share, based on a risk-adjusted NPV analysis. Our valuation includes the NanoTherm opportunity in the US and Europe in both prostate cancer and GBM, probability adjusted to reflect the current stage of development, with 100% in Europe for GBM where it is approved. Start of the IDE clinical studies in the US could lead us to increase our current 50% probability.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	0.0	(6.7)	(33.7)	0.0	N/A	N/A
12/14	0.0	(7.9)	(32.8)	0.0	N/A	N/A
12/15e	3.6	(7.5)	(29.4)	0.0	N/A	N/A
12/16e	6.8	(4.6)	(18.0)	0.0	N/A	N/A

Source: MagForce, Edison Investment Research

Pharma & biotech

Price	€5.31
Market cap	€136m

Share price graph

Share details

Code	MF6
Shares in issue	25.6m
Net cash (€m) at end June 2015	5.4

Business description

MagForce is a German firm with a European approved nanotechnology-based therapy to treat brain tumours. NanoTherm therapy consists of nanoparticle injection into the tumour, activated by an external magnetic field, producing heat and thermally destroying or sensitising the tumour.

Bull

- EU approved nanotechnology-based cancer therapy with an installed base in Germany.
- Funds to execute US development and IDE filed.
- Limited treatment options for GBM.

Bear

- Commercial roll-out could take time.
- Will need physician acceptance to utilise a novel technology.
- Clinical trial delays or failures.

Analyst

Dr Philippa Gardner +44 (0)20 3681 2521

healthcare@edisongroup.com

MagForce is a research client of Edison Investment Research Limited

Mologen AG

Pharma & biotech

Pivotal cancer immunotherapy player

Mologen is developing cancer immunotherapies for the post-chemo maintenance setting. Lead product, MGN1703, is in three clinical trials for different indications. Following the €28.3m (gross) proceeds from the rights issue in April 2015, Mologen should have sufficient funds to reach full recruitment of IMPALA (Phase III in colorectal cancer) and top-line data from IMPULSE (Phase II in lung cancer); the latter could positively affect partnering or financing options for MGN1703. We value Mologen at €384m.

Multiple clinical trials underway

MGN1703, an innovative best-in-class TLR9 agonist, is currently in three clinical trials. Data from the pivotal study, IMPALA, in metastatic colorectal cancer (mCRC), are due by end 2017, a significant value inflection point for Mologen. Meanwhile, top-line data from the fully recruited Phase II IMPULSE study in small cell lung cancer (SCLC) are expected in H216 and could prompt licensing discussions. Finally, recruitment has completed for the Phase I TEACH study to treat HIV, the first non-cancer study for MGN1703; promising data from the study could expand the use of MGN1703 beyond cancer applications.

MGN1703: Building on IMPACTful data

MGN1703 is an immunomodulating drug that broadly activates the immune system, enabling it to increase the recognition and combat of cancer cells. To date, Mologen has reported encouraging preliminary overall survival (OS) data from a 59-pt Phase II study in mCRC (IMPACT). In patients who initially responded to induction chemo, there was a pronounced OS benefit (24.5 months) vs placebo (15.1 months). This underscores the IMPALA trial design, which only includes chemo-responders.

MGN1601: Unique renal cancer cell vaccine

The 19-pt Phase I/II ASET study found MGN1601 to be safe. Additionally, it showed promising OS data in a subgroup of patients and certain predictive biomarkers were identified. A Phase II study is planned subject to financing and/or a partner.

Valuation: Risk-adjusted NPV of €384m

We value Mologen at €384m, or €17/share, based on a risk-adjusted NPV analysis of the product portfolio (MGN1703 and MGN1601). The rights issue extended the cash runway into 2017, incorporating key milestones: IMPULSE top-line data (H216) and full enrolment of IMPALA (Q416). We forecast fresh financing of €30m in 2017 to complete IMPALA; however, we note that a partnership could be secured ahead of this, on the back of positive IMPULSE data.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/13	0.2	(9.9)	(0.64)	0.0	N/A	N/A
12/14	0.0	(17.0)	(1.01)	0.0	N/A	N/A
12/15e	0.0	(18.1)	(0.90)	0.0	N/A	N/A
15/16e	0.0	(20.0)	(0.96)	0.0	N/A	N/A

Source: Mologen, Edison Investment Research

Price	**€3.63**
Market cap	**€82m**

Share price graph



Share details

Code	MGN
Shares in issue	22.6m
Net cash (€) at 30 June 2015	34.9

Business description

Mologen is a German biotech company developing novel cancer immunotherapies. The lead products are MGN1703 (TLR9 agonist) for metastatic colorectal cancer maintenance and SCLC, which has also recently started a study in HIV; and MGN1601, an allogeneic renal cancer cell vaccine.

Bull

- Phase II study with MGN1703 showed pronounced OS benefit in certain subgroups.
- MGN1703's mechanism of action means use could be extended beyond cancer indications.
- Immunotherapy is a multi-billion dollar market.

Bear

- Dependent on fresh financing/partnership to complete IMPALA study.
- Partner not secured on back of IMPACT study.
- Trials conducted to date in small patient numbers.

Analysts

Dr Lucy Codrington +44 (0)20 3681 2527

healthcare@edisongroup.com

Mologen is a research client of Edison Investment Research Limited

EDISON

MorphoSys AG

Pharma & biotech

Shifting focus to internal pipeline

MorphoSys is in the process of transforming itself into a fully integrated biopharmaceutical company by focusing on its proprietary programmes rather than those of its partners. The company will commence Phase II trials for MOR208 in diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL) over the next six months, with a Phase III trial in DLBCL expected to start in 2017. MOR202 Phase I/IIa trials in multiple myeloma (MM) are ongoing with a Phase III expected to commence in 2017.

A large, but partner-focused pipeline to date

Historically, the company has been focused on partnered programmes that will provide it with a mid-single digit royalty once the programmes are approved (two of these, bimagrumab and guselkumab, are expected to have NDA filings in 2016). As of the end of June, MorphoSys had a total of 102 programmes, 88 of which were partnered (20 in the clinic) and 14 of which were internal (four in the clinic).

MOR208: The tip of the spear

The lead proprietary programme is MOR208 (anti-CD19 antibody), which has had promising Phase II monotherapy data in DLBCL. MorphoSys plans to further develop the product in a Phase II in combination with lenalidomide in second-line relapsed/refractory DLBCL patients in Q415 and a Phase II trial in CLL in combination with idelalisib in BTKi-failures in Q116. A pivotal study of MOR208 in combination with bendamustine is expected to commence in 2017. We project potential peak sales of ~$1.5bn for this product.

MOR202: Rejuvenating to relicense

Celgene returned the rights to MOR202 in MM earlier this year for strategic reasons and MorphoSys plans to continue development and relicense the product. It released promising interim data at ASCO and IMW and intends to initiate a Phase III combination trial in 2017. We project potential peak sales of $880m.

Valuation: DCF valuation of €1.78bn

We value Morphosys at €1.78bn (€67.24 per share). As the company has 24 clinical programmes, there are lots of potential catalysts that could increase the valuation, including additional data from MOR208 and MOR202 at the American Society of Hematology conference (ASH, 5-8 December) and the filing of bimagrumab and guselkumab by partners.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	78.0	14.0	43.5	0.0	N/A	N/A
12/14	64.0	(1.6)	(1.3)	0.0	N/A	N/A
12/15e	105.7	19.9	68.2	0.0	N/A	N/A
12/16e	48.5	(72.5)	(188.9)	0.0	N/A	N/A

Source: Morphosys, Edison Investment Research

Price	**€57.31**
Market cap	**€1,490m**

Share price graph

Share details

Code	MOR
Shares in issue	26.0
Net cash (€) at 30 June 2015	347.4

Business description

MorphoSys is a German biotechnology company. It uses its proprietary technologies to develop human antibodies and peptides for therapeutic use and has 24 antibodies in its clinical pipeline. Its lead proprietary R&D programmes are MOR208 for DLBCL and CLL, as well as MOR202 for MM.

Bull

- A large, diverse pipeline of 102 programmes, including 24 in the clinic.
- MOR208 and MOR202 are proprietary programmes targeting large commercial opportunities.
- Well-funded through at least 2017 and longer with additional partnership deals and partnered programme approvals.

Bear

- Developing proprietary programmes can be expensive and risky.
- Partnered programmes will not contribute meaningful royalties until 2018-19 at the earliest.
- Novartis partnership scheduled to expire at the end of 2017 (although there is an option for a two-year extension). Its conclusion would eliminate €40m in annual funding.

Analyst

Maxim Jacobs +1 646 653 7027

healthcare@edisongroup.com

MorphoSys is a research client of Edison Investment Research Limited

EDISON

Newron Pharmaceuticals S.p.A

Pharma & biotech

First Xadago sales; US decision by end Q116

Xadago for the treatment of Parkinson's disease is now generating initial sales in Europe following first launch in Germany, leading to royalty income to Newron from partner Zambon. The US regulatory review was recently extended by three months to end March 2016. Beyond Xadago, Newron has prioritised development of orphan drug sarizotan for Rett syndrome (a rare genetic condition) with a pivotal trial planned to start in Q415. Partnering candidate NW-3509 for schizophrenia is also advancing.

First Xadago royalties on initial sales in Germany

Newron has received first royalties from commercial partner Zambon on initial sales of Xadago in Parkinson's disease (PD) in Germany following launch in mid-May. Xadago is priced at around a 40-60% premium to closest comparable Azilect. This is suggestive that health authorities in Germany recognise that Xadago can offer advantages over Azilect (including long-term benefits), which should also aid with physician and patient uptake. We expect further launches across Europe as pricing and reimbursement are agreed by partner Zambon in coming months.

US regulatory decision now in March 2016

The FDA review process was recently extended by three months to process additional submissions (not data-related). The new PDUFA decision date is 29 March 2016. Zambon continues to focus on sub-licensing in this key region.

Pivotal sarizotan trial planned

Newron has a pipeline of three Phase II orphan drugs, which include sarizotan for Rett syndrome (RS), sNN0031 for severe PD and sNN0029 for ALS/Lou Gehrig's disease. These could all be commercialised alone. Newron has prioritised sarizotan and a placebo-controlled Phase II/III trial to investigate breathing disorders associated with RS is being planned, which could potentially support filings. In addition, Newron is advancing NW-3509 as a potential treatment for schizophrenia patients who are poor responders to antipsychotics ahead of potential partnering.

Valuation: Risk-adjusted NPV of CHF526m

We value Newron at CHF526m or CHF24.9/share based on a risk-adjusted NPV analysis, which includes Xadago, the portfolio of orphan drugs and NW-3509. Our valuation includes €450m of peak Xadago PD sales (in the US and Europe) in addition to a contribution in dyskinesia.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	3.5	(7.7)	(61.8)	0.0	N/A	N/A
12/14	1.6	(10.7)	(79.7)	0.0	N/A	N/A
12/15e	7.1	(11.1)	(82.4)	0.0	N/A	N/A
12/16e	5.8	(11.1)	(79.9)	0.0	N/A	N/A

Source: Newron, Edison Investment Research

Price	**CHF29.35**
Market cap	**CHF411m**

Share price graph



Share details

Code	NWRN
Shares in issue	14.0m
Net cash (€m) at end June 2015	43.1

Business description

Newron Pharmaceuticals is an Italian CNS-focused biotechnology company. Safinamide/Xadago for Parkinson's disease has been approved in mid-late PD in Europe and launched in Germany; the US PDUFA date is 29 March 2016. Safinamide is partnered with Zambon and Meiji Seika.

Bull

- Xadago approved in Europe and launched in Germany by partner Zambon.
- Xadago could have a unique profile (once a day, clean safety) in the growing PD market.
- Pipeline of orphan drugs, which could be commercialised alone.

Bear

- Xadago US regulatory setbacks or delays.
- Zambon does not have a presence in certain markets, including the US.
- Clinical trial failures with the orphan drug pipeline.

Analysts

Dr Philippa Gardner	+44 (0)20 3681 2521
Christian Glennie	+44 (0)20 3077 5727

healthcare@edisongroup.com

Newron Pharmaceuticals is a research client of Edison Investment Research Limited

EDISON

Paion AG

Healthcare

Late-stage specialty pharma

Paion is at an advanced stage in developing its ultra-short acting sedative remimazolam in pivotal studies in the US in procedural sedation. Paion has also launched the Phase III European study in lead indication general anaesthesia, focusing on efficacy and safety vs standard of care. Paion is evaluating its commercial options in the US, Europe and Japan, which will determine potential deal economics.

US studies underway in procedural sedation

Paion has initiated two pivotal Phase III US trials for remimazolam. The first is in procedural sedation during colonoscopy. The double-blind midazolam and placebo-controlled study will enrol 460 patients undergoing colonoscopy (c 20m procedures per year). The second study will test remimazolam in a frailer patient group undergoing bronchoscopy. There is a strong economic rationale to use remimazolam in place of approved generic sedatives, given the potential for cost savings from increased patient throughput or reduced patient supervision.

Europe Phase III kick-off in general anaesthesia

Paion's European strategy focuses on remimazolam's potential in general anaesthesia as a safer alternative to gold-standard propofol, which has known side effects including cardiopulmonary depression. The Phase III programme, launched in August, includes a randomised, prospective two-arm study in up to 530 higher-risk patients. A European Phase II study and Phase III Japanese programme confirmed remimazolam's excellent safety profile.

H115 cash position covers trial costs

Paion ended H115 with €47m in net cash, sufficient to finance US and European trials. Operating expenses increased to €14.7m vs €6.2m in H114, including €12m of R&D expense for US Phase III studies. Paion states a further €10m is required to establish a supply chain, securing preproduction of market material (stockpiling) for launch and for the Japan filing dossier. We add €5m of this cost in FY16 taking year-end 2016 cash to €9m from €14.5m.

Valuation: Sum-of-the-parts DCF valuation €224m

Our sum-of-the-parts DCF valuation is €224m or €4.4/share based on peak sales of Remimazolam of $825m. Catalysts include confirmation of Paion's commercial strategy and clarity on the timing of the Japanese filing of remimazolam.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	4.2	(2.6)	(7.2)	0.0	N/A	N/A
12/14	3.5	(11.6)	(22.9)	0.0	N/A	N/A
12/15e	0.0	(30.6)	(50.6)	0.0	N/A	N/A
12/16e	1.0	(26.8)	(48.8)	0.0	N/A	N/A

Source: Paion, Edison Investment Research

Price	€2.2
Market cap	€112m

Share price graph

Share details

Code	PA8
Shares in issue	50.7m
Net cash (€m) at Q215	47

Business description

Paion is an emerging specialty pharma company developing anaesthesia products. Its lead product, remimazolam, is partnered with Yichang in China, Hana Pharma in South Korea, Pendopharm in Canada and R-Pharm in CIS, Turkey and MENA.

Bull

- Three Phase III studies underway.
- Remimazolam has an excellent safety profile and a substantial body of clinical data.
- Paion is funded to cover Phase III studies.

Bear

- Generic sedatives are available.
- Single clinical product in development.
- Around €10m of funding is needed to cover pre-marketing and commercial-scale production expenses.

Analysts

Emma Ulker +44 (0)20 3077 5738

Christian Glennie +44 (0)20 3077 5727

healthcare@edisongroup.com

Paion is a research client of Edison Investment Research Limited

EDISON

Probiodrug AG

Pharma & biotech

Pure-play Alzheimer's disease

Probiodrug is a pure-play Alzheimer's disease (AD) company, developing a clinical pipeline that focuses on a novel, earlier-stage AD target, pGlu-Abeta, which could allow successful development of a disease-modifying therapy for AD. With the growing AD market, this could represent a multi-billion dollar opportunity. Current cash should provide sufficient funding until data readout of the Phase II trial of PQ912, after which Probiodrug will likely seek a partner. We value Probiodrug at €217.5m or €32.1/share.

Targeting earlier-stage Alzheimer's disease

Probiodrug's pipeline targets pGlu-Abeta, a toxic variant of amyloid-beta (Abeta), which has been implicated as an initiating and sustaining factor in the pathological cascade leading to AD. There is revived confidence in an Abeta-directed approach, with recent data of two antibodies targeting Abeta suggesting a disease-modifying effect. Probiodrug believes that its more refined approach, acting earlier in the Abeta pathway, could prove even more effective with potentially fewer side-effects.

New insights in AD drug development

The failures of previous therapies and recent successes of new therapies targeting Abeta have led to new insights into how to optimise chances of success in AD trials. Current thinking is that treatments must be given earlier in the disease course to be effective and patients should be screened to ensure AD pathology is present. Accordingly, Probiodrug is focusing on early-stage AD, and using CSF biomarkers to ensure patients included in trials have pathological evidence of AD disease.

Lead product in Phase II with data mid-2016

Recruitment for the Phase IIa trial of PQ912 is on track. Although the trial is primarily a safety and tolerability study, data from exploratory readouts should provide important insights into the drug's potential interference with AD pathology, resulting in cognitive benefits. The trial is on track to deliver first data in mid-2016, and if positive, this could trigger a partnership.

Valuation: Risk-adjusted rNPV of €217.5m

We value Probiodrug at €217.5m, or €32.1/share, based on a risk-adjusted NPV analysis, including net cash and PQ912 in mild AD. Our model suggests net cash of €14.8m at end-H115 should be sufficient to fund operations to mid-2016, around the time initial data from the Phase IIa study are expected.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/13	0.0	(9.8)	(2.30)	0.0	N/A	N/A
12/14	0.0	(11.4)	(2.35)	0.0	N/A	N/A
12/15e	0.0	(11.7)	(1.73)	0.0	N/A	N/A
12/16e	0.0	(12.1)	(1.79)	0.0	N/A	N/A

Source: Probiodrug, Thomson Reuters

Price	**€20.00**
Market cap	**€136m**

Share price graph

Share details

Code	PBD
Shares in issue	6.8m
Net cash (€) as at 30 June 2015	14.8

Business description

Probiodrug is a German biopharmaceutical company developing its clinical pipeline for the treatment of Alzheimer's disease. Lead product candidate, PQ912, has entered Phase IIa. PQ912 is a small molecule inhibitor of glutaminyl cyclase (QC), which is essential for the formation of pGlu-Abeta. Two further products are in preclinical stages.

Bull

- Recent successes of therapies targeting Abeta.
- Disease-modifying therapy would have blockbuster potential; AD market growing.
- Cash to reach major milestone.

Bear

- AD drug development has high failure-rate.
- Will require further funding and/or partner to advance preclinical pipeline before SAPHIR data.
- Regulatory setbacks or delays.

Analysts

Dr Lucy Codrington +44 (0)20 3681 2527

Dr Philippa Gardner +44 (0)20 3681 2521

healthcare@edisongroup.com

Probiodrug is a research client of Edison Investment Research Limited

Stratec Biomedical AG

Healthcare equipment & services

Black forest biopsy

Stratec, the German designer and builder of automated OEM diagnostic systems, is poised for rapid growth in 2016 and 2017 due to the intensive level of activity on new systems in the late-development and pre-launch, ramp-up stages. A new development area of liquid cancer biopsy analysis is being developed plus smaller, flexible systems. Revenue guidance remains at 8-12% CAGR for 2013-17; growth should be stronger from 2016. Management expects an FY15 EBIT margin over 17.9%. It is considering acquisitions that may affect dividends; Q3 cash was €54.7m.

Design them...

Stratec projects require software, engineering and electronic expertise with systems becoming more complex; Stratec retains critical IP. The emerging liquid-biopsy diagnostic area is one of several new development activities. In 2015 ytd Stratec incurred €15.8m of development expenditure and capitalised €10.2m. Capitalised amounts are recognised as revenues as projects progress. Stratec plans to expand its development activities due to client demand.

... build them – and then sell service parts for them

System sales ytd were lower than management expected due to some placement weaknesses by partners in Asia. Service part sales are reported to be improving. The UK middleware subsidiary is doing well. Total revenues in 2015 ytd were up 1.8% to €107.2m. Stratec generated a higher gross margin of 37% ytd vs 34% for FY14. This was due to increased purchasing efficiencies; however a lower level of development revenue recognition and increased service part sales might have helped.

Valuation: Strong growth projected from 2016

Management guidance of an 8-12% CAGR over 2013-17 implies 2017 revenues of between €174m and €201m. The bulk of the growth from 2016 must come from new system launches, growth from recently launched products and from a rise in development project activities; this will also increase headcount and costs. EBIT margin ytd was 17.9% and is guided by management to exceed this for FY15. On our revised EBIT expectations the current share price implies a prospective 2017 P/E of 18x. Stratec has generally traded at a historic P/E of about 24x. Management has indicated that major strategic acquisitions are being considered. This may affect future dividend payments.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/13	128.0	19.5	1.8	0.60	27.8	1.2
12/14	144.9	24.1	2.2	0.70	22.8	1.4
12/15e	148.4	26.7	2.3	0.70	21.8	1.4
12/16e	165.2	30.6	2.5	0.70	20.0	1.4

Source: Stratec Biomedical, Edison Investment Research

Price	**€50.05**
Market cap	**€593m**

Share price graph

Share details

Code	SBS
Shares in issue	11.85m
Net cash (€m) at 30 September 2015	49.5

Business description

Stratec designs and manufactures OEM diagnostic systems. It is profitable with five key global clients. Design and assembly of systems is in central Germany and Switzerland. It has US and UK subsidiaries in optical measurement and software and a Berlin DNA extraction business.

Bull

- Leading expertise in diagnostic system design and owns key patents on system technologies.
- Expect high growth in 2016 and 2017 from new system launches.
- Full order book on new system development to drive future growth.

Bear

- Very dependent on three to five key customers and their market success and timelines.
- Opaque accounting due to complex treatment of development contracts.
- Most profit from service parts sales that have been volatile and hard to predict.

Analysts

Dr John Savin MBA +44 (0)20 3077 5735

healthcare@edisongroup.com

Stratec Biomedical is a research client of Edison Investment Research Limited

EDISON

Sygnis AG

Pharma & biotech

Truly sunny sequencing technologies

Sygnis uses its own website and an international distributor network to sell its own-brand TruePrime kits for gene analysis. A new enzyme, SunScript, has been added to the range. A new product for research in cancer diagnosis and monitoring could be added in 2016. These kits offer increased reliability and efficiency over older products, due to the novel engineered enzymes designed and produced by Sygnis. Cash at 30 June was €1.3m. H115 had revenues of €196k; H1 cash outflow was €2.4m.

Proprietary and sophisticated technology

Amplification is a core molecular biology technique used before DNA analysis and gene sequencing. Sygnis's core IP is a range of novel engineered enzymes sold as a key part of high-value molecular biology kits. TruePrime kits copy and amplify the whole genome, which enables a single cell to be sequenced. SunScript converts abundant, but delicate, RNA messages in cells to DNA for analysis or sequencing. SunScript is stable with high yields and sensitivity claimed and can be combined with TruePrime to enable sequencing. A new 2016 market might be cell-free tumour DNA for 'liquid biopsy' in cancer diagnostics.

Commercial development

Most revenues (H115 €0.2m, FY14 €0.3m) are licence fees from Caco cells (used in preclinical drug development). Royalties from Qiagen were disappointing at €15k in FY14. Own brand sales in H115 were 102 kits, with good user feedback reported by management; product revenues were low due to launch promotions. The distributor network set up in H115 is extensive and should start to deliver increased volumes and revenues in the autumn. A major boost to sales would be a deal to sell OEM kits with next-generation sequencing systems. In April 2015, Dr Viribay joined Sygnis as VP, sales and marketing from Thermo Fisher.

Valuation: 2015 launches, 2016 growth expectations

Management guides FY15 sales of €0.5-0.7m with €2.5m in 2016. This puts Sygnis on a prospective FY16 market cap to sales multiple of c 13.2x, implying high growth expectations. Sygnis raised €4.9m gross in equity in late 2014. H115 cash outflow was €2.4m. H1 cash was €1.3m. Management states that cash plus H215 sales and planned financial cash inflows will provide sufficient liquidity to cover operating expenses until break-even, which management estimates to be in 2016. A €0.9m debt to some shareholders is due for payment by year end, but might be extended.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	0.48	(3.05)	(32.1)	0.0	N/A	N/A
12/14	0.39	(1.92)	(19.3)	0.0	N/A	N/A
12/15e	0.65	(1.76)	(14.0)	0.0	N/A	N/A
12/16e	2.50	(0.06)	(1.1)	0.0	N/A	N/A

Source: Company data, Edison Investment Research

Price	**€2.46**
Market cap	**€33m**

Share price graph



Share details

Code	LIO1
Shares in issue	13.3
Net debt (€m) at 30 June 2015	1.6

Business description

Sygnis develops molecular tools for DNA and RNA analysis. Its expertise is engineering polymerases for the amplification and sequencing of DNA. Sygnis has direct sales of its TruePrime and SunScript-branded products and uses a network of distributors. A product, SensiPhi, is partnered with Qiagen.

Bull

- Brand ownership gives strong basis for value-added growth from web and distributor sales.
- Proprietary technology allows clear differentiation against older methods.
- Company restructured and focused with smaller Heidelberg laboratory and office now established.

Bear

- Qiagen sales slow on exclusive SensiPhi enzyme-based kits.
- Web brand slow to build in crowded market on limited sales budget, so heavy use of promotions.
- Needs more scientific papers to validate enzymes; work with key opinion leaders is underway.

Analyst

Dr John Savin MBA +44 (0)20 3077 5735

healthcare@edisongroup.com

Sygnis is a research client of Edison Investment Research Limited

EDISON

Transgene S.A.

Pharma & biotech

Restructuring to focus on R&D

Transgene is a biopharmaceutical company focused on the discovery, development and manufacture of immunotherapies for the treatment of cancer and infectious diseases. Its pipeline includes two Phase III-ready candidates, TG4010 (lung cancer) and Pexa-Vec (liver cancer), and TG1050 (hepatitis B), which is due to start Phase I in Q415. In June, Transgene announced a restructuring programme to focus the business on R&D, with plans to close its pharmaceutical development and bio-manufacturing capabilities (c €1.7m of revenue in 2014). Our valuation and financials are under review, pending further details.

Multiple clinical trials planned

The first patient is expected to be dosed in the Phase I trial of TG1050 for the treatment of chronic HBV in Q415. In addition to this, the Phase III trial of the oncolytic virus Pexa-Vec is also expected to be initiated in Q415. Transgene and its partner SillaJen have an SPA with the FDA for the design of the Phase III study in first-line hepatocellular carcinoma (HCC). While a Phase III trial of TG4010 in non-squamous non-small cell lung cancer (NSCLC) remains on hold until a partner is found, Phase II studies of TG4010 in combination with checkpoint inhibitors are planned, and should begin by the end of H116.

TG4010 combination trials could trigger partnership

A licensing deal could be triggered by evidence of synergistic action of TG4010 with checkpoint inhibitors in the planned Phase II trials. The trials will build on the Phase IIb stage of the TIME trial in non-squamous NSCLC, which demonstrated a significant overall survival benefit of 3.8 months versus chemotherapy alone; this improved to 4.9 months in those patients with low TrPAL biomarker expression.

Short-term costs for long-term gain

The closure of the standalone pharmaceutical development and bio-manufacturing business will affect c 120 personnel. Transgene plans to provide a strategic update once approval from French authorities is received. We expect that the initial costs of restructuring and loss of revenues will be justified by longer-term cost savings.

Valuation: Under review

Our valuation and financials are under review while we await the strategic business update (expected by end-2015). As TG4010 forms the bulk of our valuation, any delay to its development timeline will have a material impact on our valuation.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	15.7	(41.5)	(136.2)	0.0	N/A	N/A
12/14	11.8	(47.3)	(127.2)	0.0	N/A	N/A
12/15e	N/A	N/A	N/A	N/A	N/A	N/A

Source: Transgene, Edison Investment Research

Price	€2.85
Market cap	€110m

Share price graph

Share details

Code	TNG
Shares in issue	38.5m
Net cash (€m) at 30 September 2015	46

Business description

Transgene is a French drug discovery and development company focused on the treatment of cancer and infectious diseases with immunotherapies. It has two Phase III-ready products and one product in Phase I in development.

Bull

- Significant overall survival advantage demonstrated with TG4010 in TIME trial.
- Potential for combination therapies for the treatment of cancer increasingly recognised.
- Cancer immunotherapy a multibillion-dollar market.

Bear

- Initiation of Phase III trial of TG4010 dependent on securing a partner.
- Additional capital will be required to complete clinical trials in absence of partnership.
- Partner not secured for TG4010 on the back of Phase II data.

Analysts

Dr Lucy Codrington +44 (0)20 3681 2527
Dr Philippa Gardner +44 (0)20 3681 2521
healthcare@edisongroup.com

Transgene is a research client of Edison Investment Research Limited

![EDISON]

Wilex AG

Pharma & biotech

Seeking new partners

Wilex's subsidiary, Heidelberg Pharma, is developing antibody targeted amanitin conjugates (ATACs), which are differentiated from first-in-class and developing antibody drug conjugates by potential efficacy against dormant and proliferating tumours. The investment case rests on the company's ability to form new partnerships for the ATAC pipeline and on clinical partnering progress for renal cancer programmes.

The power of ATACs

Wilex's ATACs use the toxin α-Amanitin from the green death cap mushroom. The principle of anti-cancer antibody drug conjugates (ADCs) is to use the very high specificity of antibodies and link them to toxic small molecules. ATACs could prevent tumour relapse and resistance in slower-growing tumours while many ADC technologies block only proliferating tumour cells. Wilex has a proprietary preclinical pipeline of undisclosed ATACs. Separately, it is developing ATACs against prostate-specific membrane antigen (PSMA) in prostate tumours.

Seeking out new ventures

In August, Roche communicated its strategic decision to discontinue its collaboration with Heidelberg Pharma in the field of ATACs. The decision was mainly based on Roche's focus on immunotherapy despite the very good progress made in the ATAC collaboration. Wilex continues to seek new research collaborations for its proprietary pipeline based on its pioneering approach in ADC cancer therapy. Preclinical results published in *Nature* this year are likely to assist Wilex in its discussions with future licence partners.

Clinical pipeline

The clinical pipeline consists of uPA-inhibitor Mesupron out-licensed in Asia and RoW regions for oncology indications. Wilex seeks separate partners to progress its Phase III clear cell renal cancer pipeline: Redectane a diagnostic, and Rencarex, an adjuvant therapy. Wilex derives services revenues (€1.4m in FY14) from Heidelberg. The company guides to a cash reach to the end of Q116.

Valuation: EV of €14m

Wilex has seen a c 30% share price fall since the announcement of the discontinuation of the Roche collaboration in August. We have withdrawn our forecasts and valuation subject to clarity on strategic plans.

Historical financials

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
11/13	19.1	(5.0)	(64.3)	0.0	N/A	N/A
11/14	5.0	(5.6)	(72.9)	0.0	N/A	N/A
11/15e	N/A	N/A	N/A	N/A	N/A	N/A
11/16e	N/A	N/A	N/A	N/A	N/A	N/A

Source: Wilex

Price	€1.98
Market cap	€18m

Share price graph



Share details

Code	WL6
Shares in issue	9.3m
Net cash (€m) at end June 2015	4.1

Business description

Wilex is focusing on the novel antibody drug conjugate (ADC) technology and contract research at its Heidelberg Pharma subsidiary. The company out-licensed Mesupron to Link Health (China, HK, Taiwan, Macao) and to RedHill Biopharma (RoW). It requires partners to progress its clear cell renal cancer programmes: Redectane, a diagnostic, and Rencarex, an adjuvant therapy.

Bull

- Differentiated ATAC technology potentially more effective than developing ADCs.
- Proprietary preclinical ATAC pipeline could attract new collaborations.
- PSMA ATAC project could yield new clinical candidates.

Bear

- Short cash reach.
- Discontinuation of Roche collaboration.
- Time has elapsed with no partnership deal being formed for renal cancer programmes.

Analysts

Emma Ulker	+44 (0)20 3077 5738
Christian Glennie	+44 (0)20 3077 5700

healthcare@edisongroup.com

Wilex is a research client of Edison Investment Research Limited

Technology

All for One Steeb AG

Technology

SAP HANA and the cloud are major opportunities

All for One Steeb is the leading supplier of SAP solutions into the German-speaking mid-market. Notwithstanding the current economic uncertainty, near and medium-term demand drivers look robust. The SAP HANA transition cycle should continue to boost performance near term, while S4 HANA should start adding incremental opportunities over the course of the next year or so. The difficulty of recruiting high calibre, skilled staff and the potential for a regional economic pullback are major challenges.

Expanding from the mid-market core

All for One Steeb's buy and build strategy has enabled the company to build scale and expand its customer footprint and range of solutions. In particular, the acquisitions of avantum (May 2014) and Grandconsult DEXINA (March 2015) have enhanced the company's capability set for larger mid-market companies. The company is a cofounder of United VARs, which was recently accredited with SAP Global VAR status. This has enhanced All for One Steeb's ability to service international businesses within its German language area regional focus.

Cross-selling and scaling opportunities

We believe that SAP's evolution and broadening of its product set provide good opportunities for All for One Steeb to sell more into its customer base. The company is now benefitting from the HANA transition cycle and the contribution from solutions related to SAP's acquired cloud businesses such as BusinessObjects and SuccessFactors is starting to become more meaningful. The uptake of SAP S4 /HANA should provide incremental opportunities within a 12-18 month time frame.

Strong growth base, hiring a margin constraint

A five-year track record of growth and margin expansion looks set to continue in FY15. The group generated 12% revenue growth in 9M15, on the back of a 20% increase in consulting and 12% growth in outsourcing revenues, while EBIT grew 57%, helped by a 2.3pp increase in operating margin to 8.0%. However, the shortage of qualified SAP staff may compress margins in FY16.

Valuation: Factoring in sustained earnings growth

The 2016e P/E of 27.4 appears to factor in significant sustained earnings growth in coming years. We believe that the company has a strong platform to deliver this, although enforced investments in HANA and the cloud, as well as the difficulty in recruiting skilled SAP consulting staff and potential economic weakness in the region, are potential headwinds for the stock on a 12 month view.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS ($)	DPS ($)	P/E (x)	Yield (%)
09/13	186.3	8.8	0.98	0.15	64.3	0.2
09/14	217.2	12.0	1.63	0.50	38.6	0.8
09/15e	240.3	15.6	2.06	0.80	30.6	1.3
09/16e	258.3	17.2	2.26	0.86	27.9	1.4

Source: Company data, Thomson Reuters

Price €63.0
Market cap €315m

Share price graph



Share details

Code	A1OS
Shares in issue	5.0m
Net debt (€m) at 30 June 2015	1.7

Business description

All for One Steeb is the leading supplier of SAP industry solutions to mid-market companies in German speaking countries. Outsourcing and consulting services generated 86% of 9M15 revenues. The company provides international customers with SAP support through United VARs.

Bull

- Market leadership position.
- Well placed to benefit from the SAP HANA and then S4 HANA transition cycles.
- High recurring revenues (46%) and scope for take-off of SaaS to boost this further.

Bear

- Challenge in hiring sufficient qualified staff in 2016.
- Potential deteriorating demand if conditions worsen for exporters in German speaking regions.
- Uncertainty over future revenue trend as one-off sales surge ahead of switch to SaaS.

Analysts

Dan Ridsdale +44 (0)20 3077 5729
Anna Bossong +44 (0)20 3077 5737
tech@edisongroup.com

FinLab AG

Technology

A builder of fintech companies

FinLab is evolving from a traditional private equity/asset management holding company into an incubator and value-added investor of fintech companies. It has made investments in three fintechs since February, aims to make another three in the next six months and build a portfolio of 7-10 investments by the end of FY16. The group's investments in Heliad Equity Partners, a private equity company, and Patriarch, a fund-of-funds manager focused on the German retail market, are cash cows that Finlab can use to help fund its fintech investment plans.

Heliad stake valued at €24m, plus management fee

FinLab's c 47% stake in Heliad alone is worth c €24m (at €5.40 share price), or two-thirds of FinLab's market capitalisation. Further, FinLab owns 100% of Heliad's management company, giving it an entitlement to a 2.5% management fee and 20% of profits. Therefore, it can expect a c €1m annual dividend from Heliad along with c € 2-5m in management fees. Heliad owns 7.7% of DEAG Deutsche Entertainment and 18.6% of FinTech Group (FTG), which together make up more than 50% of Heliad's NAV. The FTG stake alone is valued at c €40m (at €13.29).

Big opportunities for disruptive technologies

FinLab has made investments in crowdfunding (50% of venturate), curated trading (60% of nextmarkets) and a retail savings deposits platform (12.75% of Deposit Solutions). The main strategy is incubating new German fintech businesses and subsequently rolling them out across Europe and globally. FinLab also operates as a value-adding venture capital investor for fintechs both in Germany and globally.

Financial results are affected by one-off gains

H1 revenues jumped from €0.6m to €3.4m, while other operating income dipped to €1.1m. Income from investments was €0.9m and costs were down sharply, enabling the group to generate net income of €4.2m. At 30 June, the group had €2.7m of cash, €1.3m of short-term securities and €1m of debt (since repaid).

Valuation: 15% discount to NAV, plus growth

Fintech is currently a hot space, with a range of potentially disruptive technologies and new business models evolving. If FinLab picks its investments well, we believe there is scope for significant upside in the shares. Meanwhile, FinLab trades at a 15% discount to its 30 June NAV of c €10.53 (Heliad share price was €5.24).

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	1.4	(0.3)	N/A	N/A	N/A	N/A
12/14	2.7	9.5	N/A	N/A	N/A	N/A
12/15e	N/A	N/A	N/A	N/A	N/A	N/A
12/16e	N/A	N/A	N/A	N/A	N/A	N/A

Source: Company data, Thomson Reuters

Price	**€8.95**
Market cap	**€40m**

Share price graph

Share details

Code	A7A
Shares in issue	4.5m
Net cash (€m) at 30 June 2015	1.7

Business description

FinLab has traditional financial services core businesses and is now rolling out its new strategy as an investor and incubator of fintech enterprises.

Bull

- The shares trade at a sizeable (c 15%) discount to NAV.
- Heliad (47% stake) appears to be undervalued with a NAV of c €10.10 per share at 30 June.
- Fintech is a hot area that could potentially benefit enormously from banking deregulation.

Bear

- Small free float (c 10%).
- Fintech investments involve a significant degree of risk, though the risk profile will increasingly diversify as the portfolio expands.
- FinLab may need to raise more funds to meet the investment targets, but management has the flexibility to reduce or dispose of its Heliad stake.

Analyst

Richard Jeans +44 (0)20 3077 5700

tmt@edisongroup.com

EDISON

GFT Group AG

Technology

Consulting and IT services for banks

GFT is building a global IT services and consulting business, focused on the growing opportunity in the financial services sector. It is diversifying geographically and broadening its customer base, and we estimate that two-thirds of revenues are recurring in nature. GFT benefits from high levels of IT spending and complex business requirements in the financial services industry and favourable outsourcing trends in banking. Q2 performance was strong, resulting in 23% organic growth in H1. Noting the strong FY16 pipeline, we upgraded our EPS forecasts by 11% in FY16 and 7% in FY17. Trading on c 19x our FY17e EPS, the stock continues to look attractive on strong earnings momentum and attractive business drivers.

Q2 results: Organic growth 23% including FX tailwind

Q2 group revenue rose 55% to €90.2m, including a full period contribution from Rule Financial and excluding the staffing business, which was sold post-period end. Rule was acquired in June 2014 and significantly boosted GFT's presence in Anglo Saxon countries and added near-shore hubs in Poland and Costa Rica to the existing ones in Spain and Brazil. The group's adjusted operating margin rose to 10.0% in Q2 and we anticipate further expansion, with revenue growth and profit recovery at Rule. For H1, total growth was 57% to €178.8m, although this includes an FX tailwind of c €3.5m, which largely relates to Rule. Margin growth was powered by the continuing GFT business, while Rule is still underutilised at its Polish nearshore centre (its H1 margins were c 2.3%).

Acquisition and disposal

After the period end, GFT made a small acquisition in Adesis Netlife, adding a headcount of 273, boosting the group's presence in Spain and Mexico, strengthening its offerings in the digital banking space and adding new service offerings in digital communication and marketing. In July, the group also announced the disposal of its resourcing division, emagine, and hence GFT is now an IT services pure play focused on the financial services sector.

Valuation: Attractive if it can maintain growth

The stock trades on 1.8x FY16e EV/revenues and c 13.5x EBITDA. These numbers look favourable when compared to c 2.3-3.4x sales and c 10.5-14.8x EBITDA for larger global IT services businesses. Our DCF model (which assumes a WACC of 10% and 13.6% long-term margins) values the shares at €17.55. However, 20% compound organic growth over FY15-18e would lift our valuation to c €27.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	264.3	18.5	55.3	25.0	47.4	1.0
12/14	365.3	32.8	97.7	25.0	26.8	1.0
12/15e	362.0	36.0	101.6	25.0	25.8	1.0
12/16e	397.0	45.5	126.1	27.0	20.8	1.0

Source: GFT Group, Edison Investment Research

Price	**€26.20**
Market cap	**€689m**

Share price graph

Share details

Code	GFT
Shares in issue	26.3m
Net debt (€m) at 30 June 2015	65.1

Business description

GFT Group (legal name: GFT Technologies) is a global technology services business primarily focused on banks and insurance companies.

Bull

- The business is growing very quickly, supported by strong structural drivers in the banking industry (digitisation and regulation/compliance).
- FinTech sector is very hot.
- Sempla, Rule and Adesis acquisitions have significantly scaled up the business internationally.

Bear

- The share price has moved up sharply and the P/E ratio has expanded.
- The group has moved into a net debt position to finance its acquisitions.
- Deutsche Bank generates c 40% of revenues.

Analyst

Richard Jeans +44 (0)20 3077 5700

tech@edisongroup.com

GFT Group is a research client of Edison Investment Research Limited

Mensch und Maschine Software SE

Technology

CAD/CAM specialist

Mensch und Maschine has generated strong growth from both its Autodesk reseller business (VAR) and proprietary CAM software business (Software). With costs well controlled, this is driving margin expansion in both business lines. The VAR business finally broke-even in FY14 and is on track to grow profitability on a multi-year basis.

Revenue and margin growth

H115 results confirmed that the strong FY14 performance had continued into 2015. Revenues grew 15.2% y-o-y (Software +8.6%, VAR +17.5%), driving the group EBITDA margin up to 7.9% compared to 5.8% a year ago (excluding Distribution earn-out in H114). The majority of revenue growth was due to stronger demand, boosted by a strengthening of the Swiss franc versus the euro. VAR profitability has been steadily improving as the business has grown – the adjusted EBITDA margin (excl. Distribution earn-out) was –5.3% in FY12, increasing to 0.7% in FY14 and 3.5% in H115. The Software business has seen steady growth in revenues, with EBITDA margin expansion from 16.3% in FY12 to 18.7% in FY14 and 20.8% in H115. The business is making good progress towards longer-term EBITDA margin targets of 25% for the software business and 10% for the VAR business.

Autodesk subscription model transition

The VAR business resells Autodesk CAD software, primarily on a perpetual licence basis with ongoing support and maintenance contracts. With Autodesk's shift to a subscription business model (perpetual licensing will stop over February-August 2016), the VAR business is seeing an acceleration in customers buying perpetual licences and multi-year support contracts to beat the deadline. The business also has a growing number of customers buying on a subscription basis, which should reduce the potential revenue downside when perpetual licensing stops.

Valuation: Margin expansion supports upside

Management expects FY15 revenues to clearly exceed €150m (H115 €81.4m), with EBITDA of €11-12m (H115 €6.4m) and net profit and EPS at a similar level to FY14 (as this included the final €3m in earn-out income). Consensus estimates are in line with this guidance, which based on H1 performance, looks achievable if not beatable. Strong revenue growth driving margin expansion combined with an attractive dividend yield support further upside to the stock price.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/13	125.8	2.6	0.17	0.20	46.5	2.5
12/14	140.0	5.9	0.24	0.20	32.9	2.5
12/15e	154.5	7.1	0.26	0.22	30.4	2.8
12/16e	168.3	11.0	0.45	0.25	17.6	3.2

Source: Company data, Thomson Reuters

Price	€7.90
Market cap	€129m

Share price graph



Share details

Code	MUM
Shares in issue	16.3m
Net debt (€m) at H115	27.9

Business description

Mensch und Maschine Software (M+M) sells proprietary and Autodesk CAD/CAM software. It reports across two business lines: M+M Software (25% of H115 revenues) and VAR (75% of H115 revenues). The company has operations in Europe, the US and Asia Pacific.

Bull

- Largest European Autodesk value-added reseller.
- High-margin internally-developed software.
- Loyal workforce.

Bear

- Reliant on Autodesk's technology development.
- Net debt position.
- Change in Autodesk business model.

Analyst

Katherine Thompson +44 (0)20 3077 5730

tmt@edisongroup.com

EDISON

Reply SpA

Technology

Entrepreneurial approach drives growth

Reply has an impressive track record of strong profitable growth and expects to continue on this path. To accelerate growth, the company is considering expansion into the US, most likely via acquisition. Over the last year the discount to peers has closed, and we believe further share price upside is possible as the market recognises the company's strong financial performance.

Price	€110.00
Market cap	€1,029m

Share price graph



Share details

Code	REY
Shares in issue	9.35m
Net cash (€m) as at H115	22.9

Business description

Reply offers consulting, systems integration and application management services, specialising in the creation and implementation of solutions based on new communication networks and digital media. The main regions of focus are Italy, Germany and UK.

Bull

- Innovative, entrepreneurial attitude.
- Experienced management.
- Strong margins.

Bear

- Acquisition risk.
- Challenge of finding enough sufficiently qualified staff.
- Large exposure to Italian economy.

Analyst

Katherine Thompson +44 (0)20 3077 5730

tech@edisongroup.com

Steady financial progress

The company has grown revenues at a CAGR of 13% from 2010 to 2014, and H115 results continued the strong trend: revenues were up 12% y-o-y with an adjusted EBIT margin of 12.4%, compared to 12.3% a year ago and 12.2% in FY14. The company had a net cash position of €22.9m at the end of H115, up from €16.3m at the end of FY14. Growth has been from a combination of organic growth and acquisitions. Management expects to continue to achieve organic double-digit revenue growth and EBIT margins of 12-14%.

Investment focused on new technologies and geographic expansion

Reply operates as a network of independent companies operating in specialist technology areas. The growth strategy has been to invest in developing in-house expertise, supplemented with the acquisition of businesses in key new areas of technology. The company has also decided to take a venture capital approach in some areas: for example, it has taken minority stakes in a variety of start-up companies related to the Internet of Things (IoT). Reply has a strong net cash position and is cash generative, providing funds for future investment. Key to future growth is the ability to identify future technology trends and invest ahead of them. Management is keen to expand into the US and is currently evaluating acquisition opportunities, as well as continuing to look for smaller acquisitions in Germany and UK to fill out the offering. This should accelerate Reply's path to a €1bn annual revenue run rate, (which on current growth rates would take roughly four years).

Valuation: Discount closing

Consensus estimates for 2015 appear more than achievable, factoring in very little growth for H2 over H1, despite Q4 typically being the strongest quarter. The stock is up more than 60% year-to-date, and is now trading in line with its peer group. However, we believe that the company's ability to grow consistently at double digits, while achieving operating margins above 10% should warrant a premium.

Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/13	560.2	61.7	3.81	0.70	28.9	0.6
12/14	632.2	79.3	4.38	0.85	25.1	0.8
12/15e	697.2	86.5	5.56	1.01	19.8	0.9
12/16e	758.2	95.5	6.36	1.10	17.3	1.0

Source: Company data, Thomson Reuters

EDISON

SinnerSchrader AG

Technology/media

Expanding margin profile

SinnerSchrader's commitment to improve efficiency was clearly evident in its results, which have seen operating margins expand to 18% on an underlying basis in Q4 from 6.3% last year. Trading is robust, and without the investment required in the NA platform, a dividend is likely, as well as a €0.5m share buyback programme; the shares offer compelling value on an FY16 annualised c 12.6x P/E, a c 35% discount to peers.

Uptick in recent trading

Management has pointed to an uptick in demand from existing and new clients, with the acquisition of Swipe mobile having a positive impact on lead generation. Preliminary revenues for the full year to August 2015 came in at €47.7m, down 2% y-o-y, and although revenues in Q4 were flat y-o-y, this should be taken in the context of c 40% growth in H214 and 18% sequential growth over Q315.

Focus on improving efficiency evident in H215

In a tighter trading environment in 2015, management renewed its efforts to improve efficiency of the agency business and has taken some tough decisions on the restructuring and divestment of the loss-making Next Audience (NA) platform. These efforts are clearly evident in the quarterly results, which show a trend of EBITA margin improvements; Q4 was especially strong with EBITA margins increasing from 3% in H1 to 7% in Q3 and over 13% in Q4. NA should no longer affect continuing results in FY16; excluding the impact of NA, Q4 margins were an impressive 18%.

Scope for further margin expansion

Without the dilutive impact of NA, and based on historical trends, EBITA margins have the scope to return to c 13% over the next few years. In FY16 we have forecast c 10%, from an underlying EBITA margin of 9.3% in FY15.

Valuation: Ratings discount very attractive

SinnerSchrader has a strong franchise in a structural growth segment, evidenced by the 15% CAGR in revenues over the past five years. With the earnings dilution from NA no longer an issue, the underlying FY16 c 35% P/E discount to digital agency peers (on FY16 annualised forecasts) has become even more visible. We see scope for both ratings expansion and earnings upgrades; current trading is robust and we believe there is room for further margin expansion.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
08/13	36.4	0.7	2.4	0.0	163.8	0.0
08/14	48.6	3.1	17.1	12.0	23.0	3.1
08/15e	47.7	2.7	19.4	11.0	20.3	2.8
08/16e	50.7	4.9	29.1	13.0	13.5	3.3

Source: SinnerSchrader, Edison Investment Research

Price €3.93
Market cap €44m

Share price graph

Share details

Code	SZZ
Shares in issue	11.3m
Net cash (€m) at Aug 2015	5.6

Business description

SinnerSchrader is a leading European independent digital agency that specialises in helping companies use the internet to sell and market goods and services. The majority of sales originate from Germany, servicing accounts such as Deutsche Bank, BMW, Allianz, Unity Media and Telefonica.

Bull

- Strong franchise in Germany.
- Scope for margin improvement.
- Significant ratings discount to peers.

Bear

- Trading can be volatile on a quarterly basis.
- Relatively dependent on key clients.
- Uncertain outlook for German economy.

Analysts

Bridie Barrett +44 (0)20 3077 57 27
Dan Ridsdale +44 (0)20 3077 5729
Fiona Orford-Williams +44 (0)20 3077 57 39
tmt@edisongroup.com

SinnerSchrader is a research client of Edison Investment Research Limited

EDISON

CENIT AG

Software & comp services

Moving up a gear internationally

CENIT is a leading supplier of PLM and EIM consultancy services and software, with a portfolio of leading blue-chip clients in Germany, the US and Japan. The core of the business is consulting and the provision of third-party software, but the company has seen rapid expansion of sales of higher-margin proprietary software in recent years. From 2016 CENIT plans to commence selling one of these lines via foreign partners in new markets, which should further boost growth. With a high-quality customer base, leading software partners, experienced management and cash-rich balance sheet, CENIT is in a good position to thrive in fat or thin times.

New growth avenue planned in proprietary software...

CENIT increased sales of its proprietary software (PS) by 25.5% in H115, helped by particularly strong demand for its digital fabrication products. From next year, it will start distributing this software via foreign partners, which will tailor the product to their clients' needs. Freed from the requirement to have a software engineer on hand in every targeted market to do this job, CENIT should have increased access to larger markets such as the UK and France and fast-growing markets such as those in the MENA area.

...to add to traction in Japan and North America

CENIT has made great strides in North America and Japan in recent years. North American revenues grew 36% y-o-y in H1, helped by demand in the digital fabrication and aerospace areas, and CENIT sees significant potential for growth in the automotive arena. In both markets CENIT's close relationship with leading software houses such as Dassault (global leader in PLM software) and established reputation as a premium provider put it in line to win highly impactful contracts. Importantly, demand in the domestic market is also firm, helped by the weak euro.

Good value for what it is, cheap for what it could be

Despite the 59% growth in the share price over the last 12 months, CENIT's valuation is still undemanding. It is trading at a 1% discount to its peers on FY16e EV/EBIT, despite the potential for margin expansion through proprietary software sales and long-term growth through geographic expansion. Defensive features of the stock include an above-average 2.9% dividend yield and a cash-rich balance sheet. Catalysts for further share price upside include continued growth of proprietary software sales and potential new acquisitions.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	EV/EBIT (x)	Yield (%)
12/13	120.1	8.4	0.7	0.4	13.6	2.0
12/14	123.9	9.4	0.8	0.9	12.1	5.1
12/15e	127.1	10.2	0.8	0.5	11.1	2.9
12/16e	130.9	10.6	0.9	0.5	10.4	2.9

Source: CENIT, Edison Investment Research

Price	**€17.5**
Market cap	**€146m**

Share price graph

Share details

Code	CSH
Shares in issue	8.37m
Net cash (€m) at 30 June 2015	34.0

Business description

CENIT AG is a leading provider of product lifecycle management (PLM) and enterprise information management (EIM) consultancy services and software. It resells software from Dassault Systèmes, IBM and SAP and is also developing proprietary software to add functionality.

Bull

- Growth opportunities in high-margin, own-proprietary software sales (up 25.5% in H115) and ongoing geographical expansion.
- Strong relationship with leading software producers, including Dassault and SAP. Also in list of tier one business customers.
- Strongly cash-generative business with cash-rich balance sheet (€4.0/share). Looking to M&A opportunities to leverage this position.

Bear

- High exposure to the German market, which contributed 75% of external sales in H115.
- High exposure to export-oriented aerospace and automotive sectors, which could be affected by a Chinese slowdown and weaker global demand on a 12-month view.
- Planned increased international expansion via resellers presents new management challenges.

Analyst

Anna Bossong +44 (0)20 3077 5737

tmt@edisongroup.com

CENIT AG is a research client of Edison Investment Research Limited

EDISON

InVision AG

Software & comp services

SaaS and eLearning leader

InVision has been a leader among European software companies in adopting the software-as-a-service (SaaS) business model. It is well placed as a leader in the growing workforce management software market for small and medium-sized call centres and is exposed to the strong potential growth in providing online training to call centre agents with The Call Center School. Its valuation multiples are high relative to other European software stocks, but few of those offer the pure SaaS story let alone the exposure to eLearning's potential.

Leader in growth markets

InVision is a leader in providing workforce management software to small and medium-sized contact centres on a SaaS basis. It is also building an early lead in developing the market for web-based training for contact centre staff with The Call Center School (TCCS). Management sees a €600m opportunity in the move to cloud-based application specific software and online training in call centres.

Clear product propositions

Workforce management in small and medium-sized contact centres is still dominated by ad-hoc in-house solutions. However, with the relatively low costs of solutions such as InVision's and the cost savings they can achieve, the shift towards professional systems is, we believe, growing. The market for online training of call centre staff is still in its infancy, but with price points at a fraction of those of traditional teaching methods and with the additional benefits of greater flexibility and control, the advantages of TCCS for potentially thousands of contact centres and hundreds of thousands of agents is clear.

Valuation: Premium to Europe, not to comparators

InVision is expected to see good underlying growth, driven by SaaS products and online training, and improving cash generation over the coming years, taking into account the transition out of traditional project-based business. While it trades at a premium to the majority of European software companies, InVision's multiples discounts to the leading SaaS players remain significant. As growth in the underlying revenues becomes more apparent and as the encouraging early progress of TCCS evolves into income, the discount may narrow.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/13	13.6	1.8	0.9	0.0	48.8	N/A
12/14	13.4	4.1	1.9	1.0	23.1	2.3
12/15e	11.9	2.4	1.0	1.1	43.9	2.5
12/16e	13.1	3.4	1.4	1.2	31.4	2.7

Source: InVision, Edison Investment Research

Price €43.90
Market cap €97m

Share price graph

Share details

Code	IVX
Shares in issue	2.2m
Net debt (€) at 30 June 2015	(0.7)

Business description

InVision provides workforce management software and online training for contact centres on a software-as-a-service platform. It is based in Germany and is focused on opportunities in North America and Europe.

Bull

- Strong position in small and medium-sized call centres.
- Scaleable SaaS business model.
- e-learning potential and impressive early take-up across Europe and US.

Bear

- Relatively small player.
- Niche markets make for relatively limited investor visibility.
- Limited liquidity of shares.

Analyst

Ian Robertson +44 (0)20 3681 2523
tmt@edisongroup.com

InVision is a research client of Edison Investment Research Limited

EDISON

migme Limited

Software & comp services

User base growth continues

migme (MIG.ASX) is headquartered in Singapore and provides a social entertainment platform targeted at the rapid growth forecast for smartphone and mobile internet usage in emerging markets. The initial focus is Indonesia, Philippines and India, where MIG has first-mover advantage. By taking a different approach to the more established Facebook, MIG believes its platform will have little competition for its freemium offering. In September 2015 MIG raised A$10.11m (A$1.00 per share) before costs, to fund further market development.

Business model

MIG's business model is based on the virtual goods model used by Tencent (700.HK), YY.com (YY.US) and others, rather than on the advertising business model used by Facebook and Twitter. Broadly speaking, MIG drives its user base by partnering with mobile phone suppliers to pre-install the migme app and with key celebrities to help to attract and engage users. It monetises its user base by offering freemium services (chat, blogging etc), which encourage users to upgrade to paid-for premium activities and virtual goods. The proceeds from selling these virtual goods are shared between MIG and the celebrity, which in turn encourages more celebrities to partner with MIG.

Growth in user numbers

MIG continues to demonstrate that it can grow monthly active users (MAUs) and is currently adding users at the rate of 1.7 million per month. The number of MAUs has increased from >5 million on listing in August 2014 to >24 million at 30 September 2015. In the same time period, the number of audience builders (artists) increased from 150 to >490 and two new territories were added – India and the Philippines. MIG believes it can achieve monetisation rates of 1%, in line with the monetisation rates achieved by YY.com, Momo and 9158.com. If the monetisation rate lifts to 1% the number of monthly paying users (MPUs) would increase from the Q115 level of 27,000 to 140,000. MPU numbers for Q215 and Q315 were not released by the company.

Valuation

We have based our valuation on the current user number growth profile, the monetisation rate and the current operating costs. Our valuation range is from A$1.23 to a blue sky or bull case of A$2.32. The DCF value based on our forecasts, which are considered a base case, is A$1.75.

Edison estimates

Year end	Revenue (A$m)	PBT (A$m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/14	2.0	(0.4)	(1.5)	0.0	N/A	N/A
12/15	9.0	(12.1)	(3.3)	0.0	N/A	N/A
12/16e	33.2	(1.6)	(0.4)	0.0	N/A	N/A
12/17e	66.0	13.7	3.7	0.0	18.9	N/A

Source: migme, Edison Investment Research

Price	A$0.70
Market cap	A$191m

Share price graph

Share details

Code	MIG
Shares in issue	273.3m
Net cash (A$m) at 30 September 2015	10.8

Business description

MIG is a social entertainment platform targeting the world's next wave of internet users, the 3.5 billion people in emerging markets. The service offers free chat, content and blogging services to acquire new users. These users buy virtual goods including gifts, games, avatar items, emoticons and stickers.

Bull

- Reduction in price of smartphones.
- Growth of mobile usage set to explode in South and South-East Asia driven by social media and entertainment.
- Scalable model.

Bear

- Deterioration of economies in target markets.
- Privacy issues.
- Competition from local players.

Analysts

Moira Daw	+61 2 9258 1161
Bridie Barrett	+44 (0)20 3077 5700

tmt@edisongroup.com

migme is a research client of Edison Investment Research Limited

PSI AG

Software

From recovery to growth

PSI develops and integrates software solutions for utilities, manufacturers and infrastructure providers, automating complex control systems to reduce costs, improve efficiency and avoid failure. Current trading and outlook looks robust, while structural initiatives to consolidate products onto a single platform and move towards a standard software revenue model should drive improvements in competitiveness and margins.

Control optimisation

PSI has three operating segments: energy management (36% of 9M15 sales), which delivers intelligent utility solutions for electricity, gas, oil, water and district heating; production management (48% of 9M15 sales), which supplies software and solutions for production planning, control and logistics; and infrastructure management (16% of 9M15 sales), which provides high-availability control solutions for monitoring and operating critical transport, public safety and environmental infrastructures.

A number of initiatives are key to improving earnings resilience and expanding margins. A shift towards a more product led versus project-based model should reduce exposure to cost overruns. The progressive migration of customers and products onto a unified technology platform should improve development, product maintenance and implementation efficiency.

Encouraging progress and outlook

Results for 9M15 are encouraging, with the volume of orders growing by 12% to $149m, sales by 7.4% to €137m and EBIT by 66% to €7.3m, driven mainly by demand in western markets, particularly in energy and production management. The company looks on track to reach our FY15 estimates and management expects to see double-digit growth in orders in early 2016, which if sustained could drive upside to our FY16 estimates.

Valuation: Growth and margin expansion potential

The shares are trading at recovery multiples (0.9x 2015e EV/Sales). Continued evidence that a sustainable recovery in growth and margins is coming through could be a catalyst for upside. Our DCF analysis shows that expansion of the EBIT margin to 12% by 2020 (vs 6% for FY15e) should justify a share price higher than €15, while achieving a margin of 15% would justify a share price closer to €20.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	176.3	4.2	10.6	0.0	119.3	0.0
12/14	175.4	7.2	27.5	0.0	46.0	0.0
12/15e	185.0	11.0	50.7	20.0	25.0	1.6
12/16e	190.9	14.6	71.3	30.0	17.7	2.4

Source: PSI, Edison Investment Research

Price	€12.65
Market cap	€199m

Share price graph

Share details

Code	PSAN
Shares in issue	15.7m
Net cash (€m) at 30 September 2015 (excluding pension deficit)	23.6

Business description

PSI develops and integrates software control systems: solutions for electricity, gas, oil and water; software for production planning, control and logistics; and solutions for monitoring and operating critical transport, public safety, environmental and disaster prevention.

Bull

- Recovery and margin expansion potential.
- Strong footprint in Germany.
- Well placed to benefit from the Industry 4.0 revolution.

Bear

- Geopolitical, economic, currency uncertainty.
- Consolidating the business onto a single technology platform is complex and will take time.
- Execution issues could be repeated.

Analyst

Dan Ridsdale +44 (0)20 3077 5729

tech@edisongroup.com

PSI is a research client of Edison Investment Research Limited

EDISON

SNP Schneider-Neureither & Partner AG

Software & comp services

New growth strategy is taking effect

In early October, SNP raised its FY15 revenue guidance by c 8%, citing the continued very strong order book and an increase in project sizes. This indicates that business remains robust in the wake of the hefty 68% organic revenue growth in Q2 and 18% in Q1. SNP has been experiencing strong demand for its business transformation consulting services and related software, and utilisation rates remain very high. The Q2 operational highlight was an extensive co-operation agreement with SAP, which we believe will help to drive growth. Based on our forecasts, revised after the Q2 results, the shares look very attractive on c 11x our FY17 EPS.

Huge transformation opportunities

SNP's T-B is the only off-the-shelf software solution that automates the process of combining, upgrading or carving out data from ERP systems. The global ERP market was valued at $25.4bn in 2013 (Gartner), and is growing in the mid- to high single digits, which provides a huge opportunity for IT landscape transformations. Further, M&A activity is clearly an important driver in ERP transformation and global M&A activity has been buoyant, with $2.87tn of deals in 9M15 (Mergermarket), meaning that 2015 might well surpass the $3.66tn record set in 2007.

Q2 results: Organic revenue growth was 68%

It has been an extremely hectic year for SNP, with an acquisition completed and successfully integrated, a prestigious new contract signed with a blue-chip US technology company worth "well over $5m", a new joint venture established to spearhead growth in the banking/insurance sector and a corporate bond issued to raise funds to finance the growth. An extensive co-operation agreement with SAP was signed and two new subsidiaries were created. Q2 revenue jumped by 95% to €14.7m, reflecting 68% organic growth and a full period contribution from RSP, the consulting business that SNP acquired in January. For H1, revenues rose 73% (including 42% organic) to €26.9m, while new orders in the period were €29.3m, giving a book-to-bill ratio of 1.09. North America represented more than 20% of revenues, up from c 10%, while revenues from partners rose to 29% of the total.

Valuation: Strong growth play in the ERP space

The stock trades on c 33x our FY15 EPS, falling to c 16x in FY16, which looks attractive given the forecast strong growth and margin recovery potential. Our DCF (WACC of 11%) values the shares at €23.34, 49% above the current share price.

Edison estimates

Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/13	23.5	(2.8)	(64.7)	8.0	N/A	0.5
12/14	30.5	(0.1)	(13.9)	13.0	N/A	0.8
12/15e	49.0	2.5	46.8	20.0	33.5	1.3
12/16e	61.3	5.3	98.4	30.0	15.9	1.9

Source: SNP Schneider-Neureither & Partner, Edison Investment Research

Price	€15.64
Market cap	€58m

Share price graph

Share details

Code	SHF
Shares in issue	3.72m
Net debt (€m) at 30 June 2015	4.7

Business description

SNP Schneider-Neureither & Partner (SNP) is a software and consulting business focused on supporting customers in implementing change, and rapidly and economically tailoring IT landscapes to new situations. It has developed a proprietary software product called SNP Transformation Backbone with SAP Landscape Transformation Software (T-B).

Bull

- SAP deal creates substantial new revenue opportunities, and means working with SAP rather than competing against the ERP giant.
- Broadening the functionality to include any-to-any transformations will give it a big advantage.
- Utilisation rates remain very high.

Bear

- The group was loss-making in FY13.
- Software sales cycle can be long and lumpy.
- Recruiting challenges in consulting.

Analyst

Richard Jeans +44 (0)20 3077 5700

tech@edisongroup.com

SNP Schneider-Neureither & Partner is a research client of Edison Investment Research Limited

Fact Sheet Profiles

2G Energy AG

Industrial

2G Energy AG is amongst the world's leading manufacturer of cogeneration systems (CHP) for decentralized energy production and supply by means of combined heat and power. The company's product portfolio includes systems with an electrical capacity between 20 kW and 4,000 kW for the operation with natural gas, biogas or bio methane and other lean gases. So far, 2G was able to successfully install thousands of CHPs in 33 countries.

*Information from http://www.boerse-frankfurt.de/

Market cap* **€79.08**

*As at 20 October 2015

Share details

Code	2GB

Designated sponsor(s)

EQUINET BANK AG

7C Solarparken AG

Industrial

Combined asset portfolio 71 MWp: Over 90% of the portfolio is located in Germany, predominantly in Bavaria and Saxony. Small historical diversification into France, Belgium and Italy with well-performing assets. High-quality components: Park performance underpinned by high quality components of leading suppliers such as First Solar, Canadian Solar, SMA and Siemens.

*Information from http://www.boerse-frankfurt.de/

Market cap* **€72.59**

*As at 20 October 2015

Share details

Code	HRPK

Designated sponsor(s)

WGZ-BANK AG W.-DEUTSCHE GEN.-ZENTRALBANK*LANG & SCHWARZ BROKER GMBH

Abivax S.A.

Pharma & biotech

Abivax specializes in the research, development and commercialization of anti-viral drugs and therapeutic vaccines for the treatment of severe infectious diseases. At the end of 2014, the Group has a portfolio of four products in preclinical development and three products in clinical development: ABX203 (therapeutic vaccine against chronic hepatitis B), ABX464 (new drug against HIV) and ABX196 (adjuvant vaccine against hepatitis B).

*Information from http://www.euronext.com

Market cap* **€175**

*As at 20 October 2015

Share details

Code	ABVX

Designated sponsor(s)

N/A

adesso AG

With more than 1400 employees and 2014 annual sales of EUR 156,9 million, adesso Group is one of the largest German IT service providers and has outstanding opportunities for growth. At its own locations in Germany, Austria, Switzerland, Turkey, USA and the UK as well as at numerous customer sites, adesso offers consulting and software development services for optimising core business processes and reducing operating costs.

*Information from http://www.boerse-frankfurt.de/

Software

Market cap*	€106m
	*As at 20 October 2015
Share details	
Code	ADN1
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

Adler Modemärkte AG

As one of the leading textile retailers in Germany, Austria, Luxembourg and Switzerland, and with more than 60 years of tradition and a high level of customer loyalty, Adler is, in its own estimation, the market leader among textile retailers for customers over 45 in Germany in the value price segment.

*Information from http://www.boerse-frankfurt.de/

Consumer

Market cap*	€190m
	*As at 20 October 2015
Share details	
Code	ADD
Designated sponsor(s)	
	ODDO SEYDLER BANK AG M.M. WARBURG & CO (AG & CO.) KGAA

Advanced Vision

AVT (Advanced Vision Technology) is the global leader in print process control, quality assurance, and press control for the packaging, labels, and commercial print industries. Backed by state-of-the-art technology and field-proven solutions, more than 7,000 AVT systems are installed at customer sites worldwide.

*Information from http://www.boerse-frankfurt.de/

Industrial

Market cap*	€67m
	*As at 20 October 2015
Share details	
Code	VSJ
Designated sponsor(s)	
	HAUCK & AUFHAEUSER PRIVATBANKIERS KGAA

AFFIMED N.V.

Pharma & Biotech

Market cap*	€186m
	*As at 20 October 2015
Share details	
Code	AFMD
Designated sponsor(s)	
	N/A

Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells.

*Information from http://www.boerse-frankfurt.de/

Ahlers AG

Consumer

Market cap*	€49m
	*As at 20 October 2015
Share details	
Code	AAH3
Designated sponsor(s)	
	N/A

Ahlers AG is a leading listed manufacturer of men's fashion in Europe. This innovative and well-capitalised company looks about on almost ninety years of swift and flexible adjustment to the requirements of the times and the markets. For many decades Ahlers has been a reliable partner to mid-sized and major specialist retailers. Ahlers is one of the major European players who live up to high standards of quality both in terms of their brands and their products.

*Information from http://www.boerse-frankfurt.de/

amp biosimilars AG

Pharma & biotech

Market cap*	€38m
	*As at 20 October 2015
Share details	
Code	A0SMU8
Designated sponsor(s)	
	N/A

amp biosimilars is a biopharmaceutical company dedicated to developing world-class biosimilars for the growing demand of the global therapeutics market. Headquartered in Hamburg, Germany, amp biosimilars is one of Europe's most innovative and dynamic biosimilar development companies. Headed by a team of leading industry experts, amp biosimilars develops biosimilars to increase access to life-improving and life-saving medications worldwide.

*Information from https://www.boerse-muenchen.de/

EDISON

ATOSS Software AG

Software

ATOSS Software AG is a provider of consulting, software and professional services in the field of demand-oriented personnel planning, and ranks as a forward-thinking pioneer in the workforce management sector. The company offers solutions for enterprises of all sizes, whatever their requirement scenarios. ATOSS solutions are renowned for maximum functionality and modern JAVA technology, offering users the benefits of total platform independence.

*Information from http://www.boerse-frankfurt.de/

Market cap* **€188**

*As at 20 October 2015

Share details

Code AOF

Designated sponsor(s)

VEM AKTIENBANK AG

AURELIUS SE & Co

Other

AURELIUS concentrates on identifying, analyzing, creating and exploiting all the opportunities afforded by the market. The AURELIUS Group views itself as a long-term “good home” for its subsidiaries. AURELIUS does not focus on particular industrial sectors when selecting its acquisition targets, although it does concentrate primarily on the following segments: industrial enterprises, chemicals, business services, consumer goods / food & beverage, and telecoms, media & technology (TMT).

*Information from http://www.boerse-frankfurt.de
http://aureliusinvest.com

Market cap* **€1284m**

*As at 20 October 2015

Share details

Code AR4

Designated sponsor(s)

ODDO SEYDLER BANK AG

AutoBank AG

Banks

Autobank AG provides motor vehicle leasing and financing solutions in Austria. It finances new and used, and demonstration vehicles for car dealerships, as well as inventories of automotive businesses. The company also leases equipment, and construction and agricultural machinery. In addition, it provides day and time deposits, as well as factoring services. The company was founded in 1990 is based in Vienna, Austria.

*Information from http://www.boerse-vienna.de/
http://www.bloomberg.com/

Market cap* **€5m**

*As at 20 October 2015

Share details

Code AW2

Designated sponsor(s)

N/A

EDISON

Basler AG

Industrial

Market cap*	€132m
	*As at 20 October 2015
Share details	
Code	BSL
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

Basler AG is one of the largest vision technology companies in the world. While we are firmly rooted in Germany, we operate on an international level. Our company headquarters is located in Ahrensburg, a town in the greater Hamburg area. At the same time, we are players in the world market of vision technology with seven subsidiaries and representative offices. More than 80% of our products are manufactured for export.

*Information from http://www.boerse-frankfurt.de/

Bastei Lübbe AG

Media

Market cap*	€93m
	*As at 20 October 2015
Share details	
Code	BST
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

Bastei Lübbe AG is a media company in the form of a publishing house. Within the scope of its business activities, Bastei Lübbe publishes books, audio books, eBooks and other digital products in the genres of fiction and popular science, as well as periodicals including novel booklets and puzzle magazines. The business activities of Bastei Lübbe also include the licensing of rights and the development, production and sale of gifts, decorative items and merchandise.

*Information from http://www.boerse-frankfurt.de/

bet-at-home.com AG

Retail

Market cap*	€311m
	*As at 22 October 2015
Share details	
Code	ACX
Designated sponsor(s)	
	LANG & SCHWARZ BROKER GMBH ODDO SEYDLER BANK AG

bet-at-home.com AG group is an online gaming and sports betting company. With more than 3.8 million registered customers around the world and shares listed on the Frankfurt stock exchange, the company and its subsidiaries make up one of the most successful online bookmakers and online gaming providers in Europe.

*Information from http://www.boerse-frankfurt.de/
www.bet-at-home.ag/en/bah/company

Biofrontera AG

Pharma & biotech

Biofrontera AG is a biopharmaceutical company specializing on the development of drugs and medicinal cosmetics for the treatment of skin diseases and the regenerative care of damaged skin. In February 2012 Biofrontera launched the prescription drug Ameluz® for the treatment of actinic keratosis on the German market. In other European countries Ameluz® is marketed through various local representatives.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€53m
	*As at 20 October 2015
Share details	
Code	B8F
Designated sponsor(s)	
	LANG & SCHWARZ BROKER GMBH

CANCOM SE

Software

As cloud architect and managed services provider with a forward-looking, business-oriented solutions portfolio CANCOM Group provides considerable added value for sustained business success. So CANCOM leads as IT and business transformation partner towards the cloud way of computing. Employing more than 3,000 people CANCOM achieves Group revenues of more than EUR 800 million.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€503m
	*As at 20 October 2015
Share details	
Code	COK
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

CARBIOS SA

General industrials

Carbios develops enzyme-based processes for biodegradation and bioproduction of plastics, with a long-term aim of displacing current recycling and production practices.

*Information from http://www.boerse-frankfurt.de/
http://www.edisoninvestmentresearch.com/research/company/carbios

Market cap*	€44m
	*As at 20 October 2015
Share details	
Code	ALCRB
Designated sponsor(s)	
	N/A

CENTROTEC Sustainable

Industrial

CENTROTEC Sustainable AG, which has its registered office in Brilon, Germany, focuses on the area of energy-saving technologies in buildings. CENTROTEC posted revenue of EUR 531 million in 2014 and expects round about the same revenues in 2015. With more than 3,000 employees worldwide, the CENTROTEC Group is one of Europe's leading players in its field thanks to its innovative energy-saving solutions, and is represented approx.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€253m
	*As at 20 October 2015
Share details	
Code	CEV
Designated sponsor(s)	
	ODDO SEYDLER BANK AG HSBC TRINKAUS & BURKHARDT AG

CEWE Stiftung & Co.

Consumer

The innovative photo and online print service company CEWE, with 11 highly-technical production operations and a staff of around 3,200 employees in 24 European countries, is both market and technological leader. In 2014 CEWE delivered around 2.3 billion prints, 5.9 million copies of the CEWE PHOTO BOOK and photo gift articles to around 30,000 retail partners to generate consolidated turnover of 523.8 million euros.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€392m
	*As at 20 October 2015
Share details	
Code	CWC
Designated sponsor(s)	
	BHF-BANK AG ODDO SEYDLER BANK AG

comdirect bank AG

Financial Services

comdirect bank AG is a member of the comdirect Group and operates in the B2C business line. comdirect is a leading direct bank and the market leader in online securities business for modern investors, offering brokerage, banking and advice. More than 1.9 million private customers have placed their trust in the bank.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€1426m
	*As at 20 October 2015
Share details	
Code	COM
Designated sponsor(s)	
	COMMERZBANK AG

EDISON

C-QUADRAT Investment AG

Financial Services

C-QUADRAT is an international asset manager which seeks to realise continuous and sustainable growth for its investors. Its fund managers in Vienna and London use both quantitative and discretionary absolute and total return strategies to achieve this goal. Institutional and private investors have relied on C-QUADRATs expertise for many years now.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€173m
	*As at 20 October 2015
Share details	
Code	C8I
Designated sponsor(s)	
	ICF BANK AG WERTPAPIERHANDELSBANK

CropEnergies AG

Industrial

CropEnergies - a member of the Südzucker Group - is a leading European supplier of sustainably produced bioethanol for the fuel sector. 'Crop' stands for 'creative regeneration of power'. Energy in the form of bioethanol is produced from renewable resources - grain and sugar beets. The components of the raw materials not used to produce bioethanol, such as proteins, are processed into high-quality food and animal feed products.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€436m
	*As at 20 October 2015
Share details	
Code	CE2
Designated sponsor(s)	
	DZ BANK AG DT. ZENTRAL-GENOSSENSCHAFTSB.*ICF BANK AG WERTPAPIERHANDELSBANK LANDESBANK BADEN-WUERTTEMBERG

Daldrup & Söhne AG

Industrial

Daldrup & Söhne AG (D & S) is a leading drilling technology specialist and full-service provider of power station projects in the geothermal sector. D & S holds stakes in geothermal power stations in Germany as well. The Company is active in four business segments 'Geothermal Energy', 'Resources and Exploration', 'Water Supply' and 'Environment, Development & Services (EDS)'.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€51m
	*As at 20 October 2015
Share details	
Code	4DS
Designated sponsor(s)	
	EQUINET BANK AG

DATAGROUP AG

Software

DATAGROUP is one of Germany's leading IT service provider. More than 1,400 employees at 16 locations in Germany design, implement and operate business applications and IT infrastructures. With CORBOX we offer customers all IT services they need for a stable IT operations.

Market cap*	€89m
	*As at 20 October 2015
Share details	
Code	D6H
Designated sponsor(s)	
	LANDESBANK BADEN-WUERTTEMBERG SUEDDEUTSCHE AKTIENBANK AG

*Information from http://www.boerse-frankfurt.de/
http://www.datagroup.de/

DEAG Deutsche

Media

DEAG Deutsche Entertainment AG is an integrated Entertainment Content company and a leading provider of Live Entertainment in Europe. In the Live Entertainment business DEAG operates as a tour promoter as well as a local promoter and sells more than 3.5 million tickets per year at present.

Market cap*	€68m
	*As at 20 October 2015
Share details	
Code	ERMK
Designated sponsor(s)	
	VEM AKTIENBANK AG

*Information from http://www.boerse-frankfurt.de/

Delticom AG

Retail

Delticom is Europe's leading online tyre retailer. Founded in 1999, the Hanover-based company has nearly 200 online shops in 41 countries, among others ReifenDirekt, www.mytyres.co.uk in UK and www.123pneus.fr in France, as well as the Tirendo shops which enjoy a high level of recognition, not least due to its brand ambassador, Sebastian Vettel.

Market cap*	€270m
	*As at 20 October 2015
Share details	
Code	DEX
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

*Information from http://www.boerse-frankfurt.de/

Deutsche Lufthansa AG

Transportation + Logistics

The Lufthansa Group is a global aviation group with a total of around 540 subsidiaries and equity investments, which in the financial year 2014 were organised into five business segments: Passenger Airline Group, Logistics, MRO, Catering and, up to the end of 2014, IT Services. All the segments occupy a leading position in their respective markets. In 2014, the Lufthansa Group generated revenue of EUR 30.0bn and employed an average of 118,973 staff.

*Information from http://www.boerse-frankfurt.de/

Market cap* €6307m

*As at 20 October 2015

Share details

Code LHA

Designated sponsor(s)

BNP PARIBAS ARBITRAGE SNC
TIMBER HILL (EUROPE) AG

Dürr AG

Industrial

The Dürr Group is one of the world's leading mechanical and plant engineering firms. Products, systems and services offered by Dürr enable highly efficient manufacturing processes in different industries. Business with automobile manufacturers and their suppliers accounts for approximately 65% of Dürr's sales.

*Information from http://www.boerse-frankfurt.de/

Market cap* €2266m

*As at 20 October 2015

Share details

Code DUE

Designated sponsor(s)

ODDO SEYDLER BANK AG

ECKERT & ZIEGLER AG

Pharma & biotech

Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with more than 700 employees, is one of the world's largest providers of isotope technology for radiation therapy and nuclear medicine.

*Information from http://www.boerse-frankfurt.de/

Market cap* €97m

*As at 20 October 2015

Share details

Code EUZ

Designated sponsor(s)

DZ BANK AG DT. ZENTRAL-
GENOSSENSCHAFTSB.*ICF BANK AG
WERTPAPIERHANDELSBANK

ecotel communication ag

Telecommunication

The ecotel Group (hereinafter »ecotel«) is a telecommunications company that has been active throughout Germany since 1998 and specialises in meeting the information and telecommunication (IT/telecom) requirements of customers. The parent company is ecotel communication ag.

Market cap*	€33m
	*As at 20 October 2015
Share details	
Code	E4C
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

*Information from http://www.boerse-frankfurt.de/

Einhell Germany AG

Consumer

Einhell Germany AG is developing and distributing solutions for craftsmen and "do-it-yourselfers" to use at home, in the garden and in leisure time. The company serves specialised trade as well as other distribution channels with assortment competence in the DIY field.

Market cap*	€51m
	*As at 20 October 2015
Share details	
Code	EIN3
Designated sponsor(s)	
	M.M. WARBURG & CO (AG & CO.) KGAA

*Information from http://www.boerse-frankfurt.de/

Elmos Semiconductor AG

Technology

Elmos Semiconductor AG develops and manufactures customer specific intergrated circuits in analog/mixed-signal CMOS technology. These application specific chips are mainly used in the automotive industry (90%), but also in consumer and household products. The so called ASICs are developed in close cooperation directly with the customers according to their needs.

Market cap*	€275m
	*As at 20 October 2015
Share details	
Code	ELG
Designated sponsor(s)	
	M.M. WARBURG & CO (AG & CO.) KGAA

*Information from http://www.boerse-frankfurt.de/

EDISON

Energiekontor AG

Industrial

Energiekontor UK Ltd was founded in 1999 and is the subsidiary of the German based Energiekontor AG. We operate a growing portfolio of onshore wind and solar sites across the UK and Europe.

Market cap*	€174m
	*As at 20 October 2015
Share details	
Code	EKT
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

*Information from http://www.boerse-frankfurt.de/
http://www.energiekontor.co.uk/

ERGOMED PLC

Pharma & biotech

Founded in 1997, Ergomed plc is a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs. It operates globally in over 40 countries. Since its formation, Ergomed plc has been providing expertise in clinical development / trial management from the largest pharmaceutical companies, as well as many small and mid-sized drug development companies.

Market cap*	€62m
	*As at 20 October 2015
Share details	
Code	2EM
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

*Information from http://www.boerse-frankfurt.de/
http://www.ergomedplc.com/about-us

euromicron AG

Technology

euromicron AG (www.euromicron.de) is an all-round solution provider for communications, transport, data and security. euromicron's network infrastructures integrate voice, video and data transport wirelessly, via copper cable and by means of fiber-optic technologies. euromicron builds leading applications, such as security, control, healthcare or surveillance systems, on the basis of these cutting-edge network infrastructures.

Market cap*	€60m
	*As at 20 October 2015
Share details	
Code	EUCA
Designated sponsor(s)	
	EQUINET BANK AG

*Information from http://www.boerse-frankfurt.de/

Evolva Holding AG

Evolva is Swiss high tech fermentation company. It has a proprietary yeast technology platform, which it uses to create and manufacture high-value speciality molecules for nutritional and consumer products.

Consumer

Market cap*	**€418m**
	*As at 20 October 2015
Share details	
Code	ADF
Designated sponsor(s)	
	N/A

*Information from http://www.boerse-frankfurt.de/
http://www.edisoninvestmentresearch.com/research/company/evolva

First Sensor AG

First Sensor AG is among the worlds leading providers of certified top-quality sensor solutions. First Sensor develops and manufactures standardized and customized sensor solutions for applications in the Industrial, Medical and Mobility growth markets. We will be among the top three providers in our core markets by 2019.

Technology

Market cap*	**€115m**
	*As at 20 October 2015
Share details	
Code	SIS
Designated sponsor(s)	
	EQUINET BANK AG

*Information from http://www.boerse-frankfurt.de/

Formycon AG

Formycon is a leading and independent developer of biosimilar drugs, meeting the highest quality standards, for marketing and distribution around the globe. The company spans the entire pharmaceutical value creation chain all the way through to phase III clinical trials and registration.

Pharma & biotech

Market cap*	**€218m**
	*As at 20 October 2015
Share details	
Code	FYB
Designated sponsor(s)	
	HAUCK & AUFHAEUSER PRIVATBANKIERS KGAA WOLFGANG STEUBING AG

*Information from http://www.boerse-frankfurt.de/
http://www.formycon.com/

EDISON

Francotyp-Postalia Holding

Industrial

Market cap*	**€68m**
	*As at 20 October 2015
Share details	
Code	FPH
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

The FP Group is the first multi-channel provider for mail communication. This global company offers a full range of products and solutions for business customers and individuals. It provides not only traditional machines for franking and inserting letters but also services including business mail collection and innovative software solutions such as fully electronic mail.

*Information from http://www.boerse-frankfurt.de/

Gesco AG

Industrial

Market cap*	**€222m**
	*As at 20 October 2015
Share details	
Code	GSC1
Designated sponsor(s)	
	EQUINET BANK AG ODDO SEYDLER BANK AG

GESCO AG is a financial holding which acquires highly profitable, strategically attractive SMEs. Its objective is to retain long-term involvement in the companies it acquires while developing their business. Since GESCO was founded in 1989 it has established a portfolio of companies rich in substance which it is enhancing with further acquisitions. GESCO has been listed in the Prime Standard since 24 March 1998 and is listed in the index SDAX since 23 June 2008.

*Information from http://www.boerse-frankfurt.de/

GK Software AG

Software

Market cap*	**€54m**
	*As at 20 October 2015
Share details	
Code	GKS
Designated sponsor(s)	
	ICF BANK AG WERTPAPIERHANDELSBANK

GK Software AG is a leading developer and provider of standard software for the retail sector, and currently counts 20 percent of the world's 50 largest retailers among its customer base. The company offers an extensive range of solutions for stores and enterprise headquarters as well as for the implementation of contemporary omni-channel retail concepts.

*Information from https://www.euronext.com/

EDISON

GLOBAL ECOPOWER

Technology

Global EcoPower specializes in producing electricity from renewable energies. The group builds plants for producing electricity from wind, solar, water, and biomass. Global EcoPower's strategy is to keep half of the plants that it builds for its own use and sell the other half to third parties. The group then operates these plants on its own behalf or for third parties.

Market cap* €18m

*As at 20 October 2015

Share details

Code ALGEP

Designated sponsor(s)

N/A

*Information from http://www.boerse-frankfurt.de/
https://www.euronext.com

Grammer AG

Automobile

GRAMMER AG, Amberg, Germany, specializes in the development and production of components and systems for automotive interiors as well as driver and passenger seats for offroad vehicles. In the Automotive Division, we supply headrests, armrests and center console systems to premium automakers and automotive system suppliers. The Seating Systems Division comprises the truck and offroad seat segments as well as train and bus seats.

Market cap* €248m

*As at 20 October 2015

Share details

Code GMM

Designated sponsor(s)

BANKHAUS LAMPE KG
M.M. WARBURG & CO (AG & CO.) KGAA

*Information from http://www.boerse-frankfurt.de/

GRENKELEASING AG

Financial Services

Grenkeleasing AG offers lease financing for information technology equipment to small- and medium-sized business customers and self-employed persons. The Company finances the leasing of personal computers, notebooks, monitors, software, and other IT related products. Grenkeleasing offers its financing through IT dealers and manufacturers.

Market cap* €2257m

*As at 20 October 2015

Share details

Code GLJ

Designated sponsor(s)

ODDO SEYDLER BANK AG
HSBC TRINKAUS & BURKHARDT AG

*Information from http://www.boerse-frankfurt.de/
http://www.bloomberg.com/quote/GLJ:GR

EDISON

Hannover Rück SE

Hannover Re, with gross premium of 14.4 billion euro, is the third-largest reinsurer in the world. It transacts all lines of property & casualty and life & health reinsurance and is present on all continents with around 2,500 staff.

*Information from http://www.boerse-frankfurt.de/

Insurance

Market cap* **€11,517m**

*As at 20 October 2015

Share details

Code	HNR1

Designated sponsor(s)

TIMBER HILL (EUROPE) AG

Hawesko Holding AG

The Hawesko Group is Germany's largest integrated merchant for premium wines and champagnes, and one of the leading sellers of wine in the world. With our three complementary business segments we open up high-end markets: Hanseatisches Wein- und Sekt-Kontor is Germany's leading wine mail-order and online business.

*Information from http://www.boerse-frankfurt.de/

Retail

Market cap* **€362m**

*As at 20 October 2015

Share details

Code	HAW

Designated sponsor(s)

ODDO SEYDLER BANK AG

Heliocentris Energy

Heliocentris Energy Solutions AG is a leading technology provider of energy management systems and hybrid power solutions for distributed stationary industrial applications, as well as of products and solutions for education, training and applied research purposes in the field of fuel cells, solar, wind and hydrogen energy technologies.

*Information from http://www.boerse-frankfurt.de/

Industrial

Market cap* **€59m**

*As at 20 October 2015

Share details

Code	H2FA

Designated sponsor(s)

LANG & SCHWARZ BROKER GMBH

HELMA Eigenheimbau AG

HELMA Eigenheimbau AG is a customer-oriented building services-provider offering a full range of services. The focus is on the development, planning, sale, and construction management of turnkey or partially completed detached and semi-detached houses using the solid construction method.

*Information from http://www.boerse-frankfurt.de/

Consumer

Market cap*	€166m
	*As at 20 October 2015
Share details	
Code	H5E
Designated sponsor(s)	
	LANG & SCHWARZ BROKER GMBH

HOCHDORF HLDG AG

Hochdorf Holding AG is a Switzerland-based holding company active in the food processing industry. The Company's activities are divided into three business areas conducted through HOCHDORF Swiss Nutrition Ltd for the food industry and the retail sector: Dairy Ingredients, Baby Care, and Cereals and Ingredients.

*Information from http://www.boerse-frankfurt.de/
https://www.google.co.uk/finance?cid=2637994117302

Other

Market cap*	€174m
	*As at 20 October 2015
Share details	
Code	1Z3
Designated sponsor(s)	
	N/A

Hypoport AG

As an independent financial product distributor that runs a B2B financial marketplace, Hypoport operates successfully in two mutually reinforcing segments. It always provides the simplest access to the best financial services. As a wholly-owned subsidiary of Hypoport, Europace AG develops and operates the web-based EUROPACE financial marketplace, which is Germany's largest platform for mortgages, building finance products and personal loans.

*Information from http://www.boerse-frankfurt.de/

Financial Services

Market cap*	€306m
	*As at 20 October 2015
Share details	
Code	HYQ
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

Indus Holding AG

As an independent financial product distributor that runs a B2B financial marketplace, Hypoport operates successfully in two mutually reinforcing segments. It always provides the simplest access to the best financial services. As a wholly-owned subsidiary of Hypoport, Europace AG develops and operates the web-based EUROPACE financial marketplace, which is Germany's largest platform for mortgages, building finance products and personal loans.

*Information from http://www.boerse-frankfurt.de/

Industrial

Market cap* **€947m**

*As at 20 October 2015

Share details	
Code	INH

Designated sponsor(s)

COMMERZBANK AG
BANKHAUS LAMPE KG

init innovation in traffic

Init innovation in traffic systems AG specializes in the area of guidance, information and payment systems for local public transport. The company was established in 1983 as a typical university spin-off and now employs more than 400 staff. Apart from its headquarters in Karlsruhe, init has subsidiaries in UK, Finland, United States, Canada, Australia, Dubai as well as in Singapore.

*Information from http://www.boerse-frankfurt.de/

Technology

Market cap* **€215m**

*As at 20 October 2015

Share details	
Code	IXX

Designated sponsor(s)

COMMERZBANK AG
ODDO SEYDLER BANK AG

Integer

Integer.pl Capital Group is one of the most successful private postal groups in Europe. In only 3 years, the InPost parcel lockers technology can be found in the following countries: Australia, Chile, Great Britain, Italy, Ireland, Iceland, Lithuania, Latvia, Ukraine, Estonia, Poland, Russia, Saudi Arabia, Cyprus, Slovakia, Czech Republic, Colombia, Costa Rica, El Salvador and Guatemala.

*Information from http://www.boerse-frankfurt.de/
http://www.gpw.pl/karta_spolki_en/PLINTEG00011/#ch

Industrials

Market cap* **€936m**

*As at 20 October 2015

Share details	
Code	ITG

Designated sponsor(s)

N/A

Intershop Communications AG

Intershop Communications AG (founded in Germany 1992; Prime Standard: ISH2) is the leading independent provider of omni-channel commerce solutions. Intershop offers high-performance packaged software for internet sales, complemented by all necessary services. Intershop also acts as a business process outsourcing provider, covering all aspects of online retailing up to fulfillment.

*Information from http://www.boerse-frankfurt.de/

Software

Market cap* **€40m**

*As at 20 October 2015

Share details

Code ISH2

Designated sponsor(s)

ODDO SEYDLER BANK AG

ISARIA Wohnbau AG

ISARIA Wohnbau is a leading project developer for residential real estate construction projects in Munich. Since 2014, the company also develops residential projects in Hamburg. The company, which was founded in 1994, is listed on the prime standard of the Deutsche Börse. The projects realised by the company range from multi-storey apartments to terraced houses as well as the revitalisation of existing buildings.

*Information from http://www.boerse-frankfurt.de/

Real Estate

Market cap* **€101m**

*As at 20 October 2015

Share details

Code IWB

Designated sponsor(s)

M.M. WARBURG & CO (AG & CO.) KGAA

ISRA VISION AG

Together with its subsidiaries, ISRA VISION AG is globally one of the top five suppliers of industrial image processing (Machine Vision) and the market leader in Europe. ISRA employs around 400 employees at 20 locations around the world. In the last eleven years, the mid-sized technologies firm has grown continuously.

*Information from http://www.boerse-frankfurt.de/

Software

Market cap* **€222m**

*As at 20 October 2015

Share details

Code ISR

Designated sponsor(s)

EQUINET BANK AG
ODDO SEYDLER BANK AG

ItN Nanovation AG

Industrial

ItN Nanovation AG based in Saarbruecken, Germany, is one of the leading nanotechnology companies in the world, developing innovative water filtration systems for large industrial customers. ItN stands for "Innovation through nanotechnology" and reflects the company's well-founded nanotechnology know how.

Market cap* **€21m**

*As at 20 October 2015

Share details

Code	I7N

Designated sponsor(s)

ODDO SEYDLER BANK AG

*Information from http://www.boerse-frankfurt.de/

IVU Traffic Technologies

Software

IVU Traffic Technologies AG has been working for 40 years with some 400 software engineers to ensure that transport in the worlds major cities operates reliably and on time. People and vehicles in expanding cities are continually on the move a logistical challenge which calls for intelligent and reliable software systems.

Market cap* **€73m**

*As at 20 October 2015

Share details

Code	IVU

Designated sponsor(s)

EQUINET BANK AG

*Information from http://www.boerse-frankfurt.de/

JDC Group AG

Financial Services

JDC Group AG, formerly Aragon AG, is a Germany-based financial services company that offers brokerage financial products and consultancy services. The Company's business is divided into two business segments: Advisory and AdvisorTech. The Advisory segment provides financial products of its subsidiaries Jung, DMS & Cie. and FiNUM to end customers via independent consultants, brokers and financial service providers.

Market cap* **€33m**

*As at 20 October 2015

Share details

Code	A8A

Designated sponsor(s)

HAUCK & AUFHAEUSER PRIVATBANKIERS KGAA

*Information from http://www.boerse-frankfurt.de/
https://www.google.co.uk/finance?cid=702869

Jenoptik AG

Financial Services

As an integrated optoelectronics group, Jenoptik divides its activities into five divisions: Lasers & Material Processing, Optical Systems, Industrial Metrology, Traffic Solutions and Defense & Civil Systems. Its customers around the world mainly include companies in the semiconductor equipment manufacturing industry, automotive and automotive supplier industries, medical technology, security and defense technology as well as the aviation industry.

*Information from http://www.boerse-frankfurt.de/

Market cap* **€798m**

*As at 20 October 2015

Share details

Code JEN

Designated sponsor(s)

ODDO SEYDLER BANK AG
HSBC TRINKAUS & BURKHARDT AG

Klöckner & Co SE

Industrials

Klöckner & Co is the largest producer-independent distributor of steel and metal products and one of the leading steel service center companies in the European and American markets combined. The core business of the Klöckner & Co Group is the warehousing and distribution of steel and nonferrous metals as well as the operation of steel service centers.

*Information from http://www.boerse-frankfurt.de/

Market cap* **€786m**

*As at 20 October 2015

Share details

Code KCO

Designated sponsor(s)

ODDO SEYDLER BANK AG
TIMBER HILL (EUROPE) AG
HSBC TRINKAUS & BURKHARDT AG

KROMI Logistik AG

Industrials

KROMI Logistik AG offers manufacturing companies end-to-end outsourcing for their supply of precision machining tools, both in Germany and abroad. The company focuses on technically advanced machining tools for metalworking (consumable and cutting tools, e.g. drills).

*Information from http://www.boerse-frankfurt.de/

Market cap* **€40m**

*As at 20 October 2015

Share details

Code K1R

Designated sponsor(s)

M.M. WARBURG & CO (AG & CO.) KGAA

KTG Agrar SE

Food & beverages

With cultivable land of approx. 45,000 hectares, KTG Agrar SE is one of the leading producers of agricultural commodities in Europe. As an integrated supplier, the company produces agricultural commodities and renewable energy and food. The Hamburg-based company's core area of expertise is the organic and traditional cultivation of market products such as cereals, potatoes, soy and rapeseed. For organic market products KTG Agrar is the European market leader.

*Information from http://www.boerse-frankfurt.de/

Market cap* **€94m**

*As at 20 October 2015

Share details

Code	7KT

Designated sponsor(s)

DZ BANK AG DT. ZENTRAL-GENOSSENSCHAFTSB.*ICF BANK AG WERTPAPIERHANDELSBANK EQUINET BANK AG>

LifeWatch AG

Medical equipment

Established in 1993, LifeWatch offers a comprehensive range of innovative mobile cardiac telemetry, cardiac monitoring and home sleep testing technologies and services that help physicians detect and analyze patient symptoms before they turn into serious health problems. Through access to real-time patient data and analytics, physicians and care teams can better collaborate, enabling detection and intervention at the earliest sign of a significant health event.

*Information from http://www.boerse-frankfurt.de/
http://www.lifewatch.com/

Market cap* **€205m**

*As at 20 October 2015

Share details

Code	GUA1

Designated sponsor(s)

N/A

LPKF Laser & Electronics

Industrials

LPKF Laser & Electronics AG is a leading global specialist in laser technology, laser material processing and drive technology. LPKF develops and distributes systems used in electronics production, the automotive industry, and in the manufacture of solar cells. Its export share is 90 per cent. The Group has approx. 800 employees worldwide.

*Information from http://www.boerse-frankfurt.de/

Market cap* **€179m**

*As at 20 October 2015

Share details

Code	LPK

Designated sponsor(s)

ODDO SEYDLER BANK AG

M.A.X. Automation AG

M.A.X. Automation AG with its headquarters in Düsseldorf is an internationally active high-tech mechanical engineering Group and a leading full-service supplier of integrated and sophisticated system and component solutions. Its operational business is divided into two segments.

*Information from http://www.boerse-frankfurt.de/

Industrials

Market cap*	€131m
	*As at 20 October 2015
Share details	
Code	MXH
Designated sponsor(s)	
	EQUINET BANK AG ODDO SEYDLER BANK AG

Manz AG

As one of the world's leading high-tech equipment manufacturers, Manz AG, based in Reutlingen, Germany, is a pioneer for innovative products in fast-growing markets. The company, founded in 1987, has expertise in seven technology sectors: automation, laser processing, vacuum coating, screen printing, measurement technology, wet-chemical and roll-to-roll processing.

*Information from http://www.boerse-frankfurt.de/

Industrials

Market cap*	€333m
	*As at 20 October 2015
Share details	
Code	M5Z
Designated sponsor(s)	
	LANDESBANK BADEN-WUERTTEMBERG EQUINET BANK AG

Masterflex SE

Masterflex SE from Gelsenkirchen is a specialist in developing and manufacturing superior connection and hose systems made of innovative high-tech plastics. Since it's foundation in 1987, we develope the manifold applications of high-tech plastics, also in combination with other materials, and convert them into new customer-oriented products.

*Information from http://www.boerse-frankfurt.de/

Industrials

Market cap*	€54m
	*As at 20 October 2015
Share details	
Code	MZX
Designated sponsor(s)	
	WGZ-BANK AG W.-DEUTSCHE GEN.- ZENTRALBANK*LANG & SCHWARZ BROKER GMBH

EDISON

MBB SE

MBB SE is a family-owned, medium-sized corporation that has expanded steadily as a result of organic growth and the acquisition of other companies since it was founded in 1995. Achieving a long-term increase in the value of the individual companies and the Group as a whole forms the heart of its business model. This business model has been highly profitable since the outset - substantial growth and sustainable returns will remain MBB SE's goal in future as well.

*Information from http://www.boerse-frankfurt.de/

Industrials

Market cap*	€131m
	*As at 20 October 2015
Share details	
Code	MBB
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

MLP AG

The MLP Group is the partner for all financial matters - for private clients, companies and institutional investors. The views and expectations of our clients always represent the starting point in each of these fields. Building on this, we then present our clients with suitable options in a comprehensible way so that they can make the right financial decisions themselves.

*Information from http://www.boerse-frankfurt.de/

Financial Services

Market cap*	€454m
	*As at 20 October 2015
Share details	
Code	MLP
Designated sponsor(s)	
	EQUINET BANK AG

Motif Bio plc

Motif Bio is a clinical stage biopharmaceutical company which specializes in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.

*Information from http://www.boerse-frankfurt.de/
http://www.motifbio.com/
http://www.londonstockexchange.com/

Pharma & biotech

Market cap*	€65m
	*As at 20 October 2015
Share details	
Code	MTFB
Designated sponsor(s)	
	N/A

MPC Capital AG

Financial Services

MPC Capital AG is an independent investment manager specialising in real asset investments and investment products, as well as their management and administration, in the three core areas Real Estate, Maritime Investment and Infrastructure. Since 1994 MPC Capital AG has launched over 300 investment projects with a total real-asset investment volume of more than EUR 19 billion.

*Information from http://www.boerse-frankfurt.de/

Market cap* **€95m**

*As at 20 October 2015

Share details

Code MPCK

Designated sponsor(s)

ODDO SEYDLER BANK AG

msg life ag

Software

As part of the independent, internationally active msg Group, msg life ag and its subsidiaries are among the leading software and consulting companies for the European insurance sector and concentrate primarily on life insurance companies and pension fund institutions. Their products and services range from standard software through consulting services to the assumption of responsibility for IT operations (cloud solutions).

*Information from http://www.boerse-frankfurt.de/

Market cap* **€69m**

*As at 20 October 2015

Share details

Code MSGL

Designated sponsor(s)

DZ BANK AG DT. ZENTRAL-GENOSSENSCHAFTSB.*ICF BANK AG WERTPAPIERHANDELSBANK

mVISE AG

Telecommunication

mVISE AG numbers among the worldwide leading full-service providers for mobile marketing, mobile internet and interactive value-added services. From our site in Germany, we support our customers in the formulation of holistic mobile strategies from advice and conception through finding collaborators to technical conversion and reliable operation.

*Information from http://www.boerse-frankfurt.de/

Market cap* **€11m**

*As at 20 October 2015

Share details

Code C1V

Designated sponsor(s)

BIW BANK FUER INV. U. WERTPAPIERE AG

mybet Holding SE

Retail

mybet Holding SE (formerly JAXX SE), established in 1998, is a financial holding company with holdings in companies in the European gaming industry. mybet Holding SE currently holds interests in companies in Germany, Austria, Spain, Italy, Belgium, Gibraltar and Malta. mybet Holding SE has its headquarters in Kiel.

Market cap*	€22m
	*As at 20 October 2015
Share details	
Code	C1V
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

*Information from http://www.boerse-frankfurt.de/

Nemetschek AG

Software

Nemetschek, Munich, is a leading global software provider for the AECM industry (Architecture, Engineering, Construction, Management). From more than 40 locations worldwide and with its 13 brands, the Nemetschek Group serves more than 1.8 million users in 142 countries.

Market cap*	€1523m
	*As at 20 October 2015
Share details	
Code	NEM
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

*Information from http://www.boerse-frankfurt.de/

NEXUS AG

Software

NEXUS develops and markets IT-solutions for the healthcare market. NEXUS supports the integrated healthcare approach which ensures the exchange of data between general practitioners, hospitals and rehabilitation clinics. Over 800 employees of the NEXUS group are developing Software- and IT-Solutions which is daily used by about 189,000 users in 25 countries worldwide.

Market cap*	€264m
	*As at 20 October 2015
Share details	
Code	NXU
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

*Information from http://www.boerse-frankfurt.de/

OTI Greentech Group AG

Technology

OTI Greentech AG is leading international CleanTech engineering group with its headquarters in Germany. Operational subsidiaries are located in Switzerland (OTI), Norway (VTT Maritime and RADA Engineering & Consulting) and in Italy (Uniservice Global).

*Information from https://www.boerse-duesseldorf.de/

Market cap*	**N/A**
	*As at 20 October 2015
Share details	
Code	A0HNE8
Designated sponsor(s)	
	N/A

OHB SE

Technology

With a history spanning almost 30 years, OHB SE is Germany's first listed technology and space Group. Two business units offer international customers sophisticated solutions and systems. In 2014, full-year consolidated total revenues came to EUR 773 million.

*Information from https://www.boerse-duesseldorf.de/

Market cap*	**€304m**
	*As at 20 October 2015
Share details	
Code	OHB
Designated sponsor(s)	
	DZ BANK AG DT. ZENTRAL-GENOSSENSCHAFTSB.*ICF BANK AG WERTPAPIERHANDELSBANK HSBC TRINKAUS & BURKHARDT AG

PANTALEON Entertainment AG

Media

PANTALEON Entertainment AG is a media enterprise mainly focused on theatrical films. It is mainly active in the development and production of theatrical feature films, and the exploitation of the rights to those films, mainly through leading international film distributors in Germany and abroad, over all links of the distribution chain.

*Information from http://www.boerse-frankfurt.de/
http://www.pantaleonentertainment.com/

Market cap*	**€39m**
	*As at 20 October 2015
Share details	
Code	PAL
Designated sponsor(s)	
	HAUCK & AUFHAEUSER PRIVATBANKIERS KGAA ODDO SEYDLER BANK AG

Pfeiffer Vacuum Technology AG

Industrials

Pfeiffer Vacuum (stock exchange symbol PFV, ISIN DE0006916604) is one of the world's leading providers of vacuum solutions. In addition to a full range of hybrid and magnetically levitated turbopumps, the product portfolio encompasses backing pumps, measurement and analysis devices, components as well as vacuum chambers and systems.

*Information from http://www.boerse-frankfurt.de/

Market cap* **€1124m**

*As at 20 October 2015

Share details

Code	PFV

Designated sponsor(s)

COMMERZBANK AG

Progress-Werk Oberkirch AG

Automobile

PWO is one of the world's leading developers and manufacturers of advanced metal components and systems in lightweight construction for automotive safety and comfort. The company has developed a unique knowledge in the forming and joining of metals over the course of its 95-year history since it was founded in 1919. The German location at Oberkirch currently employs over 1,500 staff members.

*Information from http://www.boerse-frankfurt.de/

Market cap* **€107m**

*As at 20 October 2015

Share details

Code	PWO

Designated sponsor(s)

ODDO SEYDLER BANK AG

publity AG

Financial Services

Since 15 years publity acts as an established investor in commercial real estate. publity acquires high-yielding commercial assets primarily in german cities like Frankfurt and Munich and delivers performance in applying its 'manage to core' approach.

*Information from http://www.boerse-frankfurt.de/

Market cap* **€207m**

*As at 20 October 2015

Share details

Code	PBY

Designated sponsor(s)

BAADER BANK AG
ACON ACTIENBANK AG*VEM AKTIENBANK AG

PVA TePla AG

Industrials

PVA TePla AG is an established supplier of systems and facilities for the production and treatment of sophisticated industrial materials, with decades of experience in these fields. As a vacuum specialist for high-temperature and plasma treatment, PVA TePla is specialised in hard-metal sintering systems, crystal growing facilities and systems for surface activation using plasma.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€57m
	*As at 20 October 2015
Share details	
Code	TPE
Designated sponsor(s)	
	ICF BANK AG WERTPAPIERHANDELSBANK

RIB Software AG

Software

RIB Software AG is an innovator in construction business. The company creates, develops, and offers iTWO³ - new thinking, new working method and new technology - for the construction business worldwide. iTWO today is the world's first Cloud / License based Big Data 5D BIM enterprise solution for construction industry.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€636m
	*As at 20 October 2015
Share details	
Code	RSTA
Designated sponsor(s)	
	EQUINET BANK AG

Rofin-Sinar Technologies Inc.

Industrials

With 40 years of experience, ROFIN-SINAR Technologies is a leading developer, designer and manufacturer of lasers and laser-based system solutions for industrial material processing applications. The Company focuses on developing key innovative technologies and advanced production methods for a wide variety of industrial applications based on a broad scope of technologies.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€809m
	*As at 20 October 2015
Share details	
Code	RSI
Designated sponsor(s)	
	ODDO SEYDLER BANK AG M.M. WARBURG & CO (AG & CO.) KGAA

S&T AG

Technology

Market cap*	€200m
	*As at 20 October 2015
Share details	
Code	SANT
Designated sponsor(s)	
	KEPLER CHEUVREUX ODDO SEYDLER BANK AG VEM AKTIENBANK AG

As a well known supplier of IT solutions, the core business of S&T AG includes development, implementation and operation of customer-specific solutions as well as outsourcing, integration and consultation in the IT sector. In addition, S&T is a well-known IT manufacturer having a broad portfolio of proprietary products, which extends from PC and server hardware through mobile solutions to special systems based on hardware and software like highly professional security appliances.

*Information from http://www.boerse-frankfurt.de/

Sartorius AG

Pharma & biotech

Market cap*	€1865m
	*As at 20 October 2015
Share details	
Code	SRT3
Designated sponsor(s)	
	ODDO SEYDLER BANK AG HSBC TRINKAUS & BURKHARDT AG

The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider covering the two segments of Bioprocess Solutions and Lab Products & Services. In 2014, the technology group earned sales revenue of 891.2 million euros. Founded in 1870, the Goettingen-based company currently employs more than 5,500 persons.

*Information from http://www.boerse-frankfurt.de/

Schaltbau Holding AG

Industrials

Market cap*	€298m
	*As at 20 October 2015
Share details	
Code	SLT
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

With annual sales of around 430 million and a workforce of more than 2,600 employees, the Schaltbau Group is one of the leading suppliers of components and systems in the field of transportation technology and the capital goods industry.

*Information from http://www.boerse-frankfurt.de/

Singulus Technologies AG

Industrials

SINGULUS TECHNOLOGIES develops innovative technologies for efficient production processes, which only make use of resources conservatively. New production technology combined with sustainable processes and the use of novel materials can decouple the use of resources from economic growth in the long-term. SINGULUS TECHNOLOGIES' innovative power and competitiveness are strengthened by these new technologic developments.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€30m
	*As at 20 October 2015
Share details	
Code	SNG
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

SKW Stahl-Metallurgie Holding AG

Chemicals

The SKW Metallurgie Group, which is headed by the Prime Standard listed SKW Stahl-Metallurgie Holding AG, is a world-leading provider of specialty chemicals. Its core business is to provide solutions in hot metal desulphurization and secondary metallurgy for leading steel producers. As a company of long-standing tradition, SKW Metallurgie has established itself as a competent partner of the global steel industry. A further business activity is QUAB Chemicals.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€26m
	*As at 20 October 2015
Share details	
Code	SK1A
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

SLM Solutions Group AG

Industrials

SLM Solutions Group AG, headquartered in Luebeck, Germany, is a leading provider of metal based additive manufacturing technology (also commonly referred to as '3D printing'). SLM Solutions focuses on the development, assembly and sales of machines and integrated system solutions in the field of selective laser melting, vacuum and metal casting.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€306m
	*As at 20 October 2015
Share details	
Code	AM3D
Designated sponsor(s)	
	BHF-BANK AG DEUTSCHE BANK AG

SMT Scharf AG

SMT Scharf Group develops, manufactures and services transport equipment for underground mines. The main products are captivated railways that are used all over the world, primarily in black coal mines, but also in mines for gold, platinum and other metals. These are needed to transport material and personnel with payloads of up to 45 tons on gradients of up to 35 degrees.

*Information from http://www.boerse-frankfurt.de/

Industrials

Market cap* **€49m**

*As at 20 October 2015

Share details

Code S4A

Designated sponsor(s)

EQUINET BANK AG

Softing AG

Softing is a global management holding company. The companies of the Softing Group produce and market hardware and software for in the industrial automation and automotive electronics segments. They develop high-quality standard technology products and customized solutions in close cooperation with their customers. Both of Softing's business segments operate in growth markets.

*Information from http://www.boerse-frankfurt.de/

Industrials

Market cap* **€84m**

*As at 20 October 2015

Share details

Code SYT

Designated sponsor(s)

ICF BANK AG WERTPAPIERHANDELSBANK
SUEDDEUTSCHE AKTIENBANK AG

Software AG

Software AG (Frankfurt TecDAX: SOW) helps organizations achieve their business objectives faster. The company's big data, integration and business process technologies enable customers to drive operational efficiency, modernize their systems and optimize processes for smarter decisions and better service.

*Information from http://www.boerse-frankfurt.de/

Software

Market cap* **€1911m**

*As at 20 October 2015

Share details

Code SOW

Designated sponsor(s)

N/A

Store Electronic Systems

Industrials

Store Electronic Systems is the leading provider of electronic shelf labels for the retail industry. Its labels allow automated price changes, thereby reducing labelling costs and pricing errors.

Market cap*	€149m
	*As at 20 October 2015
Share details	
Code	SESL
Designated sponsor(s)	
	N/A

*Information from http://thomsonreuters.com/
http://www.edisoninvestmentresearch.com/research/company

SURTECO SE

Basic Resources

SURTECO SE is the holding company for a group of mutually complementary companies in the field of surface technology. The product portfolio of the SURTECO Group comprises edgebandings and finish foils based on paper and plastics, decorative printings, impregnates and release papers for the international wood-based, flooring and furniture industry. The product range is completed by skirtings made of plastics and technical extrusions (profiles) for various industries.

Market cap*	€276m
	*As at 20 October 2015
Share details	
Code	SUR
Designated sponsor(s)	
	JOH. BERENBERG, GOSSLER & CO. KG EQUINET BANK AG

*Information from http://www.boerse-frankfurt.de/

SÜSS MicroTec AG

Technology

SUSS MicroTec is a leading supplier of equipment and process solutions for microstructuring in the semiconductor industry and related markets. In close cooperation with research institutes and industry partners SUSS MicroTec contributes to the advancement of next-generation technologies such as 3D Integration and nanoimprint lithography as well as key processes for MEMS and LED manufacturing.

Market cap*	€121m
	*As at 20 October 2015
Share details	
Code	SMHN
Designated sponsor(s)	
	EQUINET BANK AG ODDO SEYDLER BANK AG

*Information from http://www.boerse-frankfurt.de/

Syzygy AG

Software

SYZYGY is an international agency group for digital marketing with some 450 employees and offices in Bad Homburg, Berlin, Frankfurt, Hamburg, London, Munich, New York und Warsaw. As a provider of creative, technological and media services, SYZYGY helps its clients to use digital media as an innovative communication and marketing tool.

Market cap*	€116m
	*As at 20 October 2015
Share details	
Code	SYZ
Designated sponsor(s)	
	EQUINET BANK AG

*Information from http://www.boerse-frankfurt.de/

TAKKT AG

Software

TAKKT is the leading B2B direct marketing specialist for business equipment in Europe and North America. The Group is represented with its brands in more than 25 countries. The product range of the TAKKT subsidiaries comprises more than 200,000 products for the areas of plant and warehouse equipment, office furniture, transport packaging, display articles, supplies for retailers, the food service industry and the hotel market.

Market cap*	€1046m
	*As at 20 October 2015
Share details	
Code	TTK
Designated sponsor(s)	
	EQUINET BANK AG

*Information from http://www.boerse-frankfurt.de/

technotrans AG

Industrials

The technotrans group produces, sells, and modernises systems and applications in the field of liquid technology. This includes cooling, temperature control, filtration, measuring, and dosing systems. With 22 sites the company from Sassenberg (Germany) is present in all the major markets worldwide.

Market cap*	€116m
	*As at 20 October 2015
Share details	
Code	TTR1
Designated sponsor(s)	
	BANKHAUS LAMPE KG EQUINET BANK AG

*Information from http://www.boerse-frankfurt.de/

telegate AG

Telecommunication

telegate AG is the second-largest German service provider for regional advertising and directory inquiries. Via the www.11880.com and www.klicktel.de online directories, the corresponding smart phone and iPad apps as well as klicktel's software products, consumers can access contact details for private subscribers, business information and regional news..

*Information from http://www.boerse-frankfurt.de/

Market cap*	€22m
	*As at 20 October 2015
Share details	
Code	TGT
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

TLG IMMOBILIEN AG

Financial Services

TLG IMMOBILIEN is a leading commercial real estate specialist in Berlin and the growth regions of Eastern Germany. As an active portfolio manager, TLG IMMOBILIEN focuses on managing a high-quality portfolio of office properties in Berlin and other regional commercial hubs, as well as a regionally diversified portfolio of retail properties in high-traffic micro-locations.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€1001m
	*As at 20 October 2015
Share details	
Code	TLG
Designated sponsor(s)	
	COMMERZBANK AG HSBC TRINKAUS & BURKHARDT AG

TOM TAILOR Holding AG

Consumer

The TOM TAILOR GROUP is one of the leading and fastest-growing fashion and lifestyle companies in Germany and Europe. With its two brands TOM TAILOR and BONITA, the Group addresses complementary target groups from 0 to 60 years of age. TOM TAILOR GROUP is represented with both brands in Germany, Austria, Switzerland, the Benelux as well as Poland and France. Additionally, the TOM TAILOR brand is well established in Russia and Eastern European markets.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€159m
	*As at 20 October 2015
Share details	
Code	TTI
Designated sponsor(s)	
	COMMERZBANK AG JOH. BERENBERG, GOSSLER & CO. KG J.P.MORGAN SECURITIES PLC

TOMORROW FOCUS AG

Software

TOMORROW FOCUS AG (ISIN DE005495329) is based in Munich, Germany, and is one of the leading exchange-listed Internet groups in Germany. The Group has a workforce of around 750. On 1 January 2014, its business operations were restructured into three new segments: Travel, Publishing and Subscription.

Market cap*	€187m
	*As at 20 October 2015
Share details	
Code	TFA
Designated sponsor(s)	
	HSBC TRINKAUS & BURKHARDT AG

*Information from http://www.boerse-frankfurt.de/

TRANSGENE S.A.

Pharma & biotech

Transgene is a French drug discovery and development company focused on the treatment of cancer and infectious diseases with immunotherapies. It has one product about to enter Phase I development and two Phase III-ready products.

Market cap*	€112m
	*As at 20 October 2015
Share details	
Code	TGNA
Designated sponsor(s)	
	N/A

*Information from http://www.boerse-frankfurt.de/
http://www.edisoninvestmentresearch.com/research/company/transgene

USU Software AG

Software

USU Software AG and its subsidiaries develop and sell complete software solutions for knowledge-based service management. The range of products includes solutions in the Business Service Management sector for efficient, cost-optimized deployment of the IT infrastructure of a company, in addition to Knowledge Solutions solutions for fine-tuning of knowledge-based business processes.

Market cap*	€202m
	*As at 20 October 2015
Share details	
Code	OSP2
Designated sponsor(s)	
	LANDESBANK BADEN-WUERTTEMBERG VEM AKTIENBANK AG

*Information from http://www.boerse-frankfurt.de/

Verona Pharma plc

Pharma & biotech

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, asthma and cystic fibrosis.

*Information from http://www.boerse-frankfurt.de/
http://www.veronapharma.com/

Market cap*	€17m
	*As at 20 October 2015
Share details	
Code	I9S
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

Villeroy & Boch AG

Consumer

Villeroy & Boch, formed in 1748, is a leading ceramics manufacturer and one of the most important international premium brands in the areas of bathroom and wellness, tableware and tiles. The listed company, which is domiciled in Mettlach, Germany, has around 7,400 employees and operates production facilities in Europe, Mexico and Thailand.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€188m
	*As at 20 October 2015
Share details	
Code	VIB3
Designated sponsor(s)	
	ODDO SEYDLER BANK AG

Viscom AG

Industrials

Viscom develops, manufactures and sells high-quality inspection systems. The product portfolio encompasses the complete bandwidth of optical and X-ray inspection operations, especially in the area of electronics assemblies. Viscom systems are used whenever 100% automatic inspection of electronics assemblies is required, such as in the production of automotive electronics, aerospace technology and industrial electronics.

*Information from http://www.boerse-frankfurt.de/

Market cap*	€120m
	*As at 20 October 2015
Share details	
Code	V6C
Designated sponsor(s)	
	DZ BANK AG DT. ZENTRAL-GENOSSENSCHAFTSB.*ICF BANK AG WERTPAPIERHANDELSBANK EQUINET BANK AG

Wacker Neuson SE

The Wacker Neuson Group is an international family of companies and a leading manufacturer of light and compact equipment with over 40 affiliates and 140 sales and service stations. The Group offers its customers a broad and deep portfolio of products, a wide range of services and an efficient, global spare parts service.

*Information from http://www.boerse-frankfurt.de/

Industrials

Market cap* **€788m**

*As at 20 October 2015

Share details

Code WAC

Designated sponsor(s)

DEUTSCHE BANK AG

WashTec AG

The WashTec Group has its registered office in Augsburg, Germany, and is the leading supplier of innovative solutions for the car wash business worldwide. WashTec employs more than 1,600 persons worldwide and is represented by its subsidiaries in the core markets of Europe, the United States and Canada, as well as in China and Australia. WashTec also has independent sales partners in about 60 countries.

*Information from http://www.boerse-frankfurt.de/

Industrials

Market cap* **€345m**

*As at 20 October 2015

Share details

Code WSU

Designated sponsor(s)

HSBC TRINKAUS & BURKHARDT AG
M.M. WARBURG & CO (AG & CO.) KGAA

WCM Beteiligungs- und Grundbesitz-Aktiengesellschaft

WCM Beteiligungs- und Grundbesitz-AG is a dynamically growing property investment company. The company's corporate strategy is focused on the acquisition and management of commercial properties, particularly offices and retail properties located in Germany's major commercial districts.

*Information from http://www.boerse-frankfurt.de/

Financial Services

Market cap* **€226m**

*As at 20 October 2015

Share details

Code WCMK

Designated sponsor(s)

BAADER BANK AG
ODDO SEYDLER BANK AG

WINCOR NIXDORF AG

Wincor Nixdorf is one of the world's leading providers of IT solutions and services to retail banks and the retail industry. The main focus of the Group's comprehensive portfolio lies on business process optimization, especially in the branch operations of both sectors. We also apply the expertise we have gained from our core business to related industries such as postal services and service station networks.

*Information from http://www.boerse-frankfurt.de/

Industrials

Market cap* **€1507m**

*As at 20 October 2015

Share details

Code WIN

Designated sponsor(s)

DEUTSCHE BANK AG
DZ BANK AG DT. ZENTRAL-GENOSSENSCHAFTSB.
*ICF BANK AG WERTPAPIERHANDELSBANK
GOLDMAN SACHS INTERNATIONAL,
LONDON*EQUINET BANK AG
TIMBER HILL (EUROPE) AG

ZhongDe Waste Technology AG

ZhongDe Group designs, invests, constructs, finances and operates waste-to-energy incineration plants generating electricity from the disposal of solid municipal and industrial waste. ZhongDe realises either EPC (Engineering, Procurement and Construction) or BOT (Build, Operate and Transfer) projects, focusing on large-scale plants with waste disposal capacities of around 1,000 tons per day.

*Information from http://www.boerse-frankfurt.de/

Industrials

Market cap* **€27m**

*As at 20 October 2015

Share details

Code ZEF

Designated sponsor(s)

HAUCK & AUFHAEUSER PRIVATBANKIERS KGAA

zooplus AG

As an online retail company zooplus sells pet supplies directly to private customers via the internet, and considers itself to be the clear European online market leader in terms of revenues and active customer base within its segment. In total, zooplus sells around 8,000 food and accessories products for dogs, cats, small animals, birds, reptiles, fish and horses.

*Information from http://www.boerse-frankfurt.de/

Retail

Market cap* **€872**

*As at 20 October 2015

Share details

Code ZO1

Designated sponsor(s)

ODDO SEYDLER BANK AG

Edison Investment Research Disclaimer

DISCLAIMER: Deutsche Börse AG

Frankfurt +49 (0)69 78 8076 960
Schumannstrasse 34b
60325 Frankfurt
Germany

London +44 (0)20 3077 5700
280 High Holborn
London, WC1V 7EE
United Kingdom

New York +1 646 653 7026
245 Park Avenue, 39th Floor
10167, New York
United States

Sydney +61 (0)2 9258 1161
Level 25, Aurora Place
88 Phillip Street, Sydney
NSW 2000, Australia

Wellington +64 (0)4 8948 555
Level 15, 171 Featherston St
Wellington 6011
New Zealand